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The T cell (or transmembrane) immunoglobulin and mucin domain (TIM) family proteins have 
attracted significant attention as novel immune regulators. Tim-3 is expressed on chronically 
stimulated, often dysfunctional, T cells. Antibodies to Tim-3 can enhance anti-viral and anti-tumor 
immune responses. It is also constitutively expressed by mast cells, NK cells and specific subsets 
of macrophages and dendritic cells. There is ample evidence for a positive role for Tim-3 in these 
latter cell types, which is at odds with the model of Tim-3 as an inhibitory molecule on T cells. On 
the other hand, polymorphisms in the TIM-1 gene, particularly in the mucin domain, have been 
associated with atopy and allergic diseases in mice and human. Genetic- and antibody-mediated 
studies revealed that Tim-1 functions as a positive regulator of Th2 responses, while certain 
antibodies to Tim-1 can exacerbate or reduce allergic lung inflammation. Tim-1 can also positively 
regulate the function of B cells, NKT cells, dendritic cells and mast cells. At this point, little is 
known about the molecular mechanisms by which Tim-1 and Tim-3 regulate the function of T 
cells or other cell types.  
We have focused on defining the effects of Tim-1 and Tim-3 ligation on mast cell 
activation, since these cells constitutively express both proteins and are activated through an 
ITAM-containing receptor for IgE (FcRI), using signaling pathways analogous to those in T cells. 
Employing a variety of gain- and loss-of-function approaches, we find that Tim-3 acts at a 
receptor-proximal point to enhance Lyn kinase-dependent signaling pathways that modulate both 
immediate-phase degranulation and late-phase cytokine production downstream of FcRI ligation. 
Using a Tim-1 mouse model lacking the mucin domain (Tim-1mucin), we show for the first time 
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that the polymorphic Tim-1 mucin region is dispensable for normal mast cell activation. We further 
show that Tim-4 cross-linking of Tim-1 enhances select signaling pathways downstream of FcRI 
in mast cells, including mTOR-dependent signaling, leading to increased cytokine production but 
without affecting degranulation. Thus, Tim-1 and Tim-3 are promising targets in development of 
therapeutics against mast cell-mediated allergic and autoimmune diseases.        
 vi 
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1.0   INTRODUCTION 
1.1 MAST CELLS 
1.1.1 Mast cell origin and tissue distribution 
Mast cells have been traditionally recognized as innate cells with central roles in atopic disorders 
and anaphylaxis. Their localization at the host-environment interface allows them to rapidly mount 
a response against invading pathogens and foreign substances. Mast cells develop from 
CD34+/CD117+ pluripotent progenitor cells originating from the bone marrow. Progression of mast 
cells through maturity is dependent on stem cell factor (SCF) produced by stromal cells. c-Kit 
(CD117), the receptor for SCF expressed on hematopoietic stem cells, is retained on mast cells 
throughout development, while its expression is down-regulated on other bone marrow cells during 
differentiation. In both mouse and human, mast cells progenitors (MCps) exit the bone marrow 
and subsequently migrate into peripheral tissues where they mature and become terminally 
differentiated mast cells, depending on the influence of cytokines and chemokines within the 
surrounding environment. Mast cells are distributed in a variety of tissues, particularly at the 
interface of the host and the external environment, i.e. sites such as skin, gastrointestinal (GI) tract, 
and the respiratory mucosa (1-4). Mast cells also reside in connective tissue surrounding blood 
vessels, nerves, hair follicles, and mucus glands (1). 
The migration of MCps occurs in a tissue-specific manner. MCps are constitutively found 
in large number in the small intestine and rely on binding of 47 integrins on mast cells to either 
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mucosal addressin cell adhesion molecule-1 (MAdCAM-1) or vascular cell adhesion molecule-1 
(VCAM-1) expressed on the endothelium for tissue homing (5), (6). In addition, CXC chemokine 
receptor 2 (CXCR2) has also been associated with migration of mast cells into the small intestine. 
Under homeostatic conditions, MCps do not accumulate in the lung but they can be recruited 
during chronic allergen-induced inflammation (7). This recruitment is promoted by interactions 
between 47 or 41 integrins with VCAM-1 and CXCR2 on the endothelium, as well as by the 
chemokine C-C motif receptor 2 (CCR2)/C-C motif ligand 2 (CCL2) axis (8).  Homing of MCps 
to the peritoneal cavity and certain regions of the skin has also been attributed to integrins (9). 
Finally, mast cells express a multitude of chemokine receptors, making them responsive to 
chemokines such as monocyte chemotactic protein-1 (MCP-1), CCL5, macrophage inflammatory 
protein-1 alpha (MIP1) at the site of inflammation (10).  
Mast cells were first described in 1878 by Paul Ehrlich as metachromatic, granulated cells 
that stained positive for the basic aniline dye. The content of these granules, together with the 
tissue location, functional, and structural characteristics helped define two subtypes of mature mast 
cells: mucosal mast cells (MMCs) and connective tissue mast cells (CTMCs) (11). In mouse, 
MMCs reside in the mucosal epithelium of the lung and GI tract, and are characterized by the 
chymases mast cell protease (MCP)-1 and MCP-2. CTMCs are found primarily in the skin, 
intestinal mucosa and peritoneum, and contain the chymase MCP-4, the tryptases MCP-5 and 
MCP-6, as well as carboxypeptidase A. Upon activation, MMCs secrete a small amount of 
histamine and large quantity of cysteinyl leukotrienes, while CTMCs release larger amounts of 
histamine and prostaglandin D2 (PGD2) (12). Furthermore, MMCs have been termed T-cell 
dependent mast cells, as they are absent in athymic nude mice (13). Using mouse bone marrow-
derived mast cells (BMMCs), studies were conducted to identify the growth factors essential for 
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mast cell growth and development. IL-3 in particular was found to be responsible for mast cell 
survival, maturation and development of mucosal mast cells (14). On the other hand, SCF alone 
was sufficient to support mast cell survival and development in vitro, although mast cell culture 
can be enriched with a combination of SCF and IL-3 (15). 
 Human mast cells are also divided into two subsets based on their protease content. The 
tryptase/chymase (MCTC) subset containing tryptases, chymases, and carboxypeptidases are found 
in skin, lymph nodes, lung, and gut mucosa. The MCT  reside in the intestinal and pulmonary 
mucosa, and stores only tryptases (16-18). In addition, MCTC but not MCT express the receptor for 
complement C5a (19).  
 
1.1.2 Mast cell biology 
Similar to other cell types of the immune system, activation of mast cells results in rapid generation 
and release of pro-inflammatory mediators. The immediate mast cell response is degranulation, 
which is characterized by expulsion of preformed cytoplasmic granule contents by exocytosis. 
Degranulation is a highly regulated process that requires assembly of granule-containing vesicles 
and fusion with the plasma membrane (20).  Mast cell granules are rich in pre-formed bioactive 
amines, most notably histamine, which induces bronchoconstriction, vasodilation, capillary 
permeability, smooth muscle contraction, mucus secretion and mucosal edema, all of which are 
associated with allergic or inflammatory reactions (21, 22).  
Mast cells also contain a significant amount of proteases, mainly tryptases and chymases 
which, as discussed above, have been used to define mast cell phenotypes depending on their 
abundance (23). Mast cell proteases have been implicated in arthritis, allergic airway 
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inflammation, innate immune defense, glomerulonephritis, and abdominal aortic aneurism 
formation (24-27).  Conversely, mast cell proteases can also have immunomodulatory role in 
allergic reactions. Specifically, -tryptase released by activated mast cells can limit the extent of 
allergic inflammation by cleaving IgE off its receptor (28).     Mast cell granules also contain 
several species of lysosomal enzymes, one of which is the ubiquitous -hexosaminidase present 
in all mast cell types and species. Thus, release of -hexosaminidase is used to quantify mast cell 
degranulation (22). It is worth noting that mast cell granules also possess pre-formed TNF, which 
can be rapidly released upon activation (29). Mast cell granules contain broad-spectrum anti-
microbial peptides against bacteria, enveloped viruses, fungi and protozoa that accumulate at sites 
of infection. Furthermore, the human anti-microbial peptide cathelicidin can also act as a 
chemoattractant for neutrophils (30).  
Aside from pre-formed mediators, activated mast cells can rapidly synthesize eicosanoids, 
a collection of inflammatory lipids that are generated from membrane phospholipids upon 
activation of phospholipase A2. These species include leukotrienes (LT), prostaglandin (PG), and 
platelet-activating-factor (PAF) with functions in vascular permeability, bronchoconstriction in 
lung, recruitment of immune effector cells, as well as wheal-and-flare responses associated with 
allergic skin reactions (31).  
While degranulation occurs within minutes of IgE crosslinking, de novo synthesis of 
cytokines and chemokines, resulting from enhanced transcriptional activation and gene expression, 
characterizes the late-phase response of mast cell activation. This leads to generation of a variety 
of pro- and anti-inflammatory cytokines, including TGF-, TNF, GM-CSF, IFN, IL-1, IL-2, IL-
3, IL-4, IL-5, IL-6, IL-10, IL-12, IL-18, IL-13, chemokines such as CCL2, CCL3, CCL4, CCL5, 
CXCL8, growth factors including SCF, FGF, VEGF, and angiogenin (12, 32). These mediators 
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can have consequential effects on the target and surrounding tissues, resulting in numerous cellular 
responses such as allergic inflammation, autoimmunity, tumorigenesis and angiogenesis. 
1.1.3 Mast cells in allergy 
Perhaps the best-known role of mast cells is their promotion of allergic reactions that occur when 
the immune system mounts an overt response against otherwise “innocuous” antigens. In allergic 
reactions such as asthma, mast cells are responsible for both the acute and late phase reactions, 
through instantaneous release of pre-formed and de novo synthesized mediators. Specifically, the 
release of histamine, PGD2, and leukotriene C4 contribute to bronchoconstriction, mucus 
secretion, and mucosal edema (33). In the late phase, mast cell-derived cytokines recruit 
eosinophils, basophils, and T cells to the site of inflammation, and subsequently orchestrate tissue 
remodeling and fibrosis, as commonly seen in asthma, allergic rhinitis and atopic dermatitis (34-
36).  
1.1.4 Mast cells in autoimmune diseases 
Since mast cells can maintain persistent inflammation and recruit immune cells to the site of 
inflammation, it is possible that this inflammatory environment becomes favorable to self-reactive 
lymphocytes that can cooperate with mast cells to inflict tissue damage. Mast cells are associated 
with several autoimmune diseases, including multiple sclerosis (MS) and rheumatoid arthritis 
(RA). Specifically, mast cell numbers and distribution have been correlated with development of 
MS (37-41). Mast cell stabilizing drugs such as sodium cromoglycate were able to relieve the 
severity of allergic encephalitis (EAE), an experimental model of MS (42). In RA, mast cells are 
 6 
found to accumulate in the synovial tissues and fluids of patients and can locally release 
inflammatory mediators (43). The complement pathway, Fc receptor binding, IL-1 and TNF have 
all been associated with RA development (44-47).  
1.1.5 Mast cells in innate immunity 
Because of their location at barrier surfaces, mast cells are among the first responders of the 
immune system to foreign pathogens, antigens, and toxin. As such, mast cells express a whole host 
of surface receptors to detect potentially harmful signals, through which they can induce rapid 
release of pre-formed and de novo synthesized mediators. Mechanisms of recognition range from 
pathogen-associated molecular pattern (PAMP) receptors such as Toll-like receptors (TLRs), 
complement receptors, immunoglobulin receptors, as well as receptors that recognize damage-
associated peptides produced by infected or injured cells (33). The responses generated by 
activated mast cells against bacteria depend on the type of PAMPs present. For example, TLR4 
binding to LPS from gram-negative bacteria, lipid A or fibrinogen results in production of pro-
inflammatory cytokines like TNF-, IL-1β and IL-6, without triggering degranulation. On the 
other hand, TLR2 recognizes peptidoglycans from gram negative bacteria and mycobacteria, 
leading to both cytokine production and degranulation (48, 49). In addition, mast cells secrete anti-
microbial peptides such as cathelicidins and defensins, reactive oxygen species, and can also 
directly phagocytose bacteria (30, 50, 51).  
The role of mast cells in viral infection is less clear. Mast cells can be infected by human 
immunodeficiency virus (HIV), dengue virus, Influenza A virus, cytomegalovirus and 
adenoviruses. Virally infected mast cells produce multiple soluble mediators, including IL-1, IL-
6, CCL3, CCL4, CCL5 and CCL8, all of which serve to recruit NK and NK T cells to site of 
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infection (52-55). Mast cells can also directly inactivate viruses by secretion of anti-microbial 
peptides (56).  
In parasitic infection, mast cell mediators can regulate tissue-derived cytokines like IL-25, 
IL-33 and thymic stromal lymphopoietin (TSLP), which are critical for optimal Th2 responses and 
worm expulsion (57). Thus, in these types of infections mast cells contribute by producing a 
favorable environment for parasite containment and clearance.  
1.1.6 Mast cells in adaptive immunity 
While less robust than dendritic cells (DCs), studies have shown that mast cells can present 
antigens via MHC class I and II complexes (51, 58, 59). Activation of mast cells through TLR7 
triggers the release of IL-1 and TNF, leading to DC recruitment to lymph nodes and induction of 
T cell cytotoxic responses (60, 61). Mast cells can also release exosomes containing co-stimulatory 
molecules to directly promote maturation and function of DCs (62). Furthermore, mast cells have 
been shown to form conjugates with T cells and can directly activate T cells through TNF 
production (63, 64). Conversely, mast cells can act to limit the magnitude and duration of an 
immune response through secretion of immunomodulatory cytokines like IL-10 and TGF- (35, 
65, 66).  
Given their broad pro-inflammatory potential, it is somewhat unexpected that mast cells 
also participate in immune tolerance. Specifically, mast cells can promote allograft tolerance 
through secretion of IL-10 and TGF-, and through cytokine-mediated interactions with regulatory 
T cells in skin and heart transplants. Mast cell-derived IL-2 was recently shown to support an anti-
inflammatory ratio of effector-to-regulatory T cells in a model of contact dermatitis (67, 68). 
Moreover, OX40L-expressing mast cells can interact with OX40-presenting regulatory T cells, an 
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interaction that serves to inhibit mast cell degranulation without affecting cytokine production (69-
71). Finally, mast cell histamine and lipid mediators also have a role in immune suppression. For 
instance, histamine binding to histamine receptor 2 (HR2) inhibits the inflammatory response to 
UVB radiation, while PGE2 can trigger IL-10 production by DCs and inhibit DC maturation (72-
74).  
1.1.7 Mast cells in tissue repair, angiogenesis, and cardiovascular disease 
In addition to promoting immune responses, mast cells participate in the maintenance of tissue 
homeostasis (75). In fact, mast cells participate in all steps of tissue repair, ranging from the initial 
inflammation to extracellular matrix remodeling. The mast cells mediators nerve growth factor 
(NGF), PDGF, VEGF and fibroblast growth factor-2 (FGF-2) induce epithelial cell and fibroblast 
proliferation (76). They activate platelets and promote both extravascular deposition of fibrin and 
the appropriate perfusion and nutrition necessary for repair (77-80). Mast cells also produce IL-1, 
IL-4, IL-6 and FGF to induce myofibroblasts, which are important for wound healing (81). Mast 
cell histamine, IL-1, IL-6, TGFβ and PDGF can all contribute to osteoclast recruitment and 
development and consequently to bone remodeling (82). 
The proximity of mast cells to blood vessels and their release of angiogenic factors, 
including angipoietin-1, FGF-2, VEGF, IL-8, TNF, histamine and heparin implicates a role for 
mast cells in angiogenesis (83). Specifically, these mediators can break down and rebuild 
extracellular matrix (ECM), induce proliferation of endothelial cells and promote the formation of 
new vessels (84). While these factors are not produced exclusively by mast cells, further support 
for a function of mast cells in angiogenesis is based on the observation that mast cell-specific 
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proteases like MCP-4, tryptase, histamine and heparin can promote vascular tube formation, 
particularly in the tumor microenvironment (12).  
Cardiac mast cells are present in the coronary arteries during spasm and accumulate in 
atherosclerotic plaques (85). Furthermore, chymase and tryptase released by mast cells can 
interfere with cholesterol efflux by macrophages leading to formation of foam cells that contributes 
to atheroma (43, 86, 87). 
1.1.8 Mast cells in cancer 
Mast cells appear to be involved in both cancer promotion and anti-tumor immunity, although the 
clinical relevance of mast cell/tumor inteactions remains to be determined. Mast cells secrete large 
quantities of pro-angiogenic factors such as angiopoetin-1, TNF, VEGF and PDGF, which promote 
ECM degradation and vascular formation (88). Mast cells can also release immunosuppressive 
cytokines like IL-10 and TNF-, which contribute to tumor growth. Mast cells also secrete 
metalloprotease (MMP)-2 and MMP-9 and heparin to promote metastasis (89-91). On the other 
hand, mast cell-derived TNF-, IL-1 and IL-6, were shown to suppress melanoma growth (92, 
93). Finally, eosinophil recruitment and survival is supported by mast cell tryptase and IL-5, which 
leads to tumor regression (88).  
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1.2 MAST CELL SIGNALING 
1.2.1 Early FcRI signaling 
While mast cells express a multiplicity of surface receptors that can trigger cellular responses, 
much focus has been placed on understanding the signaling mechanisms downstream of antigen-
IgE-dependent aggregation of the high affinity IgE receptor (FcRI). FcRI belongs to the 
immunoglobulin receptor superfamily and is expressed as a tetrameric complex composed of the 
IgE-binding α chain, which is unique to this receptor, the membrane-tetraspanning  chain and a 
disulfide-linked  homodimer, shared among other immune receptors (94-98). (99, 100)The  
chain serves as a signal amplifier while the  chains impart signaling competence for the receptor 
(99, 100). Upon antigen cross-linking of IgE-bound FcRI, receptor aggregation leads to 
transphosphorylation of the immunotyrosine-based activation motifs (ITAMs) of the  and  
chains by the Src family kinase (SFK) Lyn, which constitutively associates with the  chain (101, 
102). Additional Lyn kinase is then recruited to the phosphorylated  chains, while the 
phosphorylated  chains serve as docking sites for the spleen tyrosine kinase (Syk) (102-104) 
(Figure 1.1). While the  and  chains are generally viewed as positive regulators of FcRI 
signaling, recent studies provided evidence suggesting that they also negatively regulate mast cell 
activation. The FcRI  ITAM possesses a non-canonical tyrosine residue in between two 
canonical tyrosines found in conventional ITAMs. The loss of the canonical tyrosine 219 (Y219) 
resulted in marked reduction of Lyn binding and partially inhibited degranulation and cytokine 
production, suggesting that this is the primary recruitment site of Lyn and mediator of positive 
signaling (105, 106). In contrast, mutation of the noncanonical Y225 unexpectedly increased NF-
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B activation and cytokine production without affecting degranulation, together with diminished 
phosphorylation of the SH2-containing phosphatases (SHP)-1 and SHP2 and the SH2-containing 
inositol phosphatase (105, 107, 108). Finally, FcRI  can recruit positive or negative regulators, 
depending on the strength of the stimulus (109). FcRI  has also been found to mediate negative 
regulation of signaling to terminate cellular activation. Studies using FcRI, a receptor that also 
uses FcRI  for activation showed that cross-linking of FcRI can inhibit FcRI-dependent mast 
cell degranulation in a process that involves association of the  ITAMs with the phosphatase SHP-
1 (110). These studies have modified the view that assigned solely positive functions to FcRI  
and  chains, and hence suggest a more complex relationship between how FcRI regulates the 
transmission of positive and negative signals.  
Antigen-mediated cross-linking of FcRI is required for robust mast cell activation. This 
is due to the increased surface receptor complex expression and stabilization upon IgE binding 
(111). There is evidence that IgE can bind to FcRI and promote mast cell survival without 
inducing antigen cross-linking (112). These results provide a potential explanation to the 
contribution of IgE as a signal amplifier of allergic reactions.  
 
 
 
 
 
 
 
 
 12 
 
 
 
 
Figure 1-1: The FcRI complex. Schematic representation of the FcRI complex. Tyrosines as reported binding sites 
for the positive and negative signaling molecules within the ITAM motifs are indicated in red. 
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1.2.2 Tyrosine kinases in FcRI proximal signaling 
Lyn is the predominant SFK in mast cells and is estimated to be at least 20-fold more abundant 
than Fyn and Hck (113, 114). Lyn association with FcRI is a pre-requisite for antigen receptor 
phosphorylation and several models have been proposed to explain the initial Lyn-mediated FcRI 
activation. Lyn, via its SH2 domain, constitutively associates with basally phosphorylated FcRI 
, while the SH4-containing domain of Lyn can also bind to FcRI  (115). Another, more 
debatable, model suggests both constitutive and stimulation-dependent interactions between FcRI 
and Lyn in the cholesterol- and phospholipid-rich lipid rafts of the membrane. This model proposes 
that a small fraction of Lyn and FcRI are constitutively present in these lipid raft microdomains, 
where a lipid-rich environment can help stabilize the FcRI-Lyn interaction and the receptor 
signaling complex after antigen stimulation (116, 117).  
Initial studies using induction of passive systemic anaphylaxis (PSA), an indicator of mast 
cell function, demonstrated that Lyn-deficient mice had diminished PSA, which correlated with 
decreased phosphorylation of Syk and other downstream molecules (118). These observations 
supported a positive role for Lyn in the initiation of FcRI signaling. Nevertheless, studies using 
Lyn-deficient mast cells reported either unchanged or enhanced degranulation in vitro (119, 120). 
These results raised the possibility that Lyn may also negatively regulate FcRI activation. It is 
now known that Lyn is required for phosphorylation of the C-terminal Src kinase (Csk)-binding 
protein (Cbp), a negative regulator of SFKs through its recruitment of Csk. Indeed, Fyn activity in 
mast cells is enhanced in the absence of Lyn, which partially explains the increase in mast cell 
degranulation (113). Furthermore, there is defective phosphorylation of the phosphatases SHP-1 
and SHIP in Lyn-deficient mast cells (109, 120). In addition, published findings show that stimulus 
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strength can dictate whether FcRI takes on a negative or positive regulatory role, and that Lyn 
association with FcRI is increased under high intensity stimulation. Thus, the function of Lyn 
in FcRI activation is clearly complex and interpreting the effects of modulating FcRI signaling 
requires taking into consideration how receptor intensity affects Lyn and in turns mast cell effector 
function.  
Studies using Lyn-deficient mast cells have revealed Fyn kinase as a positive regulator of 
the complementary pathway downstream of FcRI activation (113). Fyn-deficiency is associated 
with diminished mast cell degranulation, which has been attributed to decreased phosphorylation 
of Grb2-associated binding protein 2 (Gab2) and subsequent activation of PI3K (113, 119, 121, 
122). Specifically, absence of Fyn led to a significant reduction in phosphatidylinositol-3,4,5-
triphosphate (PIP3), a product of PI3K, and also reduced degranulation. Fyn has also been shown 
to promote calcium influx by either phosphorylating the plasma membrane calcium channel 
transient receptor potential channel (TRPC) or activating the sphingosine-1-phosphate kinase 2 
(SphK2) (123, 124). In addition, Fyn can affect degranulation in calcium-independent ways. Fyn 
is involved in chemotaxis, vesicular trafficking, cytoskeleton reorganization and regulation of 
microtubule formation (125, 126). Thus, Fyn augments many aspects of FcRI signaling required 
for mast cell activation and effector function.        
Syk is indispensable for FcRI signal propagation and effector responses, as Syk-deficient 
mast cells do not exhibit degranulation and cytokine production (127, 128). Furthermore, Syk-
deficient mast cells are unable to activate NF-B or NFAT (129, 130). Binding of Syk, via its Src-
homology 2 (SH2) domains, to phoshorylated FcRI  ITAMs results in conformational changes 
that disrupts the inhibitory interaction between COOH-terminal/SH2-interdomain leading to Syk 
activation and increased enzyme activity (103, 129). Tyrosine phosphorylation of Syk upon 
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receptor aggregation is mostly due to autophosphorylation, with limited contribution from other 
tyrosine kinases like Lyn (131, 132). Phosphorylation mapping with in vitro kinase reactions 
identified ten tyrosines that are autophosphorylated (133). These phosphorylated Syk tyrosines 
mediate either positive or negative regulatory roles in FcRI signaling. For instance, mutation of 
Syk Y317 in RBL-2H3 basophilic cells enhanced PLC phosphorylation and increased 
degranulation, while mutations of Y519 and Y520 led to decreased degranulation (134-136). 
Furthermore, phosphorylation of Syk Y346 is entirely dependent on Lyn, while tyrosines 317, 342, 
519, and 520 are regulated by both auto-phosphorylation and trans-phosphorylation by Lyn (131). 
The activation state of Syk is important, as these tyrosine phosphorylation events provides binding 
sites for both positive and negative regulators of downstream signaling. The c-Cbl protein, which 
binds to Y317, mediates ubiquitination of FcRI and Syk after antigen activation, likely to dampen 
antigen receptor signaling (137). On the other hand, Y342 is required for binding and Syk-
mediated phosphorylation of SLP-76, LAT and PLC2, which lead to calcium mobilization and 
degranulation (Zhang, 2002). Finally, mutations in the conserved tyrosines 624 and 625 decrease 
Syk binding to phosphorylated ITAMs, leading to decreased kinase activity and reduced 
degranulation, MAPK kinases activation and NFAT and NF-B activation (129, 133, 138).   
The SFKs Fgr, Hck and Src are also expressed in mast cells, but their precise roles are less 
clear (99). Fgr is able to phosphorylate PLD2 and likely contributes to degranulation in that manner 
(139). Src was reported to bind PKC, a kinase that phosphorylates FcRI, although the effect of 
this interaction is not known (140). Studies using Hck-deficient mast cells showed that Hck is a 
positive regulator of mast cell degranulation and cytokine production, and can negatively regulate 
Lyn (114). Collectively, these findings suggest a relatively modest, non-dominant role for these 
kinases in mast cell function.  
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The cytosolic Tec family kinases Btk, Itk, Rlk and Tec are expressed in mast cells but only 
Btk and Itk have been shown thus far to have significant effects on mast cell activation (141). Btk 
is activated by Src-dependent tyrosine phosphorylation within its activation loop, which has been 
shown to depend on Lyn in mast cells (142, 143). In antigen activated mast cells, Btk translocates 
to the membrane via binding of its PH domain to membrane-associated PIP3, where it associates 
with PKC1 and likely phosphorylate PLC1 and PLC2, thereby contributing to degranulation 
and cytokine production (143-145). The relative contribution of Itk in mast cells has also been 
examined, with conflicting results. Mouse bone marrow-derived mast cells (BMMCs) lacking Itk 
show no obvious defects in antigen-induced degranulation. However, IL-13 and TNF- release is 
enhanced and is associated with increased nuclear NFAT activity (146). On the other hand, in the 
same study, transfer of Itk-/- BMMCs to mast cell-deficient mice was still able to rescue histamine 
release in vivo, suggesting that the defective responses are not due to absence of Itk in mast cells 
(146). 
1.2.3 FcRI signaling in degranulation and cytokine production 
Antigen cross-linking of FcRI induces phosphorylation of Syk, which mediates the 
phsophorylation of several adaptor proteins essential for further binding and recruitment of 
signaling molecules. Active Syk phosphorylates four tyrosine residues on the protein linker for 
activation of T cells (LAT) that serve as binding sites for Grb2/SOS, PLC, and Gads (135, 147, 
148). Activation of LAT also recruits the key adaptor protein SH2 domain-containing leukocyte-
specific phosphoprotein of 76kD (SLP-76), which is constitutively bound to Gads (149-152). This 
localization of SLP76 allows Syk to phosphorylate three N-terminal tyrosines of SLP-76 for 
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recruitment of Vav, Nck and Btk (153). More importantly, activation of LAT and SLP-76 results 
in recruitment of PLC1 and PLC2 to this multimolecular complex, leading to their 
phosphorylation by Btk and/or Syk (154-156). PLC1 and PLC2 activation leads to conversion 
of phosphatidylinositol 4.5-bisphosphate into inositol triphosphate (IP3) and diacylglycerol 
(DAG). Generation of IP3 drives mobilization of intracellular Ca
2+ that is then sustained by influx 
of extracellular Ca2+, a critical event for mast cell degranulation (157). Downstream of the Ca2+ 
response, mast cell degranulation culminates in membrane fusion for granule exocytosis. This 
regulated event is mediated by the membrane fusion proteins soluble N-ethyl-maleimide-sensitive 
factor-attachment protein receptors (SNAREs) and the Rab GTPases (99, 158-161).  
Phosphorylation of LAT also activates Ras/Raf, resulting in phosphorylation of the 
MAPKs extracellular signal-regulated kinases (ERK1,2,5), p38 and c-Jun N-terminal kinase 
(JNK) (162). These MAPKs go on to regulate activation of multiple transcription factors, including 
(AP)-1, NFAT and NF-B, and thus has a role in cytokine production (163-165). Furthermore, 
DAG generated by phosphorylated PLC phosphorylation activates protein kinase C (PKC) and 
PKC in mast cells, contributing to Fos and Jun activation (166). In addition, ERK is involved in 
phosphorylation of PLA2 and thus have a role in eicosanoid generation (167, 168). In addition to 
degranulation, PLC is also involved in cytokine production, primarily due to its ability to 
influence NFAT activity. The Ca2+ signal downstream of PLC1 is required for calcineurin-
mediated dephosphorylation and nuclear translocation of the transcriptional factor NFAT, and 
subsequent cytokine gene transcription and translation (169). Taken together, the signaling 
pathways discussed above form the Lyn/Syk/LAT/PLC axis that makes up the primary activation 
pathway downstream of FcRI activation.  
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Due to its contribution to degranulation and cytokine production, Fyn kinase is responsible 
for mediating the complimentary signaling pathway in antigen activated mast cells. This pathway 
does not involve LAT but rather activation of PI3K downstream of Gab2 phosphorylation (122). 
PI3K phosphorylates plasma-membrane-associated phosphoinositides at the 3’ position, providing 
docking sites for PH domain-containing molecules such as PLC1, PLC2, Vav and Btk (149, 
170). It has been proposed that PI3K might regulate FcRI-mediated degranulation by recruiting 
Btk and PLC to the plasma membrane where PLC can be phosphorylated by Btk (163). On the 
other hand, PI3K can activate phospholipase D (PLD), which subsequently regulates the 
sphingosine kinase (SK)-S1P pathway involved in calcium mobilization in an IP3-independent 
manner (171, 172). Similar to the LAT/PLC pathway, PI3K-mediated cytokine production may 
require the structurally similar non-T-cell activation linker (NTAL) as a transmembrane adaptor 
molecule (mainly to maintain, but not initiate, the calcium signal for optimal degranulation (149, 
173-175).  
The PI3K pathway has also been implicated in mast cell cytokine production since PI3K 
pharmacologic inhibition in mast cells and BMMCs with p110 mutation showed reduced 
cytokine production capacity (176). While the precise mechanisms leading to cytokine production 
are less clear compared to degranulation, PI3K activation can recruit the serine/threonine kinase 
3-phosphoinositide-dependent protein kinase (PDK)-1 to phosphorylate Akt at the plasma 
membrane (177). In mast cells, Akt can promote NF-B activation by phosphorylating IB (178). 
Furthermore, through calcium mobilization, PI3K may be able to augment NFAT activation 
downstream of PLC. While the Fyn/Gab2/PI3K axis involves activation of different signaling 
molecules to regulate similar functional outcomes, it shares common downstream targets with the 
Lyn/Syk/LAT pathway, i.e. the activation of PLC and Vav, suggesting that these molecules may 
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be involved in integration and coordination of both pathways. Thus, how these pathways 
differentially regulate antigen-mediated activation of specific transcription factors for gene 
expression merits further study.     
 
 
 
 
 
Figure 1-2: FcRI-mediated signaling pathways. 
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1.2.4 Signaling by other mast cell surface receptors  
The stem cell factor (SCF) receptor c-kit is crucial for mast cell growth, differentiation, survival 
and homing. Unlike FcRI, c-kit is a single-chain receptor with intrinsic protein-tyrosine-kinase 
activity (179). Nevertheless, SCF induces similar signaling pathways as FcRI signaling, including 
PLC1 activation, calcium mobilization, PI3K and MAPK activation, albeit with delayed kinetics 
and to a lower magnitude. Moreover, these signals are not sufficient to induce mast cell 
degranulation, but need to couple with the FcRI signaling pathways to impact mast cell activation 
(180).   
The ability to induce degranulation and cytokine release is not restricted to FcRI and c-
kit, but occurs upon ligand encounter by a wide range of mast cell receptors. A series of pathogen 
recognition receptors (PRRs) such as Toll-like receptors (TLRs), nod-like receptors (NLRs) and 
retinoic acid-inducible gene 1 (RIG-1)-like receptors (RLRs) are expressed by mast cells. 
Specifically, stimulation of mast cell TLR culminated in the myeloid differentiation primary 
response gene (MyD88)-mediated activation of PI3K, MAPKs and NF-B (181, 182). 
Mast cells can be positively or negatively regulated by FcRI and FcRIII IgG or FcRIIb 
respectively. These receptors allow mast cells to participate in humoral defense and antibody-
induced pathologies (183). FcRI and FcRIII receptors belong to the same immunoglobulin 
receptor superfamily and share the same ITAM-containing  subunit with FcεRI. As a result, 
aggregation of these receptors induce similar patterns of mediator release (184, 185). In contrast 
to FcRI and FcRIII, FcRIIb contains immunoreceptor tyrosine-based inhibitory motifs (ITIMs), 
and when aggregated with ITAM-containing receptors, can promote ITIM phosphorylation by 
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SFKs (186). Phosphorylated ITIMs can recruit phosphatases like SHIP-1 and SHIP-2, leading to 
suppression of signaling and downstream mediator release (187). 
Mast cells also express receptors for the C3a and C5a complement components. The C3a 
receptor is a G-protein coupled receptor (GPCR) and upon activation promotes degranulation and 
production of MCP-1 and RANTES in human mast cells (188). Similarly, other GPCR receptors 
like adenosine 3, sphingosine 1 phosphate-2 (S1P2), C-C Chemokine Receptor type 1 (CCR1), 
corticotropin-releasing hormone receptor (CRHR) and the beta-adrenoceptor are also present on 
mast cells and able to modulate antigen-mediated mediator release (189).  
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2.0  T CELL, TRANSMEMBRANE, IMMUNOGLOBULIN, MUCIN DOMAIN  
FAMILY OF PROTEINS 
2.1 IDENTIFICATION OF TIM GENES 
A complex interplay between environmental factors and genetic susceptibility is thought to 
underlie atopic diseases like asthma, atopic dermatitis and allergic rhinitis. Asthma susceptibility 
in particular has been linked to chromosome 5p23-35 because this region contains candidate genes 
like those encoding IL-12 p40, IL-9, the -adrenergic receptor and the IL-4 cytokine cluster (IL-
4, IL-5, and IL-13). To identify an asthma susceptibility gene from this complicated linked region, 
McIntire et al utilized congenic inbred mouse strains that differed only in discrete regions. They 
delineated a single region on chromosome 11, syntenic to human chromosome 5q, that conferred 
protection against T helper type 2 (Th2) responsiveness and airway hyperreactivity (AHR), a 
hallmark of asthma (190). This region is separate from the IL-4 cytokine gene cluster and was 
termed the T cell and airway phenotype regulator (Tapr).  Within this region was identified a 
family of genes that encode T cell membrane glycoptoteins, a conserved immunoglobulin variable 
domain (IgV) and mucin domain. Due to their structures, these gene products were hence termed 
the T cell, immunoglobulin domain and mucin domain (Tim) proteins. There are 8 Tim genes on 
mouse chromosome 11 and 3 TIM genes on human chromosome 5q33. Murine Tim-1, 2, 3, 4 
encode functional proteins, while murine Tims 5-8 appear to be pseudo-genes. Murine Tim-1 and 
Tim-2 are homologous to human TIM-1, and murine Tim-3 and Tim-4 bear strong sequence 
homology to human TIM-3 and TIM-4. Further sequence analysis revealed that mouse Tim-1 is 
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homologous to rat Kim1, or kidney injury molecule 1. In addition, mouse Tim-1 is homologous 
with human and monkey hepatitis A virus cellular receptor (hHAVcr1). 
Around the same time that the Tapr region was cloned, Kuchroo and colleagues were 
searching for specific markers of Th1 T cells using an antibody (Ab)-generation approach. They 
identified a particular monoclonal antibody (mAb) that was able to recognize Th1 cell clones and 
de novo-generated Th1 T cells, but not naïve or Th2 T cells. Upon analysis of the antigen, it was 
determined to be murine Tim-3 (191). They also provided the first evidence that Tim-3 may 
function as an inhibitory molecule, since administration of a Tim-3 Ab exacerbated disease in the 
experimental autoimmune encephalomyelitis (EAE) model (191). Since the identification of the 
Tim family, others have reported their roles in immune regulation, including allergy, infection, 
autoimmune disease and cancer.  
 
2.2 TIM PROTEIN STRUCTURE 
The TIM genes encode type I immunoglobulin (Ig)-like domain proteins that also include a mucin 
domain with O-linked glycosylation and N-linked glycosylation sites close to the membrane, a 
single transmembrane domain and a cytoplasmic tail with tyrosine phosphorylation motif, except 
in Tim-4 (190). The crystal structures for the Ig-like domains of murine Tims 1-4 reveal that they 
are of the immunoglobulin V type (192, 193). This IgV domain is important for Tim-2 
dimerization, while homophilic Tim-1: Tim-1 interactions require both the IgV and mucin domain 
(193). The IgV domain is composed of two anti-parallel  sheets, with short strands B, E, D in one 
(BED -sheets) and A, G, F, C, C’ and C’’ β-strands in the other (GFC -sheets). The most striking 
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feature is the deep pocket flanked by two hydrophobic loops that can extend into membranes. All 
Tim IgV domains contain six conserved cysteine residues, and the first and last of the cysteine 
residues bridge the -sheets. The other four cysteines found in all Tim proteins form two disulfide 
bonds that create the folded CC’ loop upward onto the GFC -sheet. As a result, the tip of the CC’ 
loop is parallel to the FG loop, and generate a distinct ligand binding pocket in Tim-1, Tim-3, and 
Tim-4, but not Tim-2 (193) (Figure 2-1). Identified by high resolution analysis of Tim-4 crystals, 
this unique pocket was shown to contain residues that coordinate with metal ions such as calcium, 
and thus has been termed the metal-ion-dependent ligand binding site (MILIBS). 
Phosphatidylserine (PS), a ligand of Tim-1, Tim-4 and Tim-3, is able to penetrate into the cavity 
of this loop, and requires metal ion coordination and conserved residues within this pocket for its 
binding (193). These conserved residues are only present in Tim proteins that bind PS but not Tim-
2, which does not, and this interaction is specific for the L-stereoisomer of PS, thereby suggesting 
that the MILIBS pocket is specific for PS recognition and has specificity for phospholipid binding 
of the Tim proteins (193).  
According to crystal structure models, the BC loop within the IgV domain of Tim-1, Tim-
2 and Tim-3 is variable and contributes to interaction with the lipid bilayers of cell membranes, 
while PS interacts with the Tim proteins (192-194). In fact, there are seven amino acid differences 
between BALB/c and HBA Tim-3 that confer PS binding specificities and they lie within the BC 
loop (194). Therefore, variations within the IgV domains may contribute to ligand binding 
affinities among the Tim proteins. For instance, Cao et al demonstrated that, while the unique CC’-
FG cleft is not required, glycosylation of Tim-3 IgV domain is needed for Tim-3 binding to the 
ligand galectin-9 (192). Furthermore, mutation of the CC’-FG cleft abolishes binding of Tim-3 to 
other cell types and transformed cell lines from different species (192). Collectively, these results 
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are consistent with a unique ligand binding function of the IgV domain and suggest the existence 
of multiple ligands for the TIM family of proteins (Figure 2-1).  
 
 
 
Figure 2-1: Structures of IgV domain and ligand binding sites. IgV domain structures of Tim-1(A), Tim-2 (B), Tim-3 
(C) and Tim-4 (D). Reported ligand binding sites are indicated by arrows, based on crystal structures, ligand 
interaction, antibody blocking, and mutational studies. Structures are generated using Cn3D with structural 
information from the public database. Tim-1 PBD ID: 2OR8; Tim-2 PBD ID: 2OR7; Tim-3 PBD ID:  3KAA; Tim-4 
PBD ID: 3BIB. 
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The size of the mucin domains varies considerably among members of the Tim family, but 
they are all rich in threonine, serine, and proline (190). Sequence analysis indicated that the Tim-
1 mucin domain has multiple sites for O-linked glycosylation and the Ig domain has two putative 
N-linked glycosylation sites. Like Tim-1, Tim-2 also has two N-linked glycosylation sites and a 
heavily O-linked glycosylated mucin domain. Tim-3 has both N- and O-linked glycosylation sites 
in its IgV domain and much less glycosylation in the mucin domain, compared to Tim-1 and Tim-
2. The IgV region of Tim-4 is not predicted to be glycosylated, but has multiple N-linked 
glycosylation sites in its mucin domain. Overall, the Tim proteins are expected to be highly 
glycosylated and bear structural resemblance to cell adhesion molecule mucosal addressin cell 
adhesion molecule-1 (MADCAM1). Of note, both murine and human TIM-4 have RGD integrin-
binding motifs in their IgV domains that has been implicated in v3 integrin binding, to promote 
growth of non-small-cell-lung cancer tissue (192, 195, 196). 
The cytoplasmic domain of Tim family proteins consists of 42-77aa and is the most 
conserved domain between human and mouse orthologs (191). There are two splice variants of 
TIM-1, the TIM1a that is mainly expressed by human liver and lacks the phosphorylation motif, 
and the TIM1b variant mainly expressed by human kidney cells and has two tyrosine residues 
including the highly conserved motif RAEDNIY (190, 197). Like Tim-1, Tim-2 also has an 
intracellular tyrosine phosphorylation motif, RTRCEDQVY, and is phosphorylated upon T cell 
activation (190, 198). Tim-3 cytoplasmic tail contains both tyrosine phosphorylation motif and an 
SH2 domain-binding motif (190). In contrast, Tim-4 does not have any conserved tyrosines, 
suggesting that it functions as a ligand rather than a signaling receptor (199). The structural 
variation in the Tim proteins suggest they have distinct intracellular signaling pathway upon ligand 
binding (Figure 2-2). 
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Figure 2-2: The TIM family proteins. Graphical representation of murine and human TIM proteins. Glycosylation 
sites in the IgV domain are indicated in blue, based on structural studies. Approximate sites of N- and O-linked 
glycosylation sites on the mucin domain are represented using NetOglyc and NetNglyc prediction servers.    
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2.3 TIM-1 (HAVCR-1) 
2.3.1 Tim-1 expression 
Mouse Tim1 encodes a 305 amino acid (aa) membrane protein that has 78% identity with rat KIM1 
and 42% identity with human HAVcr-1. KIM-1, or kidney injury molecule, is upregulated on 
kidney tubular epithelial following injury (200). Tim-1 is expressed on activated and Th2-
polarized T cells but not naïve or CD8 T cells (201). Angiari et al recently reported that high levels 
of Tim-1 expression could be found both on the surface and intracellularly of Th1 and Th17 cells 
(202). Tim-1 is also expressed by DCs (203), germinal and regulatory B cells (204, 205), natural 
killer T (NKT) cells ((206) and mast cells (96).  
2.3.2 Tim-1 as HAV cellular receptor and link to atopy  
Human TIM-1 was originally identified as a receptor for HAV in African green monkeys and 
humans (207, 208). Sequence homology between murine Tim-1 and human TIM-1 allowed 
mapping of HAV binding to the IgV domain of Tim-1 (193). Tim-1 is highly polymorphic in mice, 
monkeys, and humans with variants ranging from single nucleotide to insertion/deletion 
polymorphisms primarily in the signal and mucin-like domains (190). Of interest is a six amino-
acid-insertion (ins) at residue 157 termed the 157insMTTTVP located in the mucin domain that is 
required for efficient HAV uncoating and entry (209). HAV infection is commonly associated with 
large family size, poor hygiene and/or attendance at day-care; there is an inverse correlation 
between HAV exposure and atopy (210). By studying 375 individuals who were tested for atopy 
and prior HAV infection, McIntire et al found that individuals who were HAV seropositive were 
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protected against atopy, but only if these individuals also harbored the 157insMTTTVP variant of 
TIM-1 (211). These findings suggest that exposure to HAV (or possibly another pathogen that is 
also on a decline due to modern sanitization and public health measures) may influence the 
development of atopy. Subsequent to the study of McIntire et al, Tim-1 polymorphisms have also 
been associated with asthma, atopic dermatitis, allergic rhinitis, autoimmune diseases, malaria, 
AIDS progression and protection against malaria (212).   
These disease associations are particularly important since an immune function for Tim-1 
was originally identified by studying congenic mouse models differing in distinct chromosomal 
regions, to screen for asthma susceptibility genes. BALB/c mice had heightened AHR and Th2-
type cytokine production when compared to HBA mice with chromosomal regions derived from 
the more asthma-resistant DBA/2 mice. These differences were later attributed to variation in the 
Tim proteins and their effects on T cell functions (190). However, human genetic linkage cannot 
fully explain the immune response differences observed between BALB/c and HBA mice, as 
BALB/c Tim-1 contains the longer mucin domain, yet also has a more atopic phenotype. 
Nevertheless, these results suggest that Tim-1 variation can regulate the balance of Th1-Th2 
responses and provide a potential molecular mechanism for the inverse relationship between 
infection and atopy. 
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Figure 2-3: Tim-1 IgV domain and predicted HAV binding sites. Tim-1 IgV domain (PBD ID: 2OR8) was generated 
using Cn3D based on structural data in the public database. Predicted binding sites and the amino acid important for 
HAV interaction with Tim-1 are indicated.  
 
2.3.3 Tim-1 as a phosphatidylserine (PS) receptor  
PS is the most abundant phospholipid, with restricted distribution in the inner leaflet of the plasma 
membrane. Redistribution and exposure of PS to the cell surface is a cardinal feature of apoptosis 
and has been shown to facilitate clearance of apoptotic by phagocytes (213). TIM-1 is also known 
as kidney injury molecule (KIM-1), since it was found to be upregulated on tubular epithelial cells 
of post-ischemic kidney (200). Expression of Tim-1 on a renal cell carcinoma cell line mediated 
phagocytosis of apoptotic cells (214). Tim-1 ecto-domain can also be shed from injured kidney 
and is now used as a biomarker for post-ischemic kidney (200). Therefore, Tim-1 may function as 
a facilitator of cell death recognition and clearance in the injured kidney. As discussed below, Tim-
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1 recognition of apoptotic cells is essential for activation of regulatory B cells in allograft tolerance 
and for natural killer T cells in non-allergic asthma (215, 216). Recently, TIM-1 has been shown 
to interact with PS to inhibit HIV release (217).  
2.3.4 Tim-1 and other ligands 
Tim-4, which is related to Tim-1, is also a ligand for Tim-1, and will be discussed in further detail 
below. IgA  chain binds specifically to Tim-1 and can enhance HAV-Tim-1 interaction, without 
interfering with HAV infection, in African monkey kidney cells (218). As a result, IgA and HAV 
may have different binding sites on Tim-1 (218). Wilker et al proposed that Tim-1 and other Tim 
proteins can bind a large repertoire of ligands across species in a calcium-sensitive manner, with 
a requirement for intact O-linked and N-linked glycosylation (219). Specifically, mouse Tim-1 
fusion protein could bind to mouse Tim-1, Tim-3 and Tim-4, as long as their mucin stalks were 
glycosylated (219). Finally, Tim-1 was recently reported to bind the selectin family member P-
selectin (202). Tim-1 binding to P-selectin was shown to mediate Th1 and Th17 capture and rolling 
in vitro and in vivo, recruitment of T cells into inflamed skin in a contact hypersensitivity model 
and induction of EAE (202).  
2.3.5 Tim-1 in T cells  
Since the identification of Tim-1, many studies have focused on delineating its functions in T cells, 
using monoclonal antibodies and endogenous ligands (195, 201, 220, 221). Specifically, Tim-1 
was shown to co-stimulate effector T cell proliferation, and has a preferential role in co-stimulation 
of Th2 cytokine production. Administration of the high affinity agonistic mAb 3B3 inhibited 
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induction of respiratory tolerance in an AHR model (201). Antibodies recognizing distinct epitopes 
of Tim-1 resulted in either enhanced or attenuated lung inflammation (220). Ligation of Tim-1 by 
a high affinity agonistic antibody was able to enhance T cell proliferation and cytokine production 
in vitro and in vivo (201, 222). Furthermore, anti-Tim-1 treatment was able to attenuate Th2-
dependent airway inflammation in a mouse model of asthma by reducing inflammatory cell 
infiltration and Th2 cytokine production (223). This evidence suggests that Tim-1 plays a role in 
airway inflammation through its regulation of Th2 type responses that are central to development 
of AHR and the pathogenesis of asthma (206).   
De Souza et al further showed that ectopic expression of Tim-1 in T cells stimulated in 
vitro under neutral conditions promoted generation of more IL-4 than INF- (222). Similarly, a co-
stimulatory function of Tim-1 was also observed during interaction of Tim-1 with Tim-4, which 
primarily expressed on APCs (195, 224). Specifically, Tim4-Ig ligation of Tim-1 delivered a 
positive signal for CD3/CD28-mediated T cell proliferation. T cells from mice immunized with 
the encephalitogenic peptide PLP and treated with Tim4-Ig produce more IL-2 and IFN- than IL-
4 and IL-10 (195). Collectively, these results provide supporting evidence that Tim-1 is a positive 
regulator of T cell response.     
Tim-1 has also been implicated in transplant tolerance and the balance between effector 
and regulatory T cells. In transplant model studies, different Tim-1 antibodies demonstrated 
opposing effects on regulatory T cell differentiation and survival. For instance, the high affinity 
antibody 3B3 promoted graft rejection by reducing Foxp3 expression and Treg development while 
promoting Th17 responses (225). On the other hands, treatment with the low avidity antibody 
RMT1-10 was able to inhibit allograft rejection by inhibiting Th1 and Th17 responses while 
maintaining the Treg population (226). 
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2.3.6 Tim-1 in B cells  
Studies of Tim-1 function using antibody treatment have been beneficial to detection of novel Tim-
1 expressing cell types and the effects of modulation of its co-stimulatory activity. Similarly, using 
a mAb generated against murine Tim-1, Ma et al  found that Tim-1 was highly expressed on splenic 
B cells after IgM and anti-CD40 stimulation (204). In addition, in vitro stimulation of activated B 
cells by Tim-1 Ab induced expression of the plasma cell marker syndecan-1. In vivo treatment 
with a Tim-1 Ab enhanced serum levels of antigen-specific antibodies, suggesting that Tim-1 
signaling in B cells can regulate antibody responses (204). Another sub-population of splenic B 
cells, termed the regulatory B (Breg) cells (227), has been demonstrated to inhibit inflammation 
in autoimmune mice in an IL-10-dependent manner (228-230). Ding et al showed that Tim-1 
expression could help define the IL-10-secreting Bregs and that Tim-1 ligation enhanced IL-4 and 
IL-10 expression in these B cells and prolonged allograft survival (231). The anti-Tim-1 Ab 
RMT1-10 was found to induce long-term allograft survival in mice when given in combination 
with rapamycin (226). It was recently found that combined treatment with RMT1-10 and anti-
CD45RB could induce Tim-1 expression on splenic B cells and promote long term islet allograft 
survival (232). These results highlight the role of Tim-1 as a regulator of not only T cells but also 
B cell alloimmunity.  
Since polymorphisms in the Tim-1 mucin domain can regulate Th2 responses in human 
and mice (190, 211), Xiao et al generated a Tim-1Δmucin mouse model that expresses Tim-1 at 
normal levels but lacks the mucin (205). Tim-1Δmucin mice appeared normal at <6 months of age 
but exhibited impaired IL-10 production by regulatory B cells at >10 months old. This was 
accompanied by hyper-activated T cell response and increased autoantibody production (205). 
These results suggest that the mucin domain is important for normal Breg function, absence of 
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which can lead to systemic autoimmunity. In addition, Tim-1Δmucin exhibited accelerated allograft 
rejection, in part due to decreased Breg induction and IL-10 production in response to apoptotic 
cells (216). Overall, recent studies have demonstrated an important role for Tim-1 in the 
maintenance of tolerance specifically through promotion of regulatory B cell function.  
2.3.7 Tim-1 and NKT cells 
NKT cells are a distinct subset of T cells expressing the semi-variant TCR V14J18 that is 
restricted by MHC class I-like molecule CD1d (233). They express both the TCR/CD3 complex 
and the NK cell markers NK1.1 and Ly49 (233). Upon activation, NKT cells produce both Th1 
and Th2 cytokines including IFN, IL-4, IL-10 and IL-13 (234, 235). As a result, NKT cells 
participate in a wide range of normal and pathological immune responses, such as tumor immunity, 
allergy, atherosclerosis and autoimmune diseases, yet the precise regulation of NKT cell cytokine 
production in vivo is not clear (206). Kim et al found constitutive expression of Tim-1 on NKT 
cells and, in the presence of TCR stimulation, ligation of Tim-1 either by antibodies or Tim-4 
inhibited IFN- production and enhanced IL-4 production. This modulation of cytokine production 
was attributed to increased GATA-3 and reduced T-bet expression. Consequently, Tim-1 
engagement aggravated bleomycin-induced pulmonary fibrosis, suggesting a regulatory role for 
Tim-1 in NKT-mediated disease (206).    
NKT cells are abundant in the liver and have been associated with several forms of hepatitis 
(236). Kim et al reported TIM-1 expression on peripheral blood NKT cells and primary NKT cell 
lines, and that this expression was required for HAV-mediated activation of NKT cells, since only 
HAV-infected, but not uninfected, hepatoma cells were lysed (237). More importantly, 
examination of 30 Argentinean patients with HAV-induced acute liver failure revealed that severe 
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liver disease was associated with a 6-aa insertion (157insMTTTVP) in the TIM1 gene, a 
polymorphism previously associated with protection against asthma and allergic diseases (211, 
237). This is in part due to more efficient binding of HAV to cells expressing this long form of the 
mucin domain. These results provide a mechanistic explanation for the relationship among HAV 
infection, allergy and TIM-1, while highlighting the critical role of TIM-1 in immune regulation.  
As a putative asthma susceptibility modifier, Tim-1 has a well-known role in asthma 
exacerbation, even though the mechanisms by which non-allergic environmental factors can 
trigger asthma is unclear. The capacity of Tim-1 to bind PS on apoptotic cells, and to regulate the 
severity of HAV infection and allergy, warranted an investigation into the role of Tim-1 in 
allergen- versus non-allergen induced asthma. Consequently, NKT cells were demonstrated to 
induce AHR in a respiratory syncytial virus (RSV)- and ozone-induced asthma, but not allergen-
induced asthma, in a Tim-1-dependent manner (215). This study further showed that ozone and 
RSV exposure induced apoptosis of airway epithelial cells, which could activate NKT cells via 
Tim-1 signaling. On the other hand, two other studies reported either no difference or even 
increased AHR in allergen-induced lung inflammation in the absence of Tim-1 (238, 239). These 
results are particularly important because they suggest that Tim-1 may be involved in clearance of 
apoptotic cells, a critical function of NKT cells, caused by chronic lung inflammation, rather than 
production of inflammatory cytokines and recruitment of inflammatory cells. 
2.3.8 Tim-1 in mast cells  
Tim-1 is constitutively expressed on bone marrow-derived mast cells (BMMCs) and peritoneal 
mast cells (PMCs) (240). Cross-linking of Tim-1 by Tim-4 could enhance IgE-sensitized and 
antigen-stimulated (IgE/Ag) production of Th2 type cytokine production without affecting 
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degranulation (240). However, the mechanisms by which Tim-1 can modulate mast cell functional 
responses are currently unknown.  
2.3.9 Tim-1 and dendritic cells (DCs)  
Xiao et al showed that Tim-1 is expressed on all subsets of CD11c+ DCs but was higher on myeloid 
(CD11b+) and lower on plasmacytoid (B220+) DCs, and this expression was up-regulated by TLR 
activation with LPS (241). Cross-linking with the high avidity Tim-1 antibody 3B3 could enhance 
Th1 and Th17 cytokine production in vitro when DCs were present in the cultures and could also 
break tolerance in a genetically resistant mouse model of EAE (241). Tim-1 cross-linking on DCs 
may also alter the frequency of Treg, although this effect was rather modest. The preference toward 
Th1 and Th17 induction in this EAE model was attributed to 3B3-mediated activation of DCs, 
which represent the majority of Tim-1 expressing cells in the CNS at the peak of EAE severity 
(241). 
2.3.10 Tim-1 signaling 
Regarding signaling pathways coupled to Tim-1, de Souza et al showed that tyrosine 276 in the 
cytoplasmic tail of Tim-1 could be phosphorylated in an Lck-dependent manner (242). This 
allowed for recruitment of the p85 and  subunits of PI3K, leading to activation of the 
downstream kinase Akt and subsequent activation of the transcription factors NFAT and AP-1 
(242). Administration of the agonistic Tim-1 antibody 3B3 induces expression of early activation 
markers CD69 and CD25 as well as IL-2 production (242). Other groups have demonstrated that 
ligation of Tim-1 by Tim-4 can activate the ERK/MAPK pathway and enhance T cell survival by 
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upregulating the anti-apoptotic protein BcL-xL (224). Additional studies revealed that Tim-1 could 
co-cap with CD3 on human T cells (243). Tim-1 ligation on T cells has also been reported to 
induce tyrosine phosphorylation of the linker for activation of T cells (LAT) and the TCR-proximal 
Syk family tyrosine kinase Zap-70 (224). Taken together, these findings suggest that Tim-1 may 
interact with proximal TCR signaling complexes. 
 
 
2.4 TIM-3 (HAVCR2) 
2.4.1 Tim-3 expression 
Tim-3 is a 281-amino acid protein that was initially identified as Th1 specific marker (191). 
Surface Tim-3 is now known to be expressed by a wide range of innate and adaptive immune cell 
types, including Th17, regulatory T cells, CD8+, natural killer (NK) cells, macrophages, 
monocytes, DCs and mast cells (96, 224, 227, 240, 244-246). An alternatively spliced form of 
Tim-3 that lacks the mucin and transmembrane domains exists as a soluble protein and, similar to 
soluble Tim-1 and Tim-4, could have relevant biological roles (247, 248). Regulation of Tim-3 
expression requires the transcription factor T-bet (249). In addition, the mitogen-activated protein 
kinase (MAPK) is also involved in Tim-3 transcription in human CD4+ T cells and the human mast 
cell line HMC-1 (250). Recently, IL-27 was shown to cooperate with IL-10 to activate interleukin 
3 regulated nuclear factor (NFIL3), leading to chromatin remodeling of the Tim-3 locus and 
induction of Tim-3 expression in Th1 cells (251).   
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2.4.2 Tim-3 and Galectin-9  
Galectins, also called S-type lectins, are a family of carbohydrate-binding proteins expressed on a 
broad range of cell types and have crucial functions in regulating immune cell homeostasis and 
inflammation (252). Galectin-9 contains two distinct carbohydrate recognition domains connected 
by a long flexible linker, and exhibits enhanced affinity for poly-N-acetyllactosamine containing 
structure (253). IFN- and IL-1 can upregulate galectin-9 expression in various tissues (254-256). 
Localized to the cytoplasm, galectin-9 is secreted through an unclear mechanism and subsequently 
binds to glycoproteins on target cells to exert its function. Galectin-9 is highly expressed on mast 
cells, and also found on T cells, B cells, macrophages, endothelial cells and fibroblasts (252). In T 
cells, galectin-9 is predominantly expressed on naïve CD4+ T cells and CD4+CD25+ regulatory T 
cells. Upon activation, galectin-9 expression is down-regulated on effector T cells but maintained 
on Treg (257, 258). Galectin-9 can also induce cell death of thymocytes and peripheral CD4+ and 
CD8+ T cells through a calcium-calpain-caspase-1-dependent pathway (259, 260).  
Zhu et al showed that galectin-9 could bind to the IgV domain of Tim-3 in a glycosylation-
dependent manner, and this binding induced Th1 cell death through a mixture of apoptotic and 
necrotic events (261). It is worth noting that galectin-9 binding is promiscuous and thus is not 
exclusive to Tim-3. Indeed, galectin-9 can bind and induce cell death of both Tim-3-deficient and 
wild type Th1 T cells, suggesting that galectin-9 can mediate its signal through other receptors. In 
addition, Su et al showed that galectin-9 could either induce apoptosis or secretion of pro-
inflammatory cytokines, both of which occurred without Tim-3 activity (262). Furthermore, 
galectin-9 has been documented to interact with CD44 and IgE (263, 264). 
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Figure 2-4: Tim-3 IgV domain and predicted galectin-9 binding site. Tim-3 IgV domain structure was rendered using 
Cn3D, based on public database entry (PDB ID: 2OYP). Potential glycosylation and galectin-9 binding sites labeled 
labeled.  
 
  
2.4.3 Tim-3 as a PS receptor 
Tim-3 recognizes apoptotic cells by binding to PS via the FG loop of its IgV domain in a galectin-
9-independent binding site (194, 265). Unlike Tim-4 which is expressed by peritoneal resident 
Mac1+ (PRM) cells (266), Tim-3 is expressed by peritoneal exudate macrophages (26), suggesting 
different types of macrophages use different Tim molecules to mediate phagocytosis. Treatment 
with anti-Tim-3 Ab inhibited phagocytosis of apoptotic cells by peritoneal macrophages both in 
vitro and in vivo, leading to enhanced autoantibody production (265).  
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Tim-3 is expressed at high levels on CD8+, but not CD8-, splenic DCs. Antibody to Tim-3 
inhibited by approximately 50% both recognition of apoptotic cells and cross-presentation by 
CD8+ DCs (265), suggesting that the Tim-3:PS interaction is important in phagocytosis. Since PS 
recognition by Tim-3 on lymphocytes does not induce phagocytosis, it is possible that this 
interaction triggers a pro-apoptotic signal on T cells similar to that of galectin-9 to Tim-3 on Th1 
and Th17 (96, 261). 
2.4.4 Tim-3 and HMGB1 
HMGB1 (high mobility group protein B1) is a nuclear protein with essential roles in activating the 
innate immune responses mediated by the nucleic acid sensing systems (267, 268). In the nucleus, 
HMGB1 is a DNA-binding protein that acts to maintain genome stability and promote 
transcription, at the level of the chromatin (269). HMGB1 is translocated to the cytoplasm and 
released into the extracellular space, or can even by actively secreted, when cells are stressed, to 
regulate various aspects of immune responses, including inflammation, DC differentiation and 
autophagy (268, 269).  
Chiba et al reported that Tim-3 could regulate nucleic acid-mediated innate immune 
responses by competing with nucleic acids for the DNA-binding A box of HMGB1 (270). As a 
result, Tim-3 was able to inhibit transport of nucleic acids to the endosome, an event normally 
mediated by HMGB1. Similar to PS, HMGB1 was shown to bind through the metal-ion-dependent 
ligand-binding site (MILIBS) in the FG loop (270). When tested in a tumor model, Tim-3 blockade 
was able to enhance anti-tumor activity when DCs were cultured with dying tumor cells exposed 
to cisplastin, a chemotherapy agent that induces “immunogenic” cell death (270).  Thus, these 
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findings indicate that Tim-3 is a negative regulator of nucleic acid-mediated anti-tumor responses 
by circumventing HMGB1-nucleic acid transport pathways.  
 
2.4.5 Tim-3 and CEACAM1 
Recently, the carcinoembryonic antigen-related cell-adhesion molecule (CEACAM)-1 has been 
proposed as a ligand of Tim-3 (271). CEACAMs are expressed by epithelial, endothelial, 
lymphoid, and myeloid cells, and generally mediate intercellular adhesion through homophilic 
and/or heterophilic interactions (272). As a result, CEACAMs have well-established roles in tumor 
development, vascular neogenesis and apoptosis (272). CEACAM1 was detected at a low level on 
mouse T cells in the absence of inflammation as well as on resting human peripheral blood CD4+ 
T cells, and was rapidly upregulated on all T cells following stimulation with IL-2, IL-7, IL-15 or 
anti-CD3 antibody (272). It has also been shown that crosslinking of CEACAM1, by CEACAM1-
specific antibodies, homophilic trans-ligation by soluble CEACAM1-Fc or with CEACAM1-
transfected cells could inhibit T cell proliferation, cytokine production, and/or cytotoxicity (273-
275). The CEACAM1 protein consists of an amino-terminal domain, a membrane distal IgV-like 
domain, followed by up to three membrane-proximal immunoglobulin-constant-region-type-2-like 
(IgC2-like) domains. The extracellular domains of CEACAM1 are heavily glycosylated. 
Homophilic intercellular binding is facilitated by a non-glycosylated -sheet (276, 277). Huang et 
al demonstrated that CEACAM1 could mediate surface expression of Tim-3 by potentially 
interacting with Tim-3 in cis and trans through carbohydrate interaction between their extracellular 
domains (271). Furthermore, Tim-3 and CEACAM1 were co-expressed in a mouse model of 
OVA-induced tolerance, while CEACAM1-deficient CD4+ T cells had reduced surface expression 
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of Tim-3 (271). In a colorectal cancer model, a significant fraction of CD8+ tumor-infiltrating 
lymphocytes were triple positive for PD-1, Tim-3 and CEACAM1 and were characterized by 
extremely low levels of IL-2 and TNF-. Finally, co-treatment with anti-CEACAM1 and anti-
Tim-3 antibodies delayed tumor growth, with a greater level of protection than PD-1 and Tim-3 
co-blockade (271). Overall, these results identify another mode of negative regulation by Tim-
3/Tim-3L in immune regulation.  
2.4.6 Tim-3 as a negative regulator of T cell responses  
Initial studies using Tim-3 antibodies suggested that Tim-3 is a co-inhibitory molecule. For 
instance, administration of the anti-Tim-3 Ab (8B.2C12) during EAE induction exacerbated 
disease symptoms and increased the number of CD11b+ cells (191). Alternatively, treatment with 
a Tim3-Ig fusion protein resulted in hyper-proliferation of Th1 cells and increased Th1 cytokine 
production, possibly due to blockade of Tim-3/Tim-3L interaction (257). In addition, Tim-3 
blockade by Tim3-Ig fusion protein accelerated diabetes onset in nonobese diabetic (NOD) mice 
and abrogated tolerance induction by co-treatment of donor specific transfusion and anti-CD40L 
Ab, possibly due to interference with regulatory T cell activity (258). Together with findings that 
Tim-3-deficient mice could not be tolerized and that galectin-9 could bind to Tim-3 to induce Th1 
cell apoptosis, modulation of Tim-3/Tim-3L interaction emerged as a promising strategy to 
dampen Th1 responses and promote immunological tolerance. 
An early focus in deciphering Tim-3 functions was on its regulation of the autoimmune 
disease MS using the mouse model EAE. Tim-3 was expressed by Th1, but not Th2, T cells. 
During development of EAE in SJL mice immunized with the myelin proteolipid protein (PLP) 
peptide, Tim-3 was upregulated on CD4+ and CD8+ T cells, and to a lesser extent on CD11b+ cells. 
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MS pathogenesis is associated with dysregulation of Th1 responses and production of pro-
inflammatory cytokines IFN- and TNF-, and treatment with galectin-9 reduced the number of 
IFN-producing cells and disease severity (261).  
In humans, T cell clones isolated from cerebrospinal fluid of MS patients secreted higher 
levels of IFN- than clones from control cerebrospinal fluid, yet expressed a lower level of TIM-
3. Furthermore, reduction of Tim-3 expression by small interfering RNA or Tim-3 blocking 
antibodies increased the number of IFN-producing CD4+ T cells, thereby supporting a negative 
regulatory of human TIM-3 in MS (278). Using ex vivo CD4+ T cells from healthy subjects and 
patients with MS, it was shown that blocking Tim-3 activity during T cell stimulation enhanced 
IFN- production in healthy controls but not in MS patients, suggesting dysregulation of Tim-3 
regulatory pathway in MS. As a part of the dysregulated phenotype, Tim-3 in MS patients also 
exhibited reduced baseline level and delayed kinetics upon T cell stimulation, which could be 
rescued upon treatment with glatiramer and IFN-, therapies that are effective in a subset of MS 
patients (279). These studies have proposed a strategy for therapeutic restoration of Tim-3 
signaling pathway in correcting immunoregulation associated with MS.  
In recent years, much attention has been given to Tim-3 as a mediator of T cell dysfunction 
in chronic viral infection. Virus-specific T cells in chronic human immunodeficiency virus (HIV) 
and hepatitis C virus (HCV) progressively develops a series of deterioration of T cell responses: 
loss of proliferative potential, IL-2, cytotoxicity and subsequently IFN production, a phenomenon 
that is referred to as T cell exhaustion (280, 281). Initial studies suggested that sustained expression 
of several inhibitory molecules, including program death (PD)-1, upon T cell activation was 
responsible for T cell exhaustion. In fact, blocking the PD-1/PD-1 ligand interaction in 
lymphocytic choriomeningitis virus (LCMV) in mice, simian immune deficiency syndrome in 
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rhesus macaques, and HIV in humans, has been demonstrated to decrease viral load in vivo, and 
enhanced T cell survival and proliferation of antigen-specific CD8+ T cells (280-282). Tim-3 
expression on CD8+ T cells was associated with progressive HIV infection and correlated with 
disease progression (283). Specifically, there were two separate populations of Tim-3hi and Tim-
3lo CD8+ T cells with the Tim-3hi cells bearing the most diminished proliferative capacity and IFN-
 production, which could be reversed by treatment with soluble Tim-3-Ig (283). Consistent with 
their functional defects, Tim-3hi T cells had impaired Stat5, Erk1/2, and p38 signaling upon 
stimulation, but also had higher basal phosphorylation of these proteins, suggesting the exhausted 
phenotype in Tim-3hi T may be due to chronic basal activation rather than T cell unresponsiveness 
(283). More importantly, the Tim-3+ population is distinct from the PD-1+ population, thus raising 
the possibility of blocking both Tim-3 and PD-1 for effective anti-viral immune responses. In 
chronic HCV infection, Tim-3 expression was increased on both CD4+ and CD8+ T cells, and 
marked the cells with lower IFN- and TNF-producing capability. Similarly, Tim-3 mAb 
treatment could reverse defects in cytokine secretion (284). 
To understand how Tim-3 expression is correlated with viral infection, Jin et al followed 
Tim-3 expression on CD8+ T cells in acute and chronic LCMV infection (2010).  Tim-3 was 
transiently expressed and rapidly down-regulated by CD8+ T cells in acute infection, but was 
maintained throughout chronic infection. Furthermore, Tim-3 was mainly co-expressed with PD-
1 (PD-1+Tim-3+) on virus-specific CD8+ T cells, which represented the most exhausted phenotype 
compared to PD-1+Tim-3- population T (285). Specifically, the PD-1+Tim-3- population had three-
fold higher proliferative capacity and two-fold higher IFN-, TNF- and IL-2 secretion compared 
to the PD-1+Tim-3+ population in response to viral peptide GP33 stimulation. Since the PD-1+Tim-
3+ also secreted high amount of IL-10, it is possible that this IL-10 producing CD8+ population 
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may exert suppressive effects on further limiting CD8+ T cell responses. Finally, blockade of Tim-
3 synergized with anti-PDL1 treatment to reduce viral burden and enhance effector T cell functions 
(285). These findings further support a role of Tim-3 in T cell exhaustion and targeting Tim-3 and 
PD-1 as a more comprehensive reversal of T cell dysregulation.  
Subsequence studies went on to characterize the mechanisms of T cell dysregulation in 
chronic viral infection. Sakhdari et al showed that while Tim-3+ CD8 T cells in HIV infected 
patients expressed high levels of granule-associated perforin, these cells were not able to 
degranulate and properly kill HIV infected autologous CD4+ T cells (286). CD8+ T cell cytotoxicity 
and target lysis were enhanced to that of healthy controls when treated with anti-Tim-3 Ab. While 
the mechanism of negative regulation mediated by Tim-3 is not well-understood, evidence 
suggests that Tim-3 can be cleaved by the matrix metalloproteinase ADAM10, resulting in a 
soluble form of Tim-3 (287), and the level of soluble Tim-3 in human plasma correlates with HIV 
disease progression (288). As a result, soluble Tim-3, like Tim-1, may represent a new marker for 
HIV pathogenesis.     
Recently, much attention has been given to Tim-3 as an immune checkpoint receptor in 
tumor-induced immune suppression as Tim-3 was found on the most suppressed and dysfunctional 
tumor infiltrating CD8+ T cell (TILs) population in solid and hematologic malignancy (289, 290). 
In both of these models, PD-1+Tim-3+ TILs had defects in cell cycle progression and IL-2, IFN- 
and TNF- production. In the colon adenocarcinoma model, Sakuishi et al demonstrated that the 
highest frequency of IFN-producing cells belongs to the Tim-3-PD-1+ TILs, an indication that 
PD-1 can mark both exhausted and effector T cells. More importantly, splenic CD8+ T cells did 
not harbor co-expression of PD-1 and Tim-3, suggesting that environmental cues could drive 
expression of PD-1 and Tim-3 (289). In the disseminated acute myelogenous leukemia (AML) 
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model, Tim-3 and PD-1 co-expression was acquired at late phase of disease progression and 
exhibited an effector phenotype (CD62L-CD44+/hi) (290). Similar to TILs in solid tumors, Tim-
3+PD-1+ TILs in AML secreted the least amount of IL-2, IFN- and TNF- (290). Overall, the 
dysfunctional phenotype of Tim3+CD8+ T cells observed in tumor models resemble the exhausted 
CD8+ T cells in chronic viral infection. As a result, blocking both Tim-3 and PD-1 was able to 
inhibit tumor growth and reverse T cell exhaustion (289, 290).  
The clinical relevance of Tim-3 blockade in anti-tumor immunity was supported in findings 
that Tim-3 is also found on T cells in patients with cancer. In patients with advanced melanoma, 
30% of CD8+ T cells specific for the antigen NY-ESO-1 upregulated Tim-3 together with PD-1 
(291). Tim-3/Tim-3L blockade synergized with PD-1/PD-1L interference to increase the 
frequency of cytokine-producing (IFN, TNF-, IL-2) NY-ESO-1-specific CD8+ T cells (291). 
Tim-3 is also found on T cells of other cancers. Tim-3+ cells account for 30% of CD8+ TILs in 
patients with follicular B cell non-Hodgkin lymphoma (292). Tim-3 is highly expressed on CD4+ 
and CD8+ T cells in the tumors of patients with non-small cell lung cancer (NSCLC) and the 
majority of those Tim-3+ cells also express PD-1 (293). In all of these cancer types, Tim-3 is co-
expressed with PD-1 and its expression is associated with defects in proliferation and cytokine 
production. Furthermore, in NSCLC tumor-mediated suppression was correlated with an increased 
frequency of Tim-3+Foxp3+ regulatory T cells, a subset of regulatory T cells with enhanced 
immunosuppressive capacity that has been observed in transplantable and de novo tumors (289). 
Collectively these data provide evidence for Tim-3 as a negative regulator in immune suppression 
and strongly support the rationale for Tim-3 blockade in the treatment of various cancers and 
chronic viral infections. 
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2.4.7 Tim-3 as a positive regulator of T cell responses 
Recent studies of infectious diseases revealed that Tim-3 can also play a positive role in T cell 
effector responses to certain infections. Jayaraman et al showed that Tim-3 interaction with its 
ligand galectin-9 expressed on macrophages could stimulate macrophage activation and induce 
caspase- and IL-1-dependent bactericidal activity in response to Mycobacterium tuberculosis 
(Mtb) (294). When examining human patients with active TB, Qiu et al found that Tim-3 
expression was upregulated on both CD4+ and CD8+ T cells, which was associated with greater 
production of IFN ,TNF-, IL-2 and IL-22 than their Tim-3- counterparts (295). Furthermore, 
antibody cross-linking of Tim-3 on these T cells upregulated IFN- production, suggesting that 
Tim-3 signaling might actually contribute to enhanced anti-TB responses. 
Gorman et al recently showed that Tim-3 may also play a supportive role in CD8+ effector 
function in response Listeria monocytogenes infection (296). Thus, Tim-3 expression was 
transiently upregulated on CD8+ T cells after Listeria infection, and was required for acquisition 
of an effector T cell phenotype. Tim-3-deficient mice exhibited impaired primary and secondary 
responses to Listeria that correlated with decreased IFN- production and degranulation (296). 
When transferred into wild-type hosts, Tim-3-deficient CD8+ T cells displayed impaired expansion 
and produced less cytokines compared to wild type control T cells. Collectively, these reports 
illustrated that the Tim-3-mediated balance between positive and negative effects during an 
immune response in vivo is complex and may be dependent on the location, duration and sequence 
of ligands interactions to generate an enhanced or diminished T cell response. The discrepancy 
with earlier studies also highlighted the need to better understand molecular mechanisms of Tim-
3 effects on T cell activation and effector function. 
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2.4.8 Tim-3 and macrophages, monocytes, and dendritic cells 
In addition to its complex function on T cells, Tim-3 also appears to have opposing effects on 
innate immune cells. Tim-3 is constitutively expressed on splenic DCs and treatment with galectin-
9 synergized with TLR signaling to induce TNF- production, likely through induction of NF-B 
transcriptional activation (227). TIM-3 staining was evident in white - but not gray - matter 
parenchyma on microglia (which are monocyte-derived) in the central nervous system (CNS), and 
was higher on monocytes and microglia in MS lesions, compared to control tissue (227). Galectin-
9 expression is also upregulated on astrocytes in MS lesions relative to normal human CNS tissue. 
These findings suggest that TIM-3-galectin-9 interaction may help regulate Th1 responses. 
However, in mice immunized for induction of EAE, CD11b+ monocytes infiltrating the CNS and 
resident microglia upregulated Tim-3 expression compared to peripheral CD11b+ macrophages. 
Tim-3 antibody treatment actually exacerbated EAE disease severity (227).Thus, these initial 
studies demonstrated that Tim-3 activation could promote inflammation on innate cells, and 
dampen Th1 effector function once an adaptive immune response has been generated. 
Subsequently, Tim-3 has been found to negatively regulate TLR signaling in macrophages 
to control sepsis, since blocking Tim-3 activity or overexpression of Tim-3 in macrophages led to 
enhanced sepsis or suppressed macrophage responsiveness to TLR4 signaling, respectively (297). 
Recently, Tim-3 on tumor-infiltrating DCs was found to interfere with nucleic acid sensing by 
interacting with HMGB1 (270). TIM-3 is constitutively expressed on resting human peripheral 
blood CD14+ monocytes/macrophages and is down-regulated upon TLR stimulation to allow for 
both IL-10 and IL-12 induction (298, 299). Thus, Tim-3 expression was inversely correlated with 
IL-12 secretion by human monocytes/macrophages in HCV-infected individuals while Tim-3 
blockade or silencing Tim-3 expression could reverse IL-12 production, decrease PD-1 expression 
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and enhance Stat1 phosphorylation (298, 299).  These findings suggest that Tim-3 plays both 
positive and negative roles in regulating inflammation in innate immune responses in a ligand- and 
cell type-dependent manner. 
2.4.9 Tim-3 and natural killer (NK) cells 
Tim-3 also has opposing effects on NK cell function, which may be disease-specific. Tim-3 was 
identified as an activating co-receptor for NK cells, as galectin-9 treatment significantly induced 
IFN- production and Tim-3 blockade diminished IFN- production by activated human NK cells 
(300). Tim-3 is highly expressed on mature CD56dimCD16+ NK cells, and is further upregulated 
on CD56dimCD16- NK cells after stimulation with IL-15 or IL-12 and IL-18 in response to cytokine 
stimulation in vitro (301). While Tim-3 expressing NK cells are responsive to cytokine stimulation, 
cross-linking by Tim-3 antibodies can inhibit NK-mediated cytotoxicity (301). The presence of 
Tim-3+NK cells correlated with advancing stages of metastatic melanoma, and exhibited 
exhausted phenotypes characterized by decreased effector function, expression of activating 
receptors including NKG2D, and increased inhibitory receptors such as KIR3DL1. Similar to T 
cells, treatment with soluble antibodies to Tim-3 was able to reverse the exhausted NK cell 
phenotype and rescue cytokine production (302). Tim-3 was further described as an inhibitory 
modulator of NK cell function in LPS-induced endotoxic shock to restrain the excessive 
inflammation mediated by IFN-producing NK cells (303)). Finally, Wang et al showed that Tim-
3 expression was upregulated on NK cells of patients with active TB, which correlated with 
impaired activation, degranulation and cytokine secretion (304). As NK cells activation utilizes a 
combination of inhibitory and activating co-receptors, it is important to examine how combined 
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Tim-3 engagement with specific NK cell co-receptors affect the functional outcome of NK cells 
in a particular disease setting.  
2.4.10 Tim-3 and mast cells 
Tim-3 is constitutively expressed on bone marrow-derived mast cells (BMMCs) and peritoneal 
mast cells (PMCs) and expression was increased six hours post IgE-sensitized antigen-mediated 
(IgE/Ag) activation (240). Cross-linking of Tim-3 with a polyclonal Ab was able to enhance 
antigen-induced IL-4, -5 and -13 production and to rescue IL-3-withdrawal-induced apoptosis in 
IgE/Ag-activated BMMCs, possibly by promoting IL-3 secretion from activated BMMCs. 
Nevertheless, Tim-3 cross-linking had no effect on mast cell degranulation (240). Transforming 
growth factor beta (TGF-) has been shown to upregulate expression of Tim-3 in tumor infiltrating 
mast cells and a human mast cell line, through a mitogen-activated protein kinase Erk-kinase 
(MEK)-dependent pathway (305).  
2.4.11 TIM-3 polymorphisms and association with allergic and autoimmune diseases 
There are seven predicted amino acid differences between BALB/c and HBA Tim-3, and these 
polymorphisms cluster in the Ig domain (190). In fact, the allelic variants of BALB/c Tim-3 found 
in the BC loop of the IgV domain were responsible for the enhanced PS binding and phagocytosis 
of apoptotic cells compared to HBA Tim-3, likely by enhancing interaction with the surface of the 
lipid bilayer of the target cell (194). These initial results suggested that Tim-3 polymorphisms may 
have functional consequences in regulating Th1/Th2 responses.  
 51 
Since the initial studies of DeKryuff and colleagues, many epidemiological studies have 
been conducted to determine if TIM-3 polymorphisms could affect human allergic and 
autoimmune diseases. In rheumatoid arthritis (RA), a Th1/Th17-mediated disease, there was an 
inverse correlation between TIM-3 expression and disease activity score. In addition, 
polymorphisms in the signal sequence and IgV domain were associated with RA in two Korean 
populations and a Chinese population (212). While the link was not as strong as in the case of 
TIM-1, TIM-3 polymorphisms have also been associated with susceptibility to Th2-mediated 
allergic disease. The -574T allele in the signal sequence was found only in asthma and allergic 
rhinitis patients, while the 4259T allele, which is close to the mucin region, was found more 
frequently in rhinitis patients in a Korean population. Meanwhile, another study of children from 
white or Hispanic parents found that two other polymorphisms, one in the signal sequence and one 
in the transmembrane domain, were associated with atopic dermatitis (212). Thus, many studies 
have documented the association of Tim-3 polymorphisms in atopy and autoimmunity in certain 
population, and Tim-3 may have an indirect effect on Th2 responses, due to its regulation of Th1 
activity.  
2.4.12  Tim-3 signaling 
The cytoplasmic tail of Tim-3 contains six conserved tyrosine residues, some of which have been 
shown to couple to intracellular signaling pathways downstream of TCR/CD3, including data from 
our previous study (212, 306, 307). Specifically, Lck and the related Src family tyrosine kinase 
Fyn can interact with Tim-3, and Fyn can directly phosphorylate tyrosines within the Tim-3 
cytoplasmic tail (308). Tim-3 phosphorylated in the region around tyrosines 256 and 263 can then 
recruit SH2-domain containing proteins including Fyn and the adaptor p85 of PI3K to mediate 
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downstream signaling (308). In addition, the Tec family kinase Itk has also been associated with 
Tim-3 phosphorylation at tyrosine 265 (tyrosine 256 in mouse) upon galectin-9 binding (307). 
Contrary to its apparent inhibitory role in vivo, ectopic expression of Tim-3 in human and murine 
T cell lines augmented CD3/CD28-stimulated NF-B and NFAT/AP1 activation in a manner that 
was dependent on the Tim-3 cytoplasmic tail, particularly residues Y256 and Y263 (308). 
Consistent with enhanced transcriptional activity, Tim-3 expression enhanced phosphorylation of 
PLC1, ERK and ribosomal protein S6 downstream of the PI3K/Akt/mTOR pathway (308). In 
terms of T cell effector function, Tim-3 co-stimulation of TCR stimulation in primary murine T 
cells induced IFN production in a manner dependent on its cytoplasmic tail, and could be blocked 
by treatment of a Tim-3 mAb (308). Overall, these results indicated that, under acute stimulation, 
Tim-3 enhances signaling pathways leading to T cell activation, and can exert its effects without 
addition of exogenous ligands. Thus, these findings are in contrast to the role of Tim-3 as largely 
a negative regulator in vivo and will require further investigation to bridge these opposing findings.  
Tim-3 has been shown to interact with the chaperone protein human leukocyte antigen B 
(HLA-B)-associated transcript 3 (Bat3) (309). Binding of Bat3 to Tim-3 cytoplasmic tail was able 
to prevent galectin9-mediated Th1 cell death and enhance IFN production. Since Bat3 can inhibit 
Tim-3 activity on Th1 cells, loss of Bat3 resulted in significant upregulation of surface Tim-3, 
reduced EAE severity and increased expression of exhaustion-associated markers (309). In terms 
of signaling mechanisms, Bat3 was reported to associate with the catalytically active form of Lck 
in a Tim-3-dependent manner (309). While Bat3 may be able to regulate Tim-3 expression and 
activity at a TCR-proximal level, it will be important to determine how TCR signaling can 
modulate the Tim3-Bat3 interaction.  
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A recent study on TIM-3 coordination in the formation of immunological synapse and 
proximal TCR signaling revealed that TIM-3 was recruited to the synapse and interacted with Lck 
in primary human CD8+ T cells (306). Specifically, Tim-3 recruitment was mediated by the 
phosphatases CD45 and CD148, and was enhanced by galectin-9 (306). As a result, Tim-3 may 
mediate its inhibitory function proximal to the TCR, by associating with phosphatases to disrupt 
synapse stability, since treatment with an antagonistic Tim-3 antibody resulted in more T cell-B 
cell conjugates with stable synapse (306).   
 
2.5 TIM-4 
Tim-4 was identified independently as SMUCKLER (spleen, mucin-containing, knockout of 
lymphotoxin), a gene downregulated in lymphotoxin (LT)- and LT-deficient mice (310). In the 
immune system, Tim-4 is expressed exclusively on antigen presenting cells, particularly 
macrophages and mature lymphoid DCs (195). Human TIM-4 is expressed by tingle-body 
macrophages in the germinal centers of tonsils and white pulp of spleen (214). Tim-4 is also a 
receptor for PS and has been shown to facilitate uptake of apoptotic thymocytes by mouse 
peritoneal macrophages via the conserved FG-CC’ binding cleft in the IgV domain (214). Tim-4 
was proposed to be a specific ligand of Tim-1, although Tim-1 and Tim-4 may bind to separate 
sites of PS-containing exosomes and thereby giving the appearance of an interaction (195, 266).  
Unlike other Tim proteins, the cytoplasmic tail of Tim-4 lacks any defined signaling motifs 
and may therefore only function as a ligand, rather than a signaling receptor (190). Treatment with 
Tim4-Ig co-stimulated T cell proliferation in vitro and enhanced T cell hyperproliferation in vivo 
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(195). However, it should be noted that the effects of Tim-4 on T cell responses may be context-
dependent, since Tim4-Ig was inhibitory to T cell proliferation at weak TCR stimulation, while 
acting as a co-stimulator under conditions of strong TCR stimulation (195). In terms of signal 
transduction, Tim4-Ig was shown to induce tyrosine phosphorylation of multiple substrates in T 
cells, as well as activation of Akt and ERK (224). Tim-4 can also play an active role in 
development of food allergy. Feng et al showed that exposure of bone marrow-derived DCs to 
cholera toxin and peanut extract upregulated Tim-4 expression and resulted in production of 
antigen-specific IgE and Th2 skewing in the intestine, when the pre-conditioned DCs were 
transferred to naïve mice (2008). Furthermore, pretreatment with anti-Tim-1 or anti-Tim-4 
antibody was able to abrogate the Th2-skewed response. Similar effects were observed in an 
intestinal model of OVA and Staphyloccoccus enterotoxin B allergy induction (311).  
2.6 TIM-2 
The Tim-2 molecule has 85% nucleotide sequence identity with Tim-1, and is unique within the 
Tim family in that it does not have an ortholog in humans. In addition, Tim-2 does not possess the 
unique MILIBS pocket that confers specificity for phospholipid binding (193). Tim-2 is expressed 
mainly on APCs, including B cells and dendritic cells, as well as on non-immune cells of the bile 
duct epithelial in the liver, and hepatocytes (312). Tim-2 is not detected on naïve or activated T 
cells but is preferentially expressed on Th2-polarized T cells (313). Staining with a Tim2-Ig fusion 
protein identified Tim-2 ligands on activated DCs and macrophages (313). Indeed, Tim-2 was first 
identified to bind to the class IV semaphorin, Sema4A, a transmembrane protein expressed by DCs 
and B cells that can enhance T cell proliferation and cytokine production (198). Tim-2 was later 
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shown to facilitate uptake of H-ferritin, an iron-storing spherical protein complex that can regulate 
both non-immune and immune events (314). Crystal structure evidence revealed that Tim-2 can 
dimerize, which may prevent binding to other Tim proteins and facilitate binding of multivalent 
ligands (193).  
Studies using Tim-2-Ig or Sema4A-Ig fusion proteins have identified Tim-2 as a Th2 
regulatory molecule. In vivo administration of Tim-2-Ig resulted in splenic cell hyperproliferation, 
enhanced production of cytokines (IL-2, IL-4 and IL-10) and a delayed onset of clinical signs in 
an EAE model (313). In fact, Tim-2-Ig given just before disease onset could still reduce the 
symptoms of EAE. Based on the mechanisms proposed for Tim-3/Tim-3L, discussed above, it is 
possible that interaction of Tim-2 with its ligand(s) triggers inhibitory signals to downregulate Th2 
responses. Thus, blocking this interaction could alter the balance of Th1/Th2 response even in a 
Th1-biased environment. Similarly, Sema4A-Fc could drive induction of both IFN- and IL-4-
producting T cells, while anti-Sema4A antibody suppressed development of MOG-induced EAE 
when given at the time of MOG immunization (198). These protective effects were attributed to 
interaction with Tim-2, since Sema4A-deficient mice have impaired Th1 responses, and Tim-2-
deficient T cells proliferated more than wild type T cells in response to antigen (315). The role of 
Tim-2 in negative regulation of Th2 responses was supported by the observation that Tim-2 
knockout mice showed exacerbated lung inflammation (315). Moreover, biochemical analysis 
demonstrated that ectopic expression of Tim-2 could downregulate NFAT/AP1 transcriptional 
activity (316). Taken together, these findings demonstrate that Tim-2 expression on Th2 cells can 
modulate expansion and induction of Th2 responses.  
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3.0  STATEMENT OF THE PROBLEM 
Ample evidence suggest that TIM family proteins have distinct expression patterns on a variety of 
cell types of both the innate and adaptive immune response. The task of deciphering how Tim-1 
and Tim-3 function is complicated by the fact that they can each interact with multiple ligands or 
even with other TIM family members via their heavily glycosylated mucin regions (195, 219). As 
a result, the precise mechanisms of immunoregulation by Tim-1 and Tim-3 are not entirely clear 
and appear to be context- and ligand-dependent.  
      The Tim genetic locus was identified in a region of tightly linked genes that are 
implicated in asthma susceptibility (190). Since then, many studies have been conducted to 
determine how Tim-1 and Tim-3 modulate the balance between Th1/Th2 responses, especially 
since polymorphisms in Tim-1, and to a lesser extent Tim-3, are associated with differential 
susceptibility to atopy, allergy, viral infection and autoimmune diseases. In addition to T cells, 
Tim-1 and Tim-3 have also been found to regulate the function of innate cells, with critical roles 
in not only allergic inflammation and autoimmunity, but also in tumorigenesis and angiogenesis.  
One of these innate cell types with high constitutive Tim-1 and Tim-3 surface expression 
is mast cells, which are first-line defenders against allergens and invading pathogens due to their 
proximity to the external environment. Antigen cross-linking of IgE bound to the high affinity IgE 
receptor FcRI leads to the release of pre-formed mediators and de novo synthesis of pro-
inflammatory and anti-inflammatory mediators and cytokines, which together serve to regulate 
hypersensitivity, autoimmunity, cardiovascular disease and tumor progression (317). In addition 
to their well-known pathologic roles in allergic responses, mast cells also contribute to defense 
against bacteria, helminths and tumors (318). While previous data suggest that Tim-1 and Tim-3 
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can function as positive regulators of mast cell activation, the molecular mechanisms behind their 
contribution to mast cell function are still unknown. Importantly, there was until now no genetic 
evidence addressing the function of Tim-1 and Tim-3 in these cells.  
We hypothesized that Tim-1 and/or Tim-3 are costimulatory molecules of mast cell 
activation through FcRI signaling to enhance mast cell mediator release. We plan to investigate 
the requirement of Tim-1 and Tim-3 in Ag-induced mast cell activation and how antibody 
modulation affects their activity on mast cells. Tim-1 and Tim-3 have been implicated in TCR 
proximal signaling (195, 219, 222, 242, 306-308, 319). Similarly, we intend to decipher the 
molecular mechanisms of Tim-1 and Tim-3 signaling at both the FcRI proximal level and its 
downstream pathways. Specifically, we will determine whether mast cell Tim-1 and Tim-3 involve 
Src family tyrosine kinases and adaptor molecules similar to those in T cells as a mean of activation 
and signal transduction leading to enhanced cytokine production. Finally, we will examine the role 
of Tim-1 and Tim-3 in vivo, using a mast cell-dependent passive cutaneous anaphylaxis model. 
The results of these studies may identify one or more novel signaling pathways leading to mast 
cell activation by Tim-1 and Tim-3. Given the interest in immunotherapies targeting Tim-1 and 
Tim-3, and the multifunctional role of mast cells, characterization of Tim-1 and Tim-3 regulation 
of mast cell function could lead to development of more effective therapies to combat cancer, 
allergy and autoimmune disease.  
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4.0  TIM-3 CROSS-LINKING ENHANCES CYTOKINE PRODUCTION AND 
DEGRANULATION IN FCEPSILON-MEDIATED ACTIVATION OF BONE 
MARROW-DERIVED MAST CELLS 
4.1 INTRODUCTION 
Antibody(Ab)-mediated functional studies have led to the identification of Tim-3 as an essential 
regulator of immune functions. Treatment with Ab’s to Tim-3 have been effective in blocking 
Tim-3 interaction with its ligands, leading to either exacerbated disease in T cell-mediated 
autoimmune settings, induction of peripheral tolerance, or reversal of T cell exhaustion in chronic 
viral infection and cancer (191, 257, 258, 261, 278, 284, 285, 289-291). On the other hands, 
antibody ligation of Tim-3 on innate cells could either promote monocyte activation in EAE, 
enhance DC-mediated anti-tumor efficacy, or inhibit NK cell activation (227, 301, 302, 320). Thus, 
antibodies to Tim-3 can be viewed as agonistic or antagonistic, depending on the cell types and 
ligands of interest.  
Tim-3 is expressed constitutively by mast cells and can be engaged with a polyclonal Ab 
(Tim3 pAb) to enhanced FcRI-mediated cytokine production (96). Here we examined the ability 
of other anti-Tim3 antibodies to co-stimulate FcRI-mediated mast cell activation. In addition, we 
determined whether the effects of Tim-3 antibodies on mast cells might be the result of 
crosslinking-induced co-stimulatory activity or, as postulated in most T cell studies, an effect of 
Tim-3 “blockade.” Our data show that, upon antigen (Ag) ligation, treatment with Tim-3 
antibodies enhances both mast cell degranulation and cytokine production. In addition, through 
analyzing mRNA expression data available from public database, we have compiled a list of genes 
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in mast cells that can be modulated by Tim-3 pAb cross-linking alone or in conjunction with FcRI 
activation. 
4.2 MATERIALS AND METHODS 
4.2.1 Antibodies and reagents 
Monoclonal anti-dinitrophenyl (DNP) antibody, IgE isotype, clone SPE-7, DNP32 –HSA, 4-
Nitrophenyl N-acetyl-β-D-glucosaminide (pNAG) were from Sigma-Aldrich (St. Louis, MO). 
Purified polyclonal antibody (Tim-3 pAb), directly fluorescent conjugated antibody to murine 
Tim-3, and normal goat IgG control were from R&D Systems (Minneapolis, MN). Purified mouse 
IgG control and mouse Fc block (clone 2.4G2) were from BD Biosciences (San Jose, CA). 
Monoclonal antibodies to murine Tim-3 (5D12, 3E3, 1B6) were obtained from Vijay Kuchroo 
(Harvard Medical School). Ionomycin was purchased from Calbiochem/EMD Biosciences (San 
Diego, CA) 
4.2.2 BMMC isolation and culture 
Bone marrow cells from C57BL/6 wild-type (WT) and knockout (KO) mice were cultured in 
RPMI 1640 supplemented with 10% BGS, non-essential amino acid, 2-ME, HEPES, pen/strep-
glutamine, and 20% IL-3-conditioned media for 4-6 weeks, after which >90% of viable cells are 
mature mast cells (c-kit+ FcRI+ by flow cytometry). 
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4.2.3 BMMC stimulation and cytokine measurement 
BMMCs were sensitized with 1 g/ml IgE overnight in complete media without IL-3. Cells were 
then stimulated either with DNP32-HSA or DNP5-BSA in IL-3-free media for indicated times. 
Supernatants were assayed for murine IL-6 and TNF- by ELISA (BioLegend) six or twenty-four 
hours post-stimulation.  
4.2.4 Mouse cytokine array 
BMMCs were sensitized with IgE and stimulated with 30 ng/ml DNP32-HSA in conjunction with 
either 5 g/ml isotype control or Tim3 pAb for six hours. Supernatant was collected and subjected 
to analysis of cytokine release using the Proteome Profiler Mouse Cytokine Array Kit, Panel A 
(R&D Systems).  
4.2.5 Beta-hexosaminidase release and flow cytometry assays for mast cell degranulation 
BMMCs (2.5 x105 cells) were stimulated as described above in Tyrode’s buffer (135 mM NaCl, 5 
mM KCl, 5.6 mM glucose, 1.8 mM CaCl2, 1 mM MgCl2, 20 mM HEPES, 0.5 mg/ml BSA). Thirty 
minutes post-stimulation, supernatants (stimulated release) were collected and cells were lysed 
with 200 l of 0.5% Triton-X100 in PBS for fifteen minutes on ice. 20 l each of lysate (content) 
and stimulated release were mixed with 20 l of 1 mM pNAG substrate for 1 hour at 37oC. 
Reaction was stopped by addition of 200 l of carbonate buffer (0.1M , pH 9.0) and absorbance 
was read at 405 nm. Percentage of beta-hexosaminidase release was calculated using the following 
equation: % release was calculated as (releasestimulated/contenttotal) x 100.  
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Measurement of degranulation by flow cytometry was conducted as previously described 
(321, 322). Briefly, BMMCs were loaded with 0.1 M of Lysotracker Deep Red (Invitrogen) for 
thirty minutes at 370C and then sensitized with 1 g/ml IgE for one hour. Receptor cross-linking 
was induced by addition of DNP32-HSA at indicated concentration or 2 M ionomycin as positive 
control for ninety minutes prior to Annexin V staining (BioLegend). %degranulation is determined 
as percentage of BMMCs that is AnnexinV+Lysotrackerlo.  
4.2.6 Microarray analysis from data available on GEO public database 
 The GEO dataset series GSE 14438 was obtained from National Center for Biotechnology 
Information (NCBI). Briefly, mouse in vitro-differentiated mast cells (BMMCs) were stimulated 
with Tim-3 pAb, isotype control alone or co-stimulated with IgE/Ag for two and sixteen hours 
prior to analysis with The Agilent Whole Mouse Genome Microarray kit. The NextBio platform 
(Illumina, Santa Clara, CA) was used to compare gene expression profile from the indicated 
stimulation conditions. The top genes with at least two-fold induction as a result of Tim3 pAb 
addition compared to isotype control were listed.  
4.2.7 Statistical analysis 
All statistical analysis was performed using Prism software (GraphPad Software). Paired, two-
tailed Student’s t-test, one-way and two-way ANOVA with Bonferroni post hoc test were used for 
data analysis and determination of p values, as appropriate. 
 
 62 
4.3 RESULTS 
4.3.1 Tim-3 antibodies enhance IgE/Ag-mediated cytokine and chemokine production in 
BMMCs  
Nakae et al tested several antibodies for potential binding to Tim-3 and functional effects on mast 
cell activation (240). We confirmed that Tim-3 pAb enhanced IL-6 secretion in IgE/Ag-stimulated 
bone marrow-derived mast cells (BMMCs) six and twenty-four hours post stimulation (Fig.4-1A). 
In testing other Tim-3 antibodies, we found that 5D12, an antibody that is thought to antagonize 
the inhibitory activity of Tim-3 in T cells (227, 308), was able to enhance mast cell IL-6 and TNF-
 cytokine release in BMMCs, albeit not to the same extent as a polyclonal Tim-3 Ab (pAb) (Fig.4-
1B). We also determined that the 5D12 antibody alone does not induce cytokine production by 
mast cells (Fig.4-1C). Another, less well-characterized, monoclonal antibody (3E3) also exhibited 
co-stimulatory activity when combined with IgE/Ag treatment (Fig.4-1D). Finally, the monoclonal 
1B6 antibody was not able to induce a statistically significant increase in mast cell activation 
(Fig.4-1E). Fc receptors, including FcRIIB, are expressed abundantly on mast cells and have 
been shown to inhibit the induction of cellular activation programs in an ITIM-dependent manner 
(323). Therefore, we compared IL-6 release by BMMCs as above, with or without addition of an 
FcR-blocking mAb. While FcR binding was not a factor at the concentrations of Tim-3 pAb 
used throughout this study (5 g/ml), blocking Fc receptor binding to the Tim-3 mAb 5D12 
actually further enhanced the agonistic effect of this antibody (Fig.4-2). Thus, the ability of Tim-
3 antibodies to enhance mast cell activation was not due to FcR binding.  
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Figure 4-1: Tim-3 antibodies enhance IgE/Ag-mediated IL-6 and TNF- production in BMMCs. BMMCs were 
sensitized with IgE overnight, then stimulated with either antigen alone, antigen with Tim-3 pAb, or isotype control 
for six and twenty-four hours (A). BMMCs were stimulated as indicated with antigen, antigen with Tim-3 pAb, mAb’s 
5D12, 3E3, 1B6, or the respective isotype controls, for six hours (B. Culture supernatants were collected and analyzed 
for IL-6 (left panels) or TNF- (right panels) by ELISA. Results shown are representative of three independent 
experiments performed in duplicates. *p < 0.05, **p < 0.005, ***p < 0.0005.  
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Figure 4-2: Tim-3 antibodies modulate mast cell activation independently of FcRI signaling. BMMCs were sensitized 
and stimulated for six hours with antigen, in the presence of isotype control, Tim-3 pAb (A) or 5D12 (B), with or 
without Fc block (2.4G2). Supernatants were harvested and analyzed by ELISA for IL-6. Results shown are based on 
duplicate samples and are representative of two independent experiments. ***p < 0.0005.  
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4.3.2 Tim-3 antibody cross-linking exerts a modest but significant effect on IgE/Ag- 
mediated degranulation in BMMCs 
As demonstrated before (240), Tim-3 antibodies did not affect Ag-induced mast cell degranulation 
as read-out by beta-hexosaminidase release thirty minutes after stimulation (Fig. 4-3A) . However, 
we were able to detect a small, but significant, increase in the percentage of mast cells 
degranulating at ninety minutes after stimulation, using a flow cytometry-based assay (Fig. 4-3B). 
In addition to yielding a higher signal-to-noise ratio that allowed for more accurate assessment of 
IgE/Ag-induced degranulation, this assay revealed that engagement of Tim-3 may need to be 
maintained for an extended period of time to mediate this particular co-stimulatory activity.  
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Figure 4-3: Tim-3 pAb enhances IgE/Ag-mediated degranulation in mast cells. BMMCs were sensitized overnight 
with IgE, stimulated with DNP32-HSA alone or together with isotype control, or Tim-3 pAb, for thirty minutes. 
Degranulation was assessed by measurement of beta-hexosaminidase release (A); alternatively, cells were labeled 
with Lysotracker Deep Red, sensitized with IgE for one hour, and stimulated with antigen in the presence of isotype 
control or indicated amount of Tim-3 pAb for ninety minutes prior to Annexin V staining and flow cytometry analysis 
(B). Results shown are average of three independent experiments performed in triplicates (A) and duplicates (B). **p 
< 0.005.   
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4.3.3 Tim3 pAb co-stimulates protein and gene expression of various mast cell mediators 
upon FcRI cross-linking 
Mast cells can secrete a wide range of pre-formed and de novo synthesized mediators upon 
activation through its antigen receptor (32). To determine if the increase in cytokine production is 
specific IL-6 and TNF-, we examined other mast cell products that may be affected by Tim3 pAb 
using a mouse cytokine array. Antigen stimulation alone induced production of well-known mast 
cell cytokines and chemokines including IL-6, IL-13, TNF-, CCL2, and CCL3 (Fig.4-4A). While 
we did not detect expression or enhancement of IL-6 and TNF, addition of Tim3 pAb induced 
production of a slightly different mediator profile including IL-7, IL-1, IL12p70, CCL4, and 
CCL12 (Fig.4-4B). In addition, we found a microarray study conducted to determine the genes 
affected by Tim-3 ligation alone or in co-stimulation with Ag (324). Thus, using the NextBio gene 
analysis platform, we observed that Tim-3 pAb alone induced a distinct gene expression profile 
compared to isotype control alone or IgE/Ag and Tim3 pAb co-treatment (Table1-4). Notably, the 
olfactory receptors, a family of G-protein-coupled receptors primarily expressed on the cell 
membrane of olfactory sensory neurons of the nasal epithelium for detection of odorant molecules 
(325), were robustly induced by Tim3 pAb alone (Table 1, 3). As the role of olfactory receptors 
on non-sensory cells are unknown, it remains to be seen whether olfactory receptor expressions on 
mast cells are functionally competent.  
On the other hand, IgE/Ag and Tim3 pAb co-stimulation in just two hours enhanced 
expression of well-known mast cell mediator genes coding for IL-6, TNF, CCL2, and GM-CSF 
(Table 2). Of note, mast cell-derived amphiregulin, an epidermal growth factor (EGF)-like growth 
factor, has been shown to be critical for suppressive function of regulatory T cells in anti-tumor 
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responses (326). Tim-3 pAb co-stimulation showed almost six-fold induction of amphiregulin 
compared to isotype treatment, suggesting that engagement of Tim-3 on mast cells may indirectly 
influence anti-tumor activity through effects on regulatory T cells (Table 2). Mast cell IL-2 gene 
expression was also upregulated over six-fold two hours post Ag stimulation, and thus represents 
another potential mechanism of mast cell modulation of T cell responses. Specifically, IL-2 
secretion by mast cells is required for maintaining a balance between activated and regulatory T 
cells in suppression of chronic allergic skin inflammation (67). These results suggested that Tim-
3 engagement can modulate release of a plethora of mediators that contribute to the multifunctional 
role of mast cells in the immune system. 
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Figure 4-4: Tim3 pAb enhances a distinct pattern of mast cell cytokine production. BMMCs were sensitized with IgE 
and stimulated with 30 ng/ml DNP32-HSA, with either 5 g/ml isotype or Tim3 pAb for six hours. Supernatant was 
collected and subjected to analysis of cytokine release using the Proteome Profiler Mouse Cytokine Array Kit, Panel 
A (R&D Systems). 
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Table 1: Gene expression induced by Tim-3 pAb stimulation alone for two hours  
 
 
Table 2: Gene expression induced by IgE/Ag and Tim-3 pAb co-stimulation for two hours 
Gene name Gene ID  Fold Change                                Notes 
Csf2 NM_009969 10.6       GM-CSF 
Il6 NM_031168 6.84  
Il31 AK005939 6.84  
Ptgs2 NM_011198 6.53 prostaglandin-endoperoxide synthase 2 
Ccl3 NM_011337 6.46  
Il2 NM_008366 6.09  
Areg NM_009704 5.75 Amphiregulin 
Map3k8 NM_007746 5.61 Tpl-2 
Tnf NM_013693 5.5 TNF𝛼 
Ccl2 NM_011333 5.17  
Il3 NM_010556 5.16  
Hbegf NM_010415 5.15 heparin-binding EGF-like growth factor 
Il11 NM_008350 4.55  
Il4 NM_021283 4.46  
Il13 NM_008355 3.12  
Gzmd NM_010372 2.98 Granzyme D 
Ifng NM_008337 2.8  
 
 
    Gene name        Gene ID    Fold change           Notes 
Olfr1015 NM_146571 6.45 Olfactory receptor 1015 
Gm8630 AK083177 3.98 Predicted gene 8630 
6530403H02Rik AK032656 3.94  
Ptprn2 NM_011215 3.61 Protein tyosine phosphatase 
Defb37 NM_181683 3.46 Defensin beta 37 
Opn1mw NM_008106 2.94 Opsin 1  
Olfr112 NM_001013575 2.68  
Lphn3 latrophilin 3 2.67 Latrophilin 3 
Wdr96 AK014581 2.5 WD repeat domain 96 
Ccl3 NM_011337 2.45  
Ccl2 NM_011333 2.31  
Fasl NM_010177 1.94  
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Table 3: Genes expression induced by Tim-3 pAb stimulation alone for sixteen hours  
Gene name Gene ID 
Fold 
Change Notes 
Lrp1b AK082259 6.13 low density lipoprotein-related protein 1B  
Olfr1015 NM_146571 4.25 olfactory receptor 1015 
Defb37 NM_181683 4.18 defensin beta 37 
Pigt NM_133779 3.99 phosphatidylinositol glycan anchor biosynthesis 
Cpm AK087332 3.41 carboxypeptidase M 
Efcab1 AK030381 3.03 EF hand calcium binding domain 1 
Cntnap2 AK043714 2.96 contactin associated protein-like 2 
Rapgef4 NM_019688 2.62 GEF4 
Stk32a AK042850 2.53 serine/threonine kinase 32A 
Olfr112 NM_001013575 2.44 olfactory receptor 112 
Grn NM_008175 2.39 Granulin 
Olfr1499 NM_146796 2.3 olfactory receptor 1499 
Jakmip1 NM_178394 2.24 
janus kinase and microtubule interacting protein 
1 
Cnr1 NM_007726  cannabinoid receptor 1 (brain) 
Csf2rb AK154286 2.04 GM-CSF receptor beta 
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Table 4: Gene expression induced by IgE/Ag and Tim-3 pAb co-stimulation for sixteen hours  
 
 
4.4 DISCUSSION 
The main focus of this study was to determine how Tim-3 engagement by antibodies modulates 
mast cell activation and mediator release. This is a relevant issue, as various Tim-3 antibodies have 
been used in pre-clinical models, and are being considered for clinical use as immunotherapeutic 
agents (327, 328). Consistent with a previous report that Tim-3 pAb could co-stimulate FcRI-
Gene name Gene ID Fold change Notes 
1600029D21Rik NM_029639 7.22 RIKEN cDNA 1600029D21 gene 
Cd209a NM_133238 4.66 CD209a antigen 
Ccl1 NM_011329 4.29  
Gm8630 AK083177 4.02 predicted gene 8630 
Gzmd NM_010372 3.95 granzyme D 
Ccl17 NM_011332 3.74  
Cntnap2 AK043714 3.73 contactin associated protein-like 2 
Aqp1 NM_007472 3.57 aquaporin 1 
Lrp4 NM_172668 3.5 low density lipoprotein receptor-related protein 4 
Sucnr1 NM_032400 3.49 succinate receptor 1 
Prss12 NM_008939 3.38 Motopsin 
Opn1mw NM_008106 3.32 Opsin 1 
Lrp1b AK082259 3.21 low density lipoprotein-related protein 1B  
Ptprn2 NM_011215 3.08 protein tyrosine phosphatase 
Olfr112 NM_001013575 3.02 olfactory receptor 112 
Dnahc12 XM_976110 2.95 Dynein 
Angpt1 AK035599 2.94 Angiopoietin 1 
Prss37 NM_026317 2.83 Serine protease 37 
Ramp2 NM_019444 2.82 Calcitonin receptor  activity modifying protein 2 
Hkdc1 NM_145419 2.77 hexokinase domain containing 1 
Ccl24 NM_019577 2.53  
Entpd1 NM_019577 2.52 ectonucleoside triphosphate diphosphohydrolase 1 
Il33 NM_133775 2.29  
NM_024435 NM_024435 2.24 neurotensin 
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stimulated IL-4, IL-5 and IL-13 (240), we showed that this co-stimulation occurred in a dose-
dependent fashion. We also identified other Tim-3 antibodies that could up-regulate Ag-stimulated 
cytokine production to varying degrees, notably the monoclonal antibody 5D12, which has often 
been used as an “antagonist” in studies of Tim-3 function in T cells (329-331).  
Our decision to focus on Tim-3 engagement by antibodies was based in part on the non-
specific binding of known Tim-3 ligands to other molecules on mast cells. Thus, 
phosphatidylserine (PS) can bind to several Tim family members besides Tim-3, including Tim-1 
and Tim-4, through a conserved binding pocket in the Ig domain (332), in addition to binding to 
other cell surface receptors (333, 334). Galectin-9 has been shown to bind to Tim-3 and mediate 
down-regulation of Th1 immunity (261). However, galectin-9 is also an IgE-binding lectin and 
can downregulate allergic responses by disrupting IgE-Ag complex formation (264). Galectin-9 
was also shown to bind to the receptor CD44, through which it can regulate inflammation at several 
levels (263, 335-337). Tim-3 expressed on tumor-infiltrating DCs interacts with the alarmin 
HMGB1, a DNA-binding protein associated with cellular injury, and interferes with an HMGB1-
activated nucleic acid sensing system in the tumor microenvironment (270). However, HMGB1 
can also bind to TLR4, which is expressed on mast cells, and the cellular receptor RAGE (338). 
Thus, engaging Tim-3 through antibody treatment offers a mechanism to more specifically 
modulate Tim-3 activity. Understanding how various antibodies can enhance or antagonize Tim-
3 signaling will be important for the development of more effective antibody-mediated Tim-3 
immunotherapies.  
Through available gene expression data on public database, we were able to analyze on a 
broader scale how Tim-3 cross-linking by pAb impacted the expression profiles of FcRI-
regulated genes. Interestingly, Tim-3 pAb treatment alone induced a unique gene expression 
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pattern compared to IgE/Ag and Tim3 pAb co-stimulation. These results show that Tim-3 
engagement alone can activate mast cells, at least at the transcriptional level, independently of 
FcRI stimulation. While we did not detect any response in cells treated with Tim-3 pAb alone 
using cytokine production as a functional read-out, it remains to be seen whether the up-regulated 
gene expression profile represents a functional response and if Tim-3 pAb may be able to co-
stimulate other receptors on mast cells.  
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5.0  TIM-3 KNOCKDOWN OR KNOCKOUT ATTENUATES ANTIGEN 
RECEPTOR-MEDIATED CYTOKINE PRODUCTION IN BMMCS 
5.1 INTRODUCTION 
While Tim-3 has been identified mostly as a negative regulator of T cell responses, recent studies 
hinted a possible positive role for Tim-3 in CD8+ T cell defense against Listeria monocytogenes 
infection (296). In contrary to observations in T cells, all of the Tim-3 antibodies tested in mast 
cells so far have a co-stimulatory function. Furthermore, when used in a mouse model of 
experimental allergic asthma, Tim-3-deficient mice were not impaired in development of lung 
inflammation (238). However, since the OVA-induced lung inflammation model used is primarily 
T cell-mediated and the role of mast cells was not examined, it remains to be seen whether Tim-3 
deficiency will affect mast cell function in vitro and in vivo. Thus, we determined whether Tim-3 
deficiency could impact the maturation and/or function of BMMCs, using Tim-3 knockout (KO) 
mice (296). Our findings demonstrated that acute knock-down or genetic deficiency of Tim-3 
rendered mast cell less responsive to antigen cross-linking of FcRI, resulting in decreased 
degranulation and cytokine production. 
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5.2  MATERIALS AND METHODS 
5.2.1 Mice 
Tim-3 KO mice were originally obtained from John Colgan (University of Iowa). The mouse strain 
had been back-crossed for at least 10 generations to C57BL/6 and was maintained in the University 
of Pittsburgh Animal Facility. Age-matched wild-type C57BL/6 mice (7-8 weeks old) were 
purchased from the Jackson Laboratory (Bar Harbor, ME) 
5.2.2 BMMC isolation and culture 
Bone marrow cells from Tim-3 WT and KO mice were cultured in RPMI 1640 supplemented with 
10% BGS, non-essential amino acid, 2-ME, HEPES, pen/strep-glutamine, and 20% IL-3-
conditioned media for 4-6 weeks, after which >90% of viable cells are mature mast cells (c-kit+ 
FcRI+ by flow cytometry).  
5.2.3 BMMC stimulation and cytokine measurement 
BMMCs were sensitized with 1 μg/ml IgE overnight in complete media without IL-3. Cells were 
then stimulated either with DNP32-HSA or DNP5-BSA in IL-3-free media for indicated times. 
Supernatants were assayed for murine IL-6 and TNF-α by ELISA (Biolegend) six or twenty-four 
hours post-stimulation. 
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5.2.4 Flow cytometry assays for mast cell degranulation 
Measurement of degranulation by flow cytometry was conducted as previously described (321, 
322). Briefly, BMMCs were loaded with 0.1μM of Lysotracker Deep Red (Invitrogen) for thirty 
minutes at 370C and then sensitized with 1μg/ml IgE for one hour. Receptor cross-linking was 
induced by addition of DNP32-HSA at indicated concentration or 2μM ionomycin as positive 
control for ninety minutes prior to Annexin V staining (Biolegend). % degranulation is determined 
as percentage of BMMCs that is AnnexinV+Lysotrackerlo.  
5.2.5 siRNA knock-down of Tim-3 in BMMC by nucleofection 
BMMCs (3 x 106 cells) were transfected with 100 pmol of non-specific or Tim-3 siRNA 
(Dharmacon) using the mouse macrophage nucleofector kit (Lonza), Y-001 program, and the 
Nucleofector II/2b device (Lonza). Transfected cells were collected after forty-eight hours and 
efficiency of knockdown was determined by Tim-3 staining, followed by flow cytometry. 
 
5.2.6 Statistical analysis 
All statistical analysis was performed using Prism software (GraphPad Software). Paired, two-
tailed Student’s t-test, one-way and two-way ANOVA with Bonferroni post hoc test were used for 
data analysis and determination of p values, as appropriate. 
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5.3 RESULTS 
5.3.1 Tim-3 deficiency does not alter mast cell maturation but attenuates mast cell 
cytokine production and degranulation 
Tim-3 deficient BMMCs exhibited normal development and maturation compared to WT controls, 
as judged by similar levels of c-kit and FcRI expression at various times during their in vitro 
development (Fig. 5-1A). Strikingly however, Tim-3 KO BMMCs displayed a significant defect 
in cytokine production in response to FcRI activation, using either low (DNP5) or high (DNP32) 
valency Ag (Fig. 5-1B). Of note, we observed significantly stronger stimulation with low valency 
Ag, likely due to the delayed engagement of negative feedback pathways that serve to  down-
regulate FcRI signaling (109, 302, 339, 340). Thus, previous studies have noted the preferential 
engagement of positive or negative signaling pathways upon stimulation with low or high valency 
(or concentration) of Ag, respectively (109, 341). Importantly, the co-stimulatory effects of Tim-
3 pAb or mAb 5D12 were severely impaired in Tim-3 KO BMMCs, which further reinforced the 
specificity of these antibodies for Tim-3 (Fig. 5-1C). In agreement with our findings (Fig. 4-3) that 
Tim-3 antibodies modestly enhance mast cell degranulation, Tim-3 deficiency impaired antigen-
induced degranulation of BMMCs, using the flow cytometry-based assay (Fig. 5-1D). Thus, Tim-
3 deficiency impaired the ability of BMMCs to generate robust responses to IgE receptor cross-
linking, demonstrating that endogenous Tim-3 modulates the intensity of FcRI signaling upon Ag 
challenge.  
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Figure 5-1: Tim-3 regulates cytokine production by BMMCs. (A) Maturity of Tim-3-WT and KO BMMCs as 
determined by FcRI and c-kit staining. Tim-3 surface expression was compared between WT and Tim-3 KO 
BMMCs, which were sensitized with IgE and stimulated as indicated. Supernatants were collected after six hours and 
analyzed by ELISA for IL-6. (B) BMMCs were stimulated with low valency (DNP5; left panel) or high valency 
(DNP32; right panel) antigen. (C) BMMCs were stimulated with high DNP32, plus isotype control, Tim-3 pAb (left 
panel) or Tim-3 mAb (right panel). Results are representative of three independent experiments performed for three 
batches of BMMCs. (D) BMMCs were stimulated with DNP32 alone (left panel), or with isotype control or Tim-3 pAb 
(right panel), followed by quantitation of degranulation by flow cytometry. Results are representative of three 
independent experiments performed in duplicate. *p < 0.05, **p < 0.005.   
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5.3.2 Acute Tim-3 deficiency resulted in decreased cytokine production 
Multiple cis- and trans-acting Tim-3 ligands have been described, and thus far include 
phosphatidylserine (PS), galectin-9, high mobility group protein B1 (HMGB1) and CEACAM1, 
none of which is specific to Tim-3 (296, 327, 330, 342). Furthermore, antibodies targeting Tim-3 
have been shown to deliver either agonistic or antagonistic actions, as interpreted in the context of 
positive or negative effects that Tim-3 may exert on the specific cell type or disease model (191, 
227, 291, 302, 343, 344). It was important to confirm that the effects of Tim-3 deficiency observed 
in the knockout mice were not due to secondary effects on mast cell development. Thus, we 
determined whether acute Tim-3 deficiency would have a direct impact on mast cell activation, by 
siRNA knockdown, while taking an agnostic view toward specific Tim-3 ligands. Consistent with 
a positive role of Tim-3, as described above, even incomplete knockdown of Tim-3 (~80% 
knockdown efficiency) resulted in a reduction of IL-6 production in Ag-stimulated BMMCs, a 
defect that was further emphasized when BMMCs were co-stimulated with Ag and Tim-3 pAb 
(Fig. 5-2A-B). Similar results were obtained across multiple batches of BMMCs, as well as when 
the anti-Tim3 mAb 5D12 was used, providing further evidence that Tim-3 functions as a positive 
regulator of FcRI-induced cytokine production in mast cells (Fig. 5-2C). Furthermore, our 
experiments with Tim-3 KO BMMC confirmed that Tim-3 pAb and 5D12 are indeed specific to 
Tim-3.  
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Figure 5-2: Tim-3 knockdown attenuates antigen-induced cytokine production by BMMC. BMMCs generated from 
C57BL/6 mice were transfected with control (non-sp) or Tim3-specific siRNA. (A) Forty-eight hours later, cells were 
analyzed by flow cytometry for Tim-3 expression. (B-C) BMMCs were sensitized overnight with IgE and stimulated 
with DNP32-HSA for six hours. IL-6 secretion was assessed by ELISA, using either Tim-3 pAb (B) or 5D12 (C) for 
co-stimulation. Results are representative of three independent experiments, performed in duplicate. *p < 0.05, 
**p<0.005, ***p < 0.0005. 
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5.4 DISCUSSION 
We have demonstrated here that Tim-3 positively contributes to mast cells activation by IgE/Ag. 
To determine whether Tim-3 plays a positive or negative role in mast cell activation, we utilized 
both siRNA knockdown of endogenous Tim-3 in BMMCs, as well as a Tim-3 deficient mouse 
strain. Tim-3 knockdown and KO BMMCs exhibited defective degranulation and cytokine 
production at both high and low intensity IgE/Ag stimulation. It should be noted that the Tim-3-
deficient mice used in this study was generated from the 129 strain embryonic stem cells and 
backcrossed to C57BL/6 mice for 10 generations. Because the Tim genes are tightly linked and are 
in close proximity with the pro-inflammatory IL-4 cytokine gene cluster, the carrying over of the 
129 form of Tim-1 or neighboring genes should be taken into consideration as a potential 
confounding factor. Nevertheless, using siRNA-mediated knockdown, we showed that the 
impaired cytokine production observed was indeed due to reduced Tim-3 expression. Thus, Tim-
3 amplifies the intensity and/or duration of signaling downstream of FcRI, leading to cytokine 
production. Even though, Tim3 pAb and 5D12 could still enhance IL-6 release in Tim-3 siRNA- 
treated BMMCs since the knockdown was not complete, there was a complete absence of 
modulatory activity in the Tim-3 KO BMMCs, thereby further supporting the specific interaction 
between these antibodies and Tim-3.  
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6.0  TIM-3 REQUIRES TYROSINE PHOSPHORYLATION OF ITS CYTOPLASMIC 
TAIL TO AUGMENT MAST CELL ACTIVATION.  
6.1 INTRODUCTION 
The cytoplasmic tail of Tim-3 contains six conserved tyrosine residues, at least some of which 
have been shown to couple to the intracellular signaling network downstream of TCR/CD3, based 
on our previous study (308). Contrary to its apparent inhibitory role in vivo, ectopic expression of 
Tim-3 in human and murine T cell lines augmented CD3/CD28-stimulated NF-B and NFAT/AP1 
activation in a manner that was dependent on the Tim-3 cytoplasmic tail, particularly residues 
Y256 and Y263 (308). Similarly, a conserved tyrosine on cytoplasmic tail of human TIM-3 was 
also phosphorylated upon galectin-9 ligation (306). Therefore, we asked whether over-expression 
of Tim-3 in a mast cell line could also augment transcriptional activation by antigen receptor 
signaling. Based on the increase in IL-6 and TNF- and our findings in T cells, we examined 
transcriptional activity of the transcription factors NF-B, NFAT, and AP1. Our findings support 
the importance of tyrosine phosphorylation in Tim-3-mediated signaling as well as reveal a Syk-
dependent regulation of Tim-3 activity downstream of IgE receptor cross-linking.    
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6.2 MATERIALS AND METHODS 
6.2.1 Antibodies and reagents 
Monoclonal anti-dinitrophenyl (DNP) antibody, IgE isotype, clone SPE-7, anti-Flag antibody M2, 
DNP32 –HSA, and anti-FLAG M2 antibody were from Sigma-Aldrich (St. Louis, MO).  Phorbol 
myristate acetate (283), ionomycin, inhibitors to Src-family kinases (PP2), and Syk (BAY61-
3606), were purchased from Calbiochem/EMD Biosciences (San Diego, CA). IL-6 luciferase 
reporter constructs (full length, mutants lacking binding sites for NF-B, AP1, C/EBP, NF-
B/C/EBP) were obtained from Sarah Gaffen (University of Pittsburgh), and were originally 
obtained from Oliver Eickelberg (Helmholtz Zentrum Munchen). Phospho-Src (Y416) was 
purchased from Cell Signaling Technology (Danvers, MA). Total tyrosine phosphorylation 
antibody 4G10 was purchased from Millipore (Darmstadt, Germany).  
6.2.2 Transcriptional luciferase assays 
MC/9 mast cells (15 x 106 cells) were transfected with 15 μg of NF-B-luc, NFAT/AP1-luc, 
NFAT-luc, AP-1-luc, IL-6-luc together with indicated amount of pCDEF3, FLAG-tagged Tim-3 
full length, truncation 1 or 2 mutants (T1 or T2) by electroporation at 290 V, 950 μF using a Gene 
Pulser II apparatus (Bio-Rad). Twenty-four hours later, transfected cells were collected and 
stimulated with 0.5 μg/ml IgE and the indicated amount of DNP32-HSA antigen for 6 hours. 
Luciferase assays were conducted as described previously. 
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6.2.3 Western blotting 
MC/9 were sensitized with 0.5 μg/ml IgE for two hours at 370C in Tyrode’s buffer. Cells were 
then pre-treated with indicated concentration of Src or Syk inhibitors for thirty minutes prior to 
stimulation with DNP32-HSA for ten minutes in Tyrode’s buffer. Cells were lysed in 1% Nonidet-
P-40 lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl) supplemented with AEBSF, aprotinin, 
leupeptin, pepstatin, sodium fluoride, sodium orthovanadate, and beta-glycerophosphate on ice for 
twenty minutes.  Lysates were centrifuged at 4oC for fifteen minutes. For western blotting analysis, 
SDS-containing sample buffer was added to lysates prior to loading onto 10% SDS-PAGE gels. 
Proteins were transferred onto polyvinylidene difluoride (PVDF) membranes using the PierceG2 
fast blotter (Pierce), probed with appropriate antibodies, and imaged on a ProteinSimple Fluochem 
M cooled CCD imager (ProteinSimple).  
6.2.4 Statistical analysis 
All statistical analysis was performed using Prism software (GraphPad Software). Paired, two-
tailed Student’s t-test, one-way and two-way ANOVA with Bonferroni post hoc test were used for 
data analysis and determination of p values, as appropriate. 
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6.3 RESULTS 
6.3.1 Transient expression of Tim-3 enhances IgE/Ag-mediated NF-B, NFAT/AP1, and 
IL-6 transcriptional activation  
We expressed our previously described full-length (FL) murine Tim-3, a truncation (T1) lacking 
the three most distal C-terminal tyrosines, and a truncation (T2) lacking all but one membrane-
proximal tyrosine, in the mouse mast cell line MC/9 (Fig. 6-1A). Similar to our findings in T cells, 
FL Tim-3 efficiently augmented NF-B, NFAT, AP1, as well as NFAT/AP1 composite reporter 
activity, compared to empty vector control, in IgE/Ag-stimulated mast cells (Fig. 6-1B-E). The 
cytoplasmic tail was important for Tim-3 signal transduction in mast cells, as all reporter co-
stimulatory activity was abrogated when the T2 Tim-3 construct was expressed. While induction 
of NFAT/AP1 activity required mainly the more N-terminal tyrosines (Fig. 6-1C), NF-B 
transcriptional activity was sensitive to deletion of both N- and C-terminal tyrosines (Fig. 6-1B). 
Intriguingly, the T2 construct appeared to possess dominant negative activity in these assays. We 
did not observe further augmentation by Tim-3 upon cross-linking by Flag antibody, further 
supporting our previous findings that Tim-3 ectopic expression was sufficient to drive Ag-
mediated transcriptional response.  
Since Tim-3 cross-linking enhanced IL-6 secretion, and there are binding sites for NF-B, 
AP1 and C/EBP in the IL-6 promoter (306, 345-349), we examined the IL-6 promoter to determine 
if it was impacted by Tim-3 overexpression. As expected, FL Tim-3 augmented IL-6 promoter 
activity in a dose-dependent manner (Fig. 6-1F). Consistent with the requirement for AP-1 and 
NF-B in IL-6 reporter activation, Tim-3 could not augment IL-6 reporter activation in the absence 
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of NF-B or AP-1 (Fig. 6-1G). On the other hand, C/EBP was not involved in Tim-3-mediated IL-
6 transcriptional activity (Fig. 6-1H). These results suggest that Tim-3 exerts its co-stimulatory 
effect on IL-6 production through transcriptional activation of NF-B and AP-1, which in turns 
drives IL-6 promoter activation and cytokine production.  
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Figure 6-1: Tim-3 cytoplasmic tail tyrosines are required to augment NF-B, NF-AT, AP-1, and IL-6 transcriptional 
activation. MC/9 mouse mast cells were transfected with empty vector (pCDEF3) or one of the indicated Flag-tagged 
Tim-3 constructs (A). Transfected MC/9 cells were stimulated with IgE and 50 ng/ml or 100 ng/ml of DNP32-HSA, 
with or without addition of anti-Flag antibody for six hours. (B-F) MC/9 mast cells were co-transfected with luciferase 
reporters for NF-κB (B), NFAT/AP-1 (C), NF-AT (D), AP-1(E), or IL-6(F). (G-H) MC/9 mast cells were co-
transfected with FL-Tim-3 and the indicated IL-6 reporter mutants. Results are representative of three independent 
experiments performed in triplicate. *p <0.05, **p<0.005, ***p < 0.0005.  
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6.3.2 IgE/Ag-mediated IL-6 reporter activation depends on Syk but not Src family 
kinases, and is mediated by tyrosine phosphorylation of Tim-3 cytoplasmic tail 
Next, we defined the role of known FcRI signaling intermediates in Tim-3 co-stimulation of mast 
cells. Using IL-6 reporter activity as a read-out, we treated FL Tim-3-transfected MC/9 mast cells 
with the Src family tyrosine kinases (SFK) inhibitor PP2 or the Syk kinase inhibitor BAY61-3606, 
which demonstrated potent inhibition of Src phosphorylation and total tyrosine phosphorylation, 
respectively (Fig. 6-2A-B). IL-6 reporter activity was severely impaired in the presence of the Syk 
inhibitor, consistent with a strict requirement for Syk in FcRI signaling (350, 351) and 
overexpression of Tim-3 did not rescue this inhibition (Fig.6-2C). By contrast, PP2 inhibited IL-6 
reporter activity only at high concentrations (10 M), where pSrc was severely diminished (Fig. 
6-2B), while lower concentrations of PP2 actually enhanced IL-6 promoter responses (Fig. 6-2D). 
Tim-3 co-stimulatory activity was also similarly modulated by high vs. low concentrations of PP2 
(Fig. 6-2D).  
              Several SFK family members are expressed in mast cells, including Lyn, Fyn and Hck, 
whose positive and/or negative regulatory function can be differentially modulated using either 
high or low dose PP2 (340). Thus, low dose PP2 appears to selectively block the negative 
regulatory functions of SFKs, while high-dose PP2 preferentially affects the positive function. 
Returning to the tyrosines within the Tim-3 cytoplasmic tail, we previously showed that 
phosphorylation of tyrosines 256 and 263 in the Tim-3 cytoplasmic tail is essential for its co-
stimulatory activity in T cells (308). Consistent with this finding, a full length Tim-3 construct 
harboring tyrosine to phenylalanine mutation at these sites (Y256/263F) also abrogated Tim-3-
augmented IL-6 reporter activation in mast cells. Phosphorylation of tyrosines 256 and 263 appears 
 90 
to be the dominant mode of activation, as additional deletion of the three C-terminal tyrosines did 
not result in further reduction of IL-6 reporter activity (Fig. 6-2E). 
 
Figure 6-2: Tim-3 cytoplasmic tail tyrosines are required to augment IL-6 transcriptional activation, in a Syk-
dependent manner. MC/9 mast cells were co-transfected with empty vector (pCDEF3) or full-length Flag-tagged Tim-
3 and an IL-6 promoter luciferase reporter. Transfected cells were stimulated with IgE and Ag in the presence of 
vehicle control (DMSO), BAY61-3606 (C), or PP2 (D) compounds for six hours. Western blotting for effects of 
BAY61-3606 on total phosphotyrosine (A) and PP2 on pSrc (B) levels. MC/9 mast cells were transfected with the 
indicated Tim-3 constructs and IL-6 promoter luciferase reporter and stimulated as described above (E). Results are 
representative of three independent experiments performed in triplicate. **p <0.005, ***p < 0.0005. 
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6.4 DISCUSSION 
FcRI is a multi-chain receptor lacking intrinsic kinase activity and as such employs Src family 
tyrosine kinases (SFKs) for signal initiation and propagation. We showed that the tyrosine-
containing cytoplasmic tail of Tim-3, which is indispensable for Tim-3 co-stimulation of T cell 
activation (308), was also required for its co-stimulatory activity in mast cells. NF-B and 
NFAT/AP1 promoter activity were most affected when five of the six tyrosines were removed. 
While it is possible that Tim-3 might signal through a tyrosine-independent mechanism, we 
consider this unlikely, given the lack of any other obvious signaling motifs in this region and our 
previous findings that Fyn kinase could associate and phosphorylate Tim-3 at these residues (308). 
Similar to transient expression on T cells, we did not observe further augmentation by Tim-3 upon 
cross-linking by Flag antibody, further supporting our previous findings that Tim-3 expression 
alone was sufficient to drive Ag-mediated transcriptional response. The Tim-3 ligand galectin-9 is 
expressed on mast cells, and phosphatidylserine (PS) is present in the system as a result of 
electroporation-induced cell death. However, the enhancement observed here does not appear to 
be due to galectin-9 or PS interaction since endogenous Tim-3 is present on MC/9 yet does not 
contribute to any significant transcriptional activation. Tim-3 ectopic expression slightly enhanced 
NF-AT reporter activity in IgE-sensitized cells, suggesting Tim-3 may contribute to an IgE-
dependent antigen-independent signaling pathway to synergize with antigen stimulation for NF-
AT activation.   
We explored the contribution of SFKs involved in mast cell activation in an IL-6 reporter 
assay using the pan-SFK inhibitor PP2. Surprisingly, Tim3-mediated IL-6 reporter activity was 
not affected by high concentrations of PP2 and was in fact enhanced at low concentrations of PP2. 
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By contrast, pharmacologic inhibition of Syk drastically diminished Tim-3-mediated IL-6 reporter 
activity. These results indicate that Tim-3 activity converges on FcRI-mediated intracellular 
pathways that require Syk for both of its catalytic and adaptor functions. Given the complex 
hierarchical network of multiple SFKs in mast cell regulation, their variable sensitivity to PP2, and 
the existence of both positive and negative regulatory activities depending on Ag affinity and 
concentration (109, 114, 302), it will be important to determine the prominent kinase(s) that 
cooperate with Tim-3 to amplify responses to Ag stimulation. Lyn is a particularly appealing 
candidate for this activity. Thus, Lyn has been shown to possess both positive and negative 
regulatory functions in FcRI activation in response to intensity of stimulus (109), and recruitment 
and activation of Syk requires phosphorylation of FcRI ITAMs by Lyn (101, 352).      
Previous studies also showed that Lyn is constitutively associated with FcRI in both 
soluble and lipid raft fractions and that this association is increased upon FcRI aggregation (114). 
Thus, the majority of the evidence points to a close association between FcRI, Lyn and Tim-3 
under basal conditions. Upon high intensity Ag stimulation, FcRI is then recruited into the lipid 
rafts, where enhanced  phosphorylation by Lyn occurs, to facilitate binding of phosphatases, 
leading to down-regulation of signaling (114). Coupled with our findings that Tim-3 cytoplasmic 
tyrosines are required for its function, Tim-3 interaction with the FcRI and its associated SFKs as 
a result of its cytoplasmic tail phosphorylation is a potential mechanism worth exploring.     
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7.0   TIM-3 SHARES SIGNALING COMPONENTS WITH ANTIGEN RECEPTOR 
PATHWAY 
7.1 INTRODUCTION 
We wanted to further explore the possibility that Tim-3 could augment FcRI signaling, as opposed 
to acting through a parallel signaling pathway. We generated BMMCs from transgenic Nur77GFP 
mice (353), to determine if antibody-modulated Tim-3 activity could supplement Ag receptor 
activation. Nur77, also known as NR4A1, is a member of the orphan nuclear receptor subfamily 
NR4A, and is an immediate early gene that can be induced upon a variety of stimuli (354-356). In 
the mast cells, expression of the NR4A subfamily can be induced upon exposure to live 
streptococci, antigen cross-linking of the IgE receptor, and calcium ionophore (357). While 
NR4A1 is phosphorylated upon mast cell activation, little is known about the precise function of 
NR4A1 in mast cell biology (357). Nur77GFP reporter mice have been useful tools to study 
development and activation of lymphocytes, as the intensity of T cell and B cell antigen receptor 
activation is proportional to GFP expression (353, 358). In this study, using two independently 
generated Nur77GFP mouse models, we report for the first time the signaling pathways leading to 
Nur77 expression upon FcRI activation. We also determine if Tim-3 engagement contributes to 
FcRI signal intensity. Overall, our results reveal that Tim-3 acts at the proximity of antigen 
receptor activation to enhance mast cell activation.    
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7.2 MATERIALS AND METHODS 
7.2.1 Mice 
The Nur77GFP reporter mouse, C57BL/6-Tg(Nr4a1-EGFP/cre)820Khog/J, referred to as Nur77-
EGFP/Cre, was purchased from the Jackson Laboratory and maintained in the University of 
Pittsburgh Animal Facility.  
7.2.2 Antibodies and reagents 
Monoclonal anti-dinitrophenyl (DNP) antibody, IgE isotype, clone SPE-7, DNP32 –HSA, and 
cyclosporin A  (CsA) were from Sigma-Aldrich (St. Louis, MO). DNP5 –BSA was purchased from 
Biosearch Technologies (Petaluma, CA). Purified polyclonal antibody (Tim-3 pAb) and normal 
goat IgG control were from R&D Systems (Minneapolis, MN). Recombinant Tim4-Fc was from 
Vijay Kuchroo (Harvard). Phorbol myristate acetate (283), ionomycin, inhibitors to Src-family 
kinases (PP2), Syk (BAY61-3606), PI3K (LY294002), MEK (UO126), and Akt (Akti 1/2) were 
purchased from Calbiochem/EMD Biosciences (San Diego, CA). Inhibitor to PKC 
(Bisindolylmaleimide (BIM) VIII) was from Cayman Chemical (Ann Arbor, MI). 
7.2.3 BMMC isolation and culture 
Bone marrow from an independently generated Nur77GFP mouse model, Nur77-EGFP, was 
obtained from Arthur Weiss (University of California San Francisco).  Nur77 GFP  bone marrow 
cells were cultured in RPMI 1640 supplemented with 10% BGS, non-essential amino acid, 2-ME, 
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HEPES, pen/strep-glutamine, and 20% IL-3-conditioned media for 4-6 weeks, after which >90% 
of viable cells are mature mast cells (c-kit+ FcRI+ by flow cytometry). 
7.2.4 BMMC stimulation and flow cytometry 
BMMCs were sensitized overnight with 1 μg/ml IgE in complete media with IL-3. Cells were then 
stimulated with DNP32-HSA or DNP5-BSA, with either goat isotype, Tim3 pAb, human IgG, or 
Tim4-Fc for indicated amount of time. For experiments involving inhibitor treatment, the indicated 
inhibitors or DMSO as vehicle control were added to the cell culture at the time of antigen 
stimulation for six hours. Cells were then analyzed for GFP expression by flow cytometry.  
7.2.5 Statistical analysis 
All statistical analysis was performed using Prism software (GraphPad Software). Paired, two-
tailed Student’s t-test, one-way and two-way ANOVA with Bonferroni post hoc test were used for 
data analysis and determination of p values, as appropriate. 
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7.3 RESULTS 
7.3.1 Tim-3 cross-linking enhances intensity of FcRI signaling in two separate Nur77GFP 
mouse models  
In the first mouse model, Nur77-EGFP (353), we found that Nur77GFP expression could be induced 
in Ag-stimulated BMMCs in a dose-dependent manner (Fig. 7-1A) and its expression was 
maintained for at least 48 hours (Fig. 7-1B-D). Consistent with findings in T and B cells, cytokine 
stimulation by IL-3 alone did not drive Nur77 GFP expression. On the other hand, c-kit receptor 
engagement by stem cell factor (SCF) could activate Nur77 transcription (Fig. 7-1B). Nur77GFP 
induction was further augmented in Tim-3 pAb co-stimulated cells (Fig. 7-1E-F), but not when 
Tim-3 pAb was used alone or administered with a low dose of either the phorbol ester PMA or 
ionomycin (Fig. 7-1H-I). The co-stimulatory effects of Tim-3pAb treatment was further 
highlighted since it could enhance both optimal and sub-optimal antigen concentrations, 50 and 10 
ng/ml respectively (Fig. 7-2A-B). Our results further revealed that the co-stimulatory effect 
observed with Tim-3 pAb is unique to Tim-3, as engagement of Tim-1, another family member 
expressed on BMMCs, did not yield similar GFP up-regulation (Fig. 7-1G). Thus, our results 
demonstrate that Tim-3 acts at point proximal to FcRI to up-regulate the magnitude of IgE/Ag-
dependent signaling, rather than signaling through a parallel pathway.   
We confirmed FcRI-dependent Nur77 expression in the independently generated 
Nur77GFP mouse model Nur77-EGFP/Cre (358) (Fig. 7-3A-B). In addition, we observed that 
antigen valency could modulate antigen receptor signal strength as the low valency antigen (DNP5) 
induced higher level of GFP expression compared to high valency antigen (DNP32) (Fig. 7-3C). 
Interestingly, we observed a different pattern of Nur77GFP expression compared to those in 
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BMMCs generated from Nur77-EGFP. Specifically, antigen stimulation in Nur77-EGFP BMMCs 
induced a shift in GFP expression that reflected both increase in cell frequency and GFP intensity 
while the shift in Nur77-EGFP/Cre BMMCs was more uniform and reflected only increase in GFP 
expression (Fig. 7-1A and 7-3A). Similarly, Nur77GFP intensity byTim-3 pAb and antigen co-
engagement reflected the patterns of the corresponding mouse models (Fig. 7-1E, 7-2A-B, and 7-
3D). These results suggest that antigen receptor signaling can be modulated quantitatively and 
qualitatively, and Tim-3 can contribute to FcRI in both ways. 
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Figure 7-1: Nur77-GFP reporter expression is induced by IgE/Ag and enhanced by co-engagement of Tim-3. BMMCs 
were generated from Nur77-EGFP reporter mice, sensitized with IgE overnight and stimulated with antigen, 5 ng/ml 
of rIL-3 or SCF. (A-D) Antigen (DNP32-HSA) was titrated over a range of 10-500 ng/ml. PMA plus ionomycin 
stimulation was used as a positive control. GFP expression was determined after stimulation for six (A-B), twenty-
four (C), and forty-eight (D) hours. (E-F) Nur77GFP BMMCs were stimulated with a fixed concentration of antigen, 
with or without Tim-3 pAb for six hours. (G) Nur77GFP BMMCs were stimulated with IgE/Ag and either Tim-3 pAb 
or Tim4-Fc (which binds to Tim-1), or appropriate isotype controls. Results are the average of three independent 
experiments (A-C, E-G), two experiments (H-I) performed in duplicate, and once for Fig. 7-1D. *p < 0.05, **p < 
0.005, ***p < 0.0005.  
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Figure 7-2: Tim-3 enhances IgE/Ag-mediated Nur77GFP reporter expression in a dose dependent manner. Nur77GFP 
BMMCs were sensitized with IgE and stimulated with 10 or 50 ng/ml DNP32-HSA, isotype control or varying amounts 
of Tim3pAb for six hours. GFP was determined by flow cytometry.   
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Figure 7-3: Tim-3 ligation augments antigen-induced Nur77GFP expression in an independently generated Nur77GFP 
mouse model. BMMCs were generated from Nur77-EGFP/Cre reporter mice, sensitized with IgE overnight and 
stimulated with increasing amount DNP32-HSA or DNP5-BSA for six hours prior to analysis of GFP expression by 
flow cytometry. (A-B) Antigen (DNP32-HSA) was titrated over a range of 10-500 ng/ml. (C) Increasing concentrations 
of DNP32-HSA or DNP5-BSA were used for BMMC stimulation. (D) Tim-3 pAb or isotype control was administered 
with 50 ng/ml DNP32-HSA. Results are average of three (A-B, D) and two (C) independent experiments performed in 
duplicates.   *p < 0.05. 
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7.3.2 Signaling pathways that mediate activation of Nur77 expression downstream of 
FcRI in BMMCs 
Nur77GFP has been demonstrated to be a faithful reporter for antigen receptor signaling in T and B 
cells, and now from our findings, in mast cells as well. Given the limited knowledge of how Nur77 
expression is regulated in mast cells, we explored the contribution of various signaling pathways 
downstream of FcRI to Nur77GFP expression using pharmacologic inhibitors in both mouse 
models. Similar to our observations with IL-6 reporter activity (Fig. 6), low doses of the Src kinase 
inhibitor PP2 actually led to an Ag-dependent increase in Nur77GFP induction, while high dose PP2 
had no effect (Fig. 7-4A, C). By contrast, the Syk inhibitor completely abrogated Ag-stimulated 
Nur77 expression, a phenomenon comparable to the effects of SFK and Syk inhibitors on Nur77GFP 
induction in B cells (Fig. 7-4A, C, and (353)). In addition, Nur77 expression was also regulated 
by MEK, PI3K/Akt, and calcineurin/NFAT (Fig. 7-4B, D). PKC inhibition led to a more 
significant induction of Nur77 expression compared to vehicle control in the Nur77-EGFP/Cre 
BMMCs, suggesting BMMCs from this strain may be more sensitive to PKC inhibition (Fig. 7-
4B, D). Thus, based on results obtained with two independent Nur77GFP reporter strains, we 
propose that Tim-3 functions to strengthen FcRI-dependent signaling itself, and not through a 
parallel pathway.  
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Figure 7-4: FcRI-induced Nur77 activation is dependent on Syk and mediated by NFAT, PI3K/Akt, and MEK/ERK 
pathways. (A-B) Nur77GFP BMMCs from Nur77-EGFP (A-B) or Nur77-EGFP/Cre (C-D) BMMCs were stimulated 
with IgE/Ag plus indicated inhibitors to Src kinases (PP2), Syk (BAY61-3606), MEK (UO126), Akt (Akti1/2), 
calcineurin (CsA), PI3K (LY294002) or PKC (BIM). GFP signal was quantified by flow cytometry. Results are the 
average of five independent experiments performed in duplicate. *p < 0.05, **p < 0.005, ***p < 0.0005.  
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7.4 DISCUSSION 
Using BMMCs generated from Nur77GFP reporter mice (Nur77-EGFP), we show for the first time 
that Nur77GFP expression can be used as a read-out for FcRI signaling intensity. Similar to T and 
B cell receptor signaling (353), we observed a bimodal distribution of GFP in Ag-stimulated 
BMMCs, with increasing antigen dosage favoring an increase in the frequency of mast cells 
expressing Nur77GFP, rather than just the amount of GFP itself. The same trend was also observed 
after co-stimulation with Tim-3 pAb. In another Nur77GFP reporter mouse (Nur77-EGFP/Cre), 
while we only detected an increase in intensity of Nur77GFP expression in response to antigen 
stimulation in mast cells, Tim-3 cross-linking also induced significant co-stimulation of FcRI-
mediated Nur77GFP expression. Thus, Tim-3 engagement acts in a similar manner to increasing 
antigen dose, leading to intensified IgE receptor activation and an increase in the number of cells 
reaching a critical threshold for activation.  
To better define which antigen receptor-induced signaling pathways were driving Nur77GFP 
expression in mast cells, we employed various pharmacologic inhibitors. Our results revealed that, 
similar to antigen receptor signaling in B cells, Syk activity is required for Nur77 transcription in 
mast cells, while calcineurin, PI3K/Akt and MAPK are less essential. In contrast to T cells where 
PKC is required for Nur77GFP expression, treatment of mast cells with the pan-PKC inhibitor BIM 
actually up-regulated GFP expression. Given the differential expression of various PKC species in 
T cells and mast cells, BIM may have prevented the activation of a particular PKC isoform that is 
normally involved in negative regulation of Nur77 expression. One candidate for this activity is 
PKC , which was previously shown to act as a negative regulator of mast cell activation (340). 
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8.0  TIM-3 ASSOCIATES WITH ANTIGEN RECEPTOR PROXIMAL SIGNALING 
COMPLEX 
8.1 INTRODUCTION 
Binding of IgE FcRI  chain stabilizes and increases surface expression of FcRI, as well as 
maintains baseline protein synthesis of the receptor components (359). Receptor proximal 
signaling occurs when antigen cross-linking of pre-bound IgE induces a series of phosphorylation 
events on the signal amplifier FcRI  chain and the signal transducer  chain by Lyn kinase as 
well as recruitment of Syk (101-104). Lyn-mediated activation of Syk leads to phosphorylation 
and recruitment of molecular adaptors and secondary messengers generated by aggregation of 
surface receptors (Rivera, 2002). Our findings thus far suggest that Tim-3 partners closely with 
FcRI and may modulate activity of FcRI components.  
In this study, we determined whether Tim-3 expression is regulated by mast cell activation, 
and how Tim-3 ligation may affect Ag-induced FcRI internalization, a hallmark of  receptor 
signaling downregulation (360). Here we show that Tim-3 expression is co-modulated with FcRI 
upon antigen aggregation while Tim-3 engagement does not alter receptor surface expression or 
internalization. In addition, we observe constitutive association of Tim-3 with FcRI  and  
subunits. Finally, we examine the presence of the proposed Tim-3 regulators Bat3 and CEACAM1 
on mast cells and show that the co-stimulatory activity of Tim-3 in mast cells is independent of 
Bat3 and CEACAM1. 
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8.2 MATERIALS AND METHODS 
8.2.1 BMMC isolation and cell line culture 
C57BL/6 purchased from Jackson Laboratory (Bar Harbor, ME) were cultured in RPMI 1640 
supplemented with 10% BGS, non-essential amino acid, 2-ME, HEPES, pen/strep-glutamine, and 
20% IL-3-conditioned media for 4-6 weeks, after which >90% of viable cells are mature mast cells 
(c-kit+ FcRI+ by flow cytometry). MC/9 mast cells were maintained in DMEM supplemented 
with 10% BGS, 2-ME, pen/strep with glutamine, and 10% IL3-conditioned media. 
8.2.2 Antibodies and reagents 
Monoclonal anti-dinitrophenyl (DNP) antibody, IgE isotype, clone SPE-7, anti-Flag antibody M2, 
and DNP32 –HSA were from Sigma-Aldrich (St. Louis, MO).  Phorbol myristate acetate (283), 
ionomycin, aprotinin, leupeptin, pepstatin, sodium orthovanadate, and 4-(2-aminoethyl)benzene 
sulfonyl fluoride (AEBSF) were purchased from Calbiochem/EMD Biosciences (San Diego, CA). 
Purified polyclonal antibody (Tim-3 pAb), directly fluorescent conjugated antibody to murine 
Tim-3, and normal goat IgG as isotype control were from R&D Systems (Minneapolis, MN). mAb 
to Tim-3 5D12 was from Vijay Kuchroo (Harvard Medical School). Anti-IgE-FITC antibody was 
from Biolegend (San Diego, CA). Antibody to FcRI  chain was from Santa Cruz Biotechnology 
(Dallas, TX). Antibodies to Bat3 and FcRI  chain were from EMD Millipore (Billerica, MA). 
Fluorescent antibodies to CEACAM1/2 (CD66a) and mouse IgG isotype control were obtained 
from eBioscience (San Diego, CA).  
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8.2.3 BMMC stimulation for modulation of Tim-3 and CEACAM1 expression 
BMMCs were sensitized with 1 g/ml IgE overnight and stimulated with 50 ng/ml DNP32-HSA 
for the indicated times. Cells were fixed with 1.5 % PFA and permeabilized with ice cold methanol 
prior to staining for total Tim-3 and flow cytometry. Surface Tim-3 and CEACAM1 was also 
determined by flow cytometry.  
8.2.4 Western blotting and immunoprecipitation 
BMMCs and MC/9 were sensitized with 0.5 μg/ml IgE for two hours at 370C in Tyrode’s buffer. 
Cells were then stimulated with DNP32-HSA for indicated times in Tyrode’s buffer. Cells were 
lysed in 1% Nonidet-P-40 lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl) supplemented 
with AEBSF, aprotinin, leupeptin, pepstatin, sodium fluoride, sodium orthovanadate, and beta-
glycerophosphate on ice for twenty minutes.  Lysates were centrifuged at 4oC for fifteen minutes. 
For western blotting analysis, SDS-containing sample buffer was added to lysates prior to loading 
onto 10% or 12% SDS-PAGE gels when analyzing for FcεRI β and γ chains. For IPs, lysates were 
incubated overnight at 4oC with appropriate antibodies. Immune complexes were precipitated at 
4oC for two hours with protein A or G agarose beads (Pierce) for rabbit or mouse Abs respectively, 
then washed with NP-40 lysis buffer three times before analysis by SDS-PAGE gels. Proteins were 
transferred onto polyvinylidene difluoride (PVDF) membranes using the PierceG2 fast blotter 
(Pierce), probed with appropriate antibodies, and imaged on a ProteinSimple Fluochem M cooled 
CCD imager (ProteinSimple).  
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8.2.5 FcRI internalization assay 
BMMCs were sensitized with 0.5 μg/ml IgE for two hours at 370C in Tyrode’s buffer. BMMCs 
were incubated with 100 ng/ml DNP32-HSA for one hour on ice to cross-linked IgE-bound 
receptors without inducing internalization. Aliquots of Ag-bound cells were removed and placed 
in a 370C water bath for indicated times to allow for receptor internalization. Surface Tim-3 and 
FcRI were determined by staining with anti-Tim-3-PE and anti-IgE-FITC prior to flow cytometry 
analysis. %receptor internalization was calculated as [MFI(time X)– MFI (time 0’)]/MFI (time 0’) 
where X indicates incubation time.    
8.2.6 TIRF microscopy and analysis 
Anti-DNP IgE was labeled with Alexa 647 (Life Technologies). BMMCs were transfected with 
Tim-3-mYFP construct by nucleofection (Lonza). Twenty-four hours post-transfection, BMMCs 
were sensitized with 1μg/ml IgE-Alexa 647 for one hour at 370C.  3 x 105 cells were loaded into 
poly-D-lysine treated glass bottom dishes (321) that were coated with 1 mg/ml DNP32-HSA 
antigen in PBS for one hour at 370C and fixed with 2% PFA. Images were captured in TIRF mode 
using Nikon Eclipse Ti Live Cell Microscope equipped with Andor Zyla VSC-00311 camera and 
Apo TIRF 100x oil DIC N2 objective, and analyzed with NIS-Elements Ar 4.20 software (Nikon 
Instruments Inc.). Colocalization analysis was performed using the Spots Colocalize function of 
the Imaris Scientific 3D/4D Imaging Processing and Analysis software (Bitplane).    
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8.3 RESULTS 
8.3.1 Tim-3 ligands Bat3 and CEACAM1 are expressed by mast cells and do not interfere 
with Tim-3 cross-linking  
The human leukocyte antigen B (HLA-B)-associated transcript 3 (Bat3) has been proposed to be 
a negative regulator of Tim-3 and to protect Th1 T cells from Tim-3-mediated cell death and 
exhaustion (309). We therefore determined whether the co-stimulatory activity of Tim-3 in mast 
cells might be due to a lack of Bat3 expression. We found that Bat3 was expressed in both primary 
BMMCs and the MC/9 mast cell line and that its expression was not affected by FcRI cross-
linking, either alone or in conjunction with Tim-3 engagement (Fig. 8-1A-B). Recently, 
carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1), a molecule inhibitory activity, 
was described as a facilitator of Tim-3 surface expression and its subsequent inhibitory function 
in CD4+ T cells by forming heterodimers with Tim-3 (271). As with Bat3, we wanted to determine 
whether lack of CEACAM1 expression might explain the co-stimulatory activity of Tim-3 on mast 
cells. We found that CEACAM1 was indeed expressed at a high level on both the MC/9 mast cell 
line and primary BMMCs (Fig. 8-1C-D). While surface and intracellular Tim-3 expression was 
reduced upon Ag stimulation, CEACAM1 levels remained relatively unchanged (Fig. 8-1E-G). 
Thus, the ability of Tim-3 to act as a co-stimulatory molecule to enhance FcRI-mediated mast 
cell activation is not due to an absence of Bat3 and/or CEACAM1 expression in these cells.  
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Figure 8-1: Tim-3 is co-modulated with FcRI after stimulation with antigen and IgE. (A-D) Tim-3-interacting 
proteins Bat3 and CEACAM1 are expressed in mast cells. BMMCs were stimulated with IgE/Ag in the presence of 
isotype control or Tim-3 pAb. Bat3 expression on BMMC (A) and MC/9 (B) was determined by western blotting. 
Constitutive CEACAM1 surface expression on BMMC (C) and MC/9 (D) was determined by flow cytometry. 
CEACAM1 and Tim-3 expression on BMMC post-stimulation with IgE/Ag at indicated times were determined by 
flow cytometry (E-G). Results are representative of two independent experiments (A-D). Results are average of three 
independent experiments (E-G). *p <0.05; **p<0.05. 
 110 
8.3.2 Antigen-mediated surface FcRI internalization is not affected by Tim-3 ligation 
Since antigen stimulation downregulated both surface and total Tim-3 expression, we determined 
if Tim-3 engagement could promote FcRI surface expression or delay receptor internalization 
post antigen stimulation, both of which may facilitate extended and intensified FcRI proximal 
signaling. As expected, longer IgE sensitization time led to increased surface expression of IgE-
bound FcRI, which was not augmented with Tim-3 pAb co-treatment (Fig. 8-2A). Similarly, we 
observed robust receptor internalization within five minutes of antigen cross-linking. However, 
additional Tim-3 pAb treatment did not alter the kinetics of FcRI internalization (Fig. 8-2B). As 
a result, while Tim-3 expression is co-modulated by FcRI activation, Tim-3 ligation does not 
appear to regulate the FcRI itself, but rather its signaling activity. 
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Figure 8-2: Antigen-mediated receptor internalization is not modulated by Tim-3 cross-linking. BMMCs were 
sensitized with IgE for the indicated times prior to determination of surface IgE-bound FcRI by flow cytometry (A). 
BMMCs were sensitized with IgE for one hour and incubated with antigen on ice for one hour prior to receptor cross-
linking for the indicated times (B). % FcRI internalization was determined by flow cytometry. Results are 
representative of two independent experiments.   
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8.3.3 Tim-3 co-localizes with components of the FcRI proximal signaling complexes 
Consistent with the findings discussed above, which suggest that Tim-3 partners closely with the 
FcRI, we observed by co-immunoprecipitation constitutive interaction between Tim-3 and the 
FcRI  and  subunits (Fig. 8-3A-B). These interactions were diminished somewhat after Ag 
stimulation, possibly due to turnover in the total amount of Tim-3 protein. Next we utilized total 
internal reflection fluorescence (TIRF) microscopy to obtain further evidence that Tim-3 localizes 
with, or proximal to, FcRI. Thus, we were able to observe partial co-localization of Tim-3 and 
the FcRI receptor at the cell surface when a Tim-3-mYFP construct was expressed in WT 
BMMCs (yellow clusters; Fig. 8-3C). Ligation of FcRI by IgE/Ag complexes has been shown to 
trigger receptor endocytosis and subsequent ubiquitin-mediated degradation, resulting in signal 
termination (360). Since we observed a reduction of surface Tim-3 upon IgE/Ag stimulation (Fig. 
8-2E), our data suggested that surface Tim-3 may be internalized by a similar mechanism, perhaps 
even as part of the same FcRI complex. We also determined if Tim-3, due to its proximity to the 
FcRI, could associate with Lyn that binds constitutively to FcRI. While we observed 
association in some experiments, the binding was not consistent, and thus will require further 
investigation.  
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Figure 8-3: Tim-3 associates with components of the FcRI signaling complexes. MC/9 were stimulated as indicated. 
Tim-3 IP’s were analyzed for the presence of FcRI  chain (A),  chain (B) (upper panels), or Tim-3 (lower panels). 
(C) BMMCs were transfected with Tim3-mYFP, sensitized with IgE-Alexa 647 for one hour, and settled onto poly-
D-lysine treated glass-bottom dishes coated with 1mg/ml DNP32-HSA at 370C. Cells were fixed with 2% PFA after 
one hour, and TIRF images were collected. The percentage of colocalized spots was derived from the average of 
twenty-one cells both labeled with anti-IgE-Alexa 647 and expressing Tim3-mYFP, in three independent experiments. 
(D) Lysates from MC/9 stimulated with IgE/Ag were subjected to Tim-3 immunoprecipitation and analyzed for the 
presence of Lyn (upper panels) and Tim-3 (lower panels). Results are representative of two independent experiments 
(A-B) and three out of seven experiments (D).  
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8.4 DISCUSSION 
In addition to the previously described “in-trans” ligands of Tim-3, we also examined other 
effector molecules that have been described as regulators of Tim-3 function. We found that the 
chaperone Bat3, a putative negative regulator of Tim-3 function in T cells (309), is expressed in 
mast cells, but mechanisms of its function are relatively unknown. CEACAM1 was recently 
described as a binding partner of Tim-3 and was observed to be co-expressed with Tim-3 during 
the induction of T cell tolerance (271). We detected CEACAM1 expression in both the MC/9 mast 
cell line and primary BMMCs, although its role in mast cell function is unclear. Thus, the potential 
roles that Bat3 and CEACAM1 may play in regulating mast cell function via Tim-3 require further 
investigation. Nonetheless, the enhancement of mast cell activation by Tim-3 cannot be solely 
attributed to the lack of expression of either Bat3 or CEACAM1.  
We observed constitutive association of Tim-3 with FcRI  and  subunits. While there 
was a slight increase of Tim-3 association to  and  upon antigen stimulation, the slight decrease 
in associated  and  was probably due to Tim-3 downregulation. In fact, antigen-induced turnover 
of surface and total Tim-3 has been consistently observed in both MC/9 and BMMCs (Fig. 8-1, 8-
3). Thus, it is possible that Tim-3 is regulated by FcRI cross-linking at the protein level, which 
further supports our hypothesis that Tim-3 is internalized and processed by the same mechanism 
as the FcεRI. To test this possibility, we performed TIRF microscopy to examine the potential 
interaction of Tim-3 with FcRI on the cell surface without interference from the intracellular pool 
of Tim-3. We were not able to detect co-localization of Tim-3 and FcRI at resting state as the 
mast cells did not attach and spread efficiently without antigen coating on the poly-D-lysine treated 
glass-bottom dishes. Since we could only image the cells that have properly attached to the plate 
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and cross-linked by antigen, it is possible that we only captured a fraction of the transected Tim-3 
pool remaining on the cell surface by the end of stimulation. Nevertheless, we did observe co-
localization of Tim-3 and IgE-bound receptor at the cell surface, suggesting Tim-3 not only shares 
signaling pathways but also physically associates with the FcRI. Future studies will focus on 
methods to promote rapid and efficient cell adherence to the glass dishes so we can observe the 
pattern of Tim-3 expression on mast cells both at basal level and upon antigen cross-linking using 
live cell imaging.  
We detected a certain level of Lyn association with Tim-3 at resting state and upon antigen 
stimulation. Previous studies also showed that Lyn is constitutively associated with FcRI in both 
soluble and lipid raft fractions and that this association is increased upon FcRI aggregation (114). 
Upon high intensity Ag stimulation, FcRI is then recruited into the lipid rafts, where enhanced  
phosphorylation by Lyn occurs, to facilitate binding of phosphatases, leading to down-regulation 
of signaling (114). Thus, the majority of the evidence points to a close association between FcRI, 
Lyn and Tim-3 under basal conditions. Therefore, it is important to determine the distribution 
pattern of Tim-3 in both lipid raft and non-raft fraction under antigen stimulation, and if Tim-3 
cross-linking will affect localization of Tim-3 or FcRI , leading to decreased association with 
phosphatases and enhanced positive antigen receptor signaling.     
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9.0  TIM-3 ENGAGEMENT ENHANCES ANTIGEN-INDUCED 
PHOSPHORYLATION OF PHOSPHOLIPASE C GAMMA AND RIBOSOMAL 
PROTEIN S6 
9.1 INTRODUCTION 
Antigen stimulation of FcRI triggers activation of the Src kinase Lyn, which controls the primary 
pathway downstream of FcRI. Receptor aggregation by Ag stimulation leads to Lyn-mediated 
phosphorylation of the FcRI  chain, as well as phosphorylation of the  subunit of the receptor, 
which promotes Syk recruitment and activation. Syk mediates phosphorylation of downstream 
adaptor molecules such as LAT and Slp76, and the enzyme PLC-1 (350, 351). Phosphorylation 
and activation of PLC-1 leads to generation of inositol triphosphate (IP3) essential to calcium 
mobilization for degranulation and activation of NF-AT for cytokine production (157). DAG 
generated by PLC-1 can activate PKC, and contributes to Fos and Jun activation (166). Thus, 
PLC-1 is an important antigen receptor proximal signaling effector with multiple involvement in 
both the immediate and late-phase mast cell activation.  
 Syk-mediated phosphorylation of the adaptor molecule LAT leads to activation of the 
Ras/Raf/MAPKs pathways including ERK, p38, and JNK (162). These MAPKs go on to regulate 
activation of transcription factors Fos and Jun, component of the activating protein (AP)-1, NFAT, 
and NF-B, and thus has a role in cytokine production (163-165). Together, the 
Lyn/Syk/LAT/PLC axis is responsible for initiating and maintaining FcRI signaling required for 
mast cell effector function. In the following study, we systematically determine how Tim-3 ligation 
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modulates both receptor proximal and downstream signaling pathways leading to enhanced 
degranulation and cytokine production in antigen-activated mast cells. We show that Tim-3 pAb 
augments total tyrosine phosphorylation in antigen-stimulated BMMCs. While Syk and MAPKs 
activation is not affected, phosphorylation of PLC1 and the mTOR substrate ribosomal S6 is 
enhanced by Tim-3 pAb co-stimulation, thus providing a potential mechanism for augmented 
cytokine production.   
9.2 MATERIALS AND METHODS 
9.2.1 Mice and BMMC culture  
The Nur77 GFP reporter mouse, C57BL/6-Tg(Nr4a1-EGFP/cre)820Khog/J, was purchased from 
the Jackson Laboratory and maintained in the University of Pittsburgh Animal Facility. C57BL/6 
mice (7-8 weeks old) purchased from the Jackson Laboratory (Bar Harbor, ME). Bone marrow 
cells were cultured in RPMI 1640 supplemented with 10% BGS, non-essential amino acid, 2-ME, 
HEPES, pen/strep-glutamine, and 20% IL-3-conditioned media for 4-6 weeks, after which >90% 
of viable cells are mature mast cells (c-kit+ FcRI+ by flow cytometry). 
9.2.2 Antibodies and reagents 
Monoclonal anti-dinitrophenyl (DNP) antibody, IgE isotype, clone SPE-7, and DNP32 –HSA, were 
from Sigma-Aldrich (St. Louis, MO). Purified polyclonal antibody (Tim-3 pAb) and normal goat 
IgG control were from R&D Systems (Minneapolis, MN). Phospho-specific Ab’s PLC-1 (Y783) 
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and total PLC-1 were obtained from BD Biosciences (San Jose, CA). Phospho-specific antibodies 
to Syk (519/520), p38 MAPK (T180/Y182), SAPK/JNK (T183/Y185), S6(S235/234), and ERK 
(T202/Y204) were from Cell Signaling Technology (Danvers, MA). Antibody against total 
tyrosine phosphorylation (clone 4G10) was from EMD Millipore (Darmstadt, Germany).  
9.2.3 BMMC stimulation and Western blotting 
BMMCs were sensitized with IgE overnight and stimulated with DNP32-HSA with either goat 
isotype or Tim-3 pAb for the indicated time. Cells were lysed in 1% Nonidet-P-40 lysis buffer (20 
mM Tris-HCl, pH 7.5, 150 mM NaCl) supplemented with AEBSF, aprotinin, leupeptin, pepstatin, 
sodium fluoride, sodium orthovanadate, and beta-glycerophosphate on ice for twenty minutes. 
Lysates were centrifuged at 4oC for fifteen minutes. For western blotting analysis, SDS-containing 
sample buffer was added to lysates prior to loading onto 10% SDS-PAGE gels. Proteins were 
transferred onto polyvinylidene difluoride (PVDF) membranes using the PierceG2 fast blotter 
(Pierce), probed with appropriate antibodies, and imaged on a ProteinSimple Fluochem M cooled 
CCD imager (ProteinSimple).  
9.2.4 BMMC stimulation and phospho-flow cytometry 
BMMCs were sensitized with IgE overnight and stimulated with DNP32-HSA either with goat 
isotype or Tim-3 pAb for indicated times. Cells were fixed with 1.5% PFA and permeabilized with 
ice cold methanol prior to staining for phospho-specific Ab’s to Syk (Y519/520), ERK 
(T202/Y204), and S6 (S235/236) and flow cytometry analysis.  
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9.3 RESULTS 
9.3.1 Tim-3 enhances Ag-triggered phosphorylation of PLC-1 
Our findings thus far demonstrated that Tim-3 expression co-stimulated NF-B and NF-AT/AP1, 
leading to IL-6 transcriptional activation and cytokine production, possibly by augmenting antigen 
receptor signaling. To determine the molecular mechanisms of Tim-3 signaling in mast cells, we 
first examined whether Tim-3 ligation could enhance total tyrosine phosphorylation. Consistent 
with our cytokine and Nur7GFP data, Tim-3 pAb alone could not stimulate mast cell activation (Fig. 
9-1A). Compared to antigen alone, addition of Tim-3 pAb induced stronger intensity of multiple 
bands ranging from 25kD to 100kD (Fig. 9-1A). The double-band at 50kD is characteristic of Src 
family kinase phosphorylation, and is not significantly modulated by Tim-3 activity. We were 
particularly interested in the bands at approximately 75kD and 100kD as they correlate with the 
size of Syk and PLC respectively. Subsequently, robust Syk phosphorylation at its auto-
phosphorylation sites, tyrosines 519 and 520 critical to Syk activity (131, 134-136) was detected 
two minutes post stimulation. However, Tim-3 cross-linking did not modify phosphorylation of 
these sites on Syk (Fig. 9-1B). On the other hand, phosphorylation of PLC-1 (at Y783) was more 
robust in BMMCs co-stimulated with Ag and Tim-3 pAb (Fig. 9-1B), compared with cells 
stimulated with Ag alone. Therefore, Tim-3 may enhance Ag-mediated NF-AT activation through 
activity of PLC in mast cells. 
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Figure 9-1: Tim-3 pAb co-stimulates Ag-mediated total tyrosine and PLC1 phosphorylation. BMMCs were sensitized 
with IgE overnight and stimulated as indicated for ten minutes, lysed and analyzed by western blotting for total 
tyrosine phosphorylation (A). BMMCs were stimulated as described for two minutes prior to determination of pSyk 
(Y519/520) by flow cytometry (B). BMMCs were simulated as indicated for ten minutes and analyzed for phospho-
PLC-1 (upper panel), total PLC-1 (middle panel), and actin (C) by western blotting. Relative proportions of PLC-
1 phosphorylation are quantified in the right panel. BMMCs were stimulated as described for two minutes prior to 
determination of pSyk (Y519/520) by flow cytometry (B). Results are representative of two (A) and three (C) 
independent experiments, and average of three independent experiments (B). 
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9.3.2 Tim-3 engagement sustains FcRI-mediated phosphorylation of ribosomal protein 
S6 but not MAPKs in BMMCs 
Next we determined if Tim-3 is involved in regulation of the p38, JNK, and ERK MAPKs 
pathways. While Ag stimulation induced robust phosphorylation of all three MAPK pathways, 
Tim-3 pAb treatment did not exert any additional effects (Fig. 9-2A-C). Similarly, transient Tim-
3 knockdown by siRNA did not alter Ag-mediated ERK phosphorylation, suggesting Tim-3 
expression or activation is not involved in regulating the MAPK, particularly ERK, pathways (Fig. 
9-2D).   
One of the major signaling pathways that regulate cell growth, protein synthesis and 
metabolism in mast cell is the PI3K/mTOR pathway (361). We observed robust phosphorylation 
of ribosomal protein S6 after thirty minutes of IgE/Ag stimulation, when 80% of BMMCs 
exhibited high levels of pS6 and Tim-3 pAb did not have any additive effect (Fig. 9-2E). However, 
Tim-3 cross-linking was able to maintain a significantly larger proportion of pS6high cells for as 
long as four hours after Ag stimulation, when pS6 levels had returned to baseline (Fig. 9-2E). More 
importantly, the increase in pS6 correlated with the intensity of FcRI engagement, as shown with 
Nur77GFP BMMCs (Fig. 9-2F). Overall, these results are consistent with a close physical and 
functional association between Tim-3 and the FcRI, as also shown above. 
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Figure 9-2: Tim-3 crosslinking enhances ribosomal protein S6 phosphorylation without affecting MAPKs signaling. 
BMMCs were stimulated as indicated, lysed and analyzed by western blotting for phospho-p38 (A), pJNK (B), and 
actin. Stimulated BMMCs were analyzed by flow cytometry for phospho-ERK (C). BMMCs were transfected with 
non-specific (NS) or Tim-3 siRNA and pmax-GFP for 48 hours. Transfected cells were stimulated as indicated and 
GFP+ cells were analyzed for phospho-ERK by flow cytometry (D). Nur77GFP BMMCs were stimulated as indicated 
and analyzed for pS6 (S235/236) by flow cytometry. Results are quantitated as %pS6hi (E) and %pS6+GFP+ cells (F). 
Results are representative of three independent experiments (A-B), two independent experiments (C-D), and average 
of three independent experiments (E-F). * p <0.05. 
 123 
9.4 DISCUSSION 
We examined the potential signaling pathways at the Ag receptor proximal level and downstream 
that lead to enhanced degranulation and cytokine production by Tim-3 pAb and Ag co-treatment. 
Consistent with a co-stimulatory role, Tim-3 pAb alone could not activate mast cells. However, 
Tim-3 cross-linking led to increased Ag-mediated total tyrosine phosphorylation, specifically 
PLC-1 phosphorylation, which is necessary for mast cell degranulation, yet failed to enhance Ag-
activated phosphorylation of ERK, JNK or p38. PLC1 is a substrate of Syk and increased PLC1 
activity implies that Syk activity may also be positively regulated by Tim-3 engagement. However, 
we did not observe increased Syk phosphorylation after Tim-3 co-stimulation. Syk is 
phosphorylated on a number of tyrosines, which are differentially regulated by either auto-
phosphorylation or trans-phosphorylation by SFKs such as Lyn (131). Since we only examined 
phosphorylation of Y519 and Y520, indicators of Syk auto-phosphorylation, it is possible that 
Lyn-mediated phosphorylation of other activating tyrosines could be promoted by Tim-3 cross-
linking. Phosphorylated Syk tyrosines can mediate either positive or negative regulatory FcRI 
signaling (134-136). Therefore, it will be important to determine if the activation state of the 
inhibitory tyrosines, particularly Y317 associated with negative regulation of PLC1 
phosphorylation, is modify by Tim-3 activity.  
Consistent with a co-stimulatory role, Tim-3 pAb alone could not activate mast cells. 
PLC2 is also phosphorylated upon FcRI stimulation, and is thus another potential Tim-3 target 
for enhanced NF-AT activation. In addition, the Tec kinase Btk may contribute to degranulation 
and cytokine production by phosphorylating PLC1 and PLC2 (143-145). Thus, future studies 
will also examine whether Btk recruitment to the plasma membrane or its activity can be altered 
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by Tim-3 engagement. Finally, calcium release, a critical functional read-out for increased PLC 
activation, warrants further investigation to support the connection between Tim-3 signaling and 
NF-AT activation.  
PI3K/mTOR signaling pathways are crucial to mast cell survival, proliferation, protein 
synthesis and metabolism. Specifically, FcRI-induced mTORC1, an upstream activator of S6, is 
constitutively active in human tumor mast cells (361). Here we showed that Tim-3 enhancement 
of Ag-activated cytokine secretion correlates with sustained S6 phosphorylation, suggesting a 
connection between Tim-3 signaling and the PI3K/mTOR pathway. Since the enhanced S6 
phosphorylation was observed in conjunction with increased Nur77 expression, these results 
illustrated that modification of S6 activity is due to positive regulation of Ag receptor signal 
strength by Tim-3. Tim-3 pAb co-stimulation was previously shown to rescue IL-3 withdrawal-
mediated apoptosis of mast cells, through induction of Ag-mediated IL-3 release (240). Overall, 
our data provide additional evidence to support a direct role for Tim-3 in mast cell survival, 
proliferation and cytokine production.   
 
 125 
10.0  TIM-3 REGULATES POSITIVE VERSUS NEGATIVE ANTIGEN RECEPTOR 
SIGNALING  
10.1 INTRODUCTION 
Our in vitro studies thus far show that Tim-3 signaling can positively regulate IgE/Ag-mediated 
mast cell degranulation and cytokine production. Since mast cells are well-known effectors of type 
I hypersensitivity, we next explored whether a similar function for Tim-3 could be observed in an 
in vivo model of mast cell-dependent anaphylaxis, with the commonly used passive cutaneous 
anaphylaxis (PCA) model. During the immediate phase, mast cells-secreted histamine increases 
vascular permeability and edema, which can be measured by ear swelling. In the late-phase PCA, 
mast cell-dependent TNF secretion recruits polymorphonuclear cells (PMNs) into the site of 
inflammation ((362). Thus, we determine whether Tim-3 has a role in regulating PCA response in 
mast cells by comparing ear thickness, cytokine secretion, and infiltration of leukocytes between 
Tim-3 WT and KO mice. Unexpectedly, we observed heightened acute phase reaction in the 
absence of Tim-3 while cytokine production was not affected compared to WT littermates. As 
these results are reminiscent of those observed in the Lyn mutant WeeB mouse strain with reduced 
Lyn kinase activity (340), we assess how Tim-3 engagement might modulate mast cell activation 
in the acute absence of Lyn expression. Overall, our data reveal that Tim-3 enhances IgE/Ag-
induced mast cell activation by regulating the positive and negative kinase activity of Lyn.   
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10.2 MATERIALS AND METHODS  
10.2.1 Mice 
Tim-3 KO mice were originally obtained from John Colgan (University of Iowa). Age-matched 
female wild-type C57BL/6 mice (7-8 weeks old) were purchased from the Jackson Laboratory 
(Bar Harbor, ME) and housed for seven days before use as control for PCA experiments. All 
studies were performed in accordance with University of Pittsburgh Institutional Animal Care and 
Use Committee procedures. 
10.2.2 Antibodies and reagents 
Monoclonal anti-dinitrophenyl (DNP) antibody, IgE isotype, clone SPE-7, DNP32 –HSA were 
from Sigma-Aldrich (St. Louis, MO). DNP5 –BSA was purchased from Biosearch Technologies 
(Petaluma, CA). Purified polyclonal antibody (Tim-3 pAb) and normal goat IgG control were from 
R&D Systems (Minneapolis, MN). Total Lyn antibody were from Cell Signaling Technology 
(Danvers, MA).  
10.2.3 Passive cutaneous anaphylaxis (PCA) 
Mice were sensitized by intradermal injection of anti-DNP IgE (50 ng/50 μl) or equal volume of 
vehicle (PBS) in each ear. Twenty-four hours later, mice were challenged i.v. with DNP32-HSA 
(100 μg/200 μl in PBS). Mouse ear edema was evaluated by measuring ear swelling at indicated 
time points. The percent change in ear thickness of PBS- or IgE-treated ears was determined as 
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changes above baseline prior to antigen challenge. Mice were euthanized twenty-four post antigen 
challenge. Ear tissues were excised and digested using T-PER tissue extraction buffer (Thermo 
Fisher). Lysates were quantified for total protein amount and subsequent IL-6 measurement by 
ELISA (BioLegend). For histologic analysis, ear tissue sections were fixed in 4% PFA, and 
processed for hematoxylin and eosin. Tissue sections were examined with the Axiostar plus 
microscope equipped with epifluorescent and a digital camera (AxioCam; Zeiss, Oberkochen, 
Germany). Images were visualized with AxioVision (Ziess). Results are represented as the mean 
± SEM. Two-way ANOVA analysis was performed with Bonferroni post hoc multiple comparison 
test. Outliers were removed using Outlier calculator (GraphPad software).  
10.2.4 BMMC isolation and culture 
Bone marrow cells from C57BL/6 WT mice were cultured in RPMI 1640 supplemented with 10% 
BGS, non-essential amino acid, 2-ME, HEPES, pen/strep-glutamine, and 20% IL-3-conditioned 
media for 4-6 weeks, after which >90% of viable cells are mature mast cells (c-kit+ FcRI+ by 
flow cytometry). 
10.2.5 BMMC stimulation and cytokine measurement 
BMMCs were sensitized with 1 g/ml IgE overnight in complete media without IL-3. Cells were 
then stimulated with either DNP32-HSA or DNP5-BSA in IL-3-free media for indicated times. 
Supernatants were assayed for murine IL-6 by ELISA (BioLegend) six hours post-stimulation.  
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10.2.6 siRNA knock-down of Lyn in BMMC by nucleofection 
BMMCs (3 x 106) were transfected with 100 pmol of non-specific or Lyn siRNA (Dharmacon) 
using the mouse macrophage nucleofector kit (Lonza), Y-001 program, and the Nucleofector II/2b 
device (Lonza). Transfected cells were collected after forty-eight hours and efficiency of Lyn 
knockdown was determined by western blotting.  
10.2.7 Western blotting 
Cells were lysed in 1% Nonidet-P-40 lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl) 
supplemented with AEBSF, aprotinin, leupeptin, pepstatin, sodium fluoride, sodium 
orthovanadate, and beta-glycerophosphate on ice for twenty minutes. Lysates were centrifuged at 
4oC for fifteen minutes. For western blotting analysis, SDS-containing sample buffer was added 
to lysates prior to loading onto 10% SDS-PAGE gels for analysis of Lyn expression. 
10.2.8 Statistical analysis 
All statistical analysis was performed using Prism software (GraphPad Software). Paired, two-
tailed Student’s t-test, one-way and two-way ANOVA with Bonferroni post hoc test were used for 
data analysis and determination of p values, as appropriate. 
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10.3 RESULTS 
10.3.1 Tim-3 functions through Lyn kinase to regulate FcRI activating versus inhibitory 
signals  
We hypothesized that the late-phase PCA response would be more impaired in the absence of Tim-
3 compared to WT controls based on our in vitro findings. To our surprise, Tim-3 KO mice 
displayed a heightened immediate-phase PCA response compared to WT littermates, as measured 
by increased ear thickness (Fig. 10-1A). Since the peak of the immediate PCA response occurs 
around two hours post Ag injection and slowly declined, we were not able to observe any 
significant edema in the ear tissue twenty-four hours post Ag treatment (Fig. 10-1A-B). There 
appeared to be higher swelling in the vehicle (PBS) ear compared to the IgE treatment. This result 
is represented in the slight increase in ear thickness, suggesting this is an IgE-independent event 
(Fig. 10-1B). Similarly, cytokine production was comparable between WT and Tim-3 KO mice. 
However, the lack of IL-6 increase in IgE-treated ears over vehicle control suggests this may be a 
technical issue that needs to be addressed further (Fig. 10-1C). 
 We detected higher levels of serum IgE in some, but not all, naïve Tim-3 KO mice (Figure 
10-1D), consistent with the slightly higher swelling observed in PBS-treated ears of Tim-3 KO 
mice (Fig. 10-1A). However, this would not seem to explain the higher PCA responses, since 
previous studies indicated that increased basal levels of IgE should result in higher receptor 
occupancy at baseline and less efficient priming with the exogenously administered IgE used in 
the PCA model (119),(340)). Nevertheless, these results indicate that the Tim-3 KO mice have a 
wider range of circulating serum IgE, which may be a confounding factor in our PCA experiments.  
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The PCA response of Tim-3 KO mice is reminiscent of enhanced anaphylaxis observed in 
the WeeB mouse strain, which expresses a mutant form of Lyn with reduced catalytic activity 
(340). Studies using WeeB  mice and mast cells revealed that the majority of Lyn kinase activity 
is required for negative regulation of mast cell signaling, while only a small fraction of Lyn activity 
is needed to induce mast cell activation (340). Given the stronger anaphylactic response in the 
absence of Tim-3, it seemed possible that Tim-3 might be involved in tuning receptor signal 
strength through Lyn kinase, and subsequently its negative effects, leading to enhanced mast cell 
responses in vivo. To further investigate a possible intimate role for Tim-3 in regulating the relative 
activity of Lyn, we performed siRNA-mediated knockdown of Lyn in WT BMMCs. We then 
activated these cells with high or low valency antigen to engage its positive and negative functions, 
respectively, in the presence of Tim-3 crosslinking. Thus, under conditions of “weaker” 
stimulation, where Lyn primarily acts to enhance FcRI signaling, knocking down Lyn expression 
resulted in decreased cytokine release that could be enhanced by Tim-3 pAb co-stimulation (Fig. 
10-1E). Strikingly, under conditions of high intensity stimulation, where the negatively regulatory 
role of Lyn is revealed, Tim-3 cross-linking was still able to maintain, or even enhance, cytokine 
secretion (Fig. 10-F). The degree of Lyn knock-down (approximately 60%) is shown in Figure 10-
1G. It should be noted that even with in vitro experiments using BMMC, we occasionally observed 
enhanced cytokine production by Tim-3 deficient mast cells, compared with WT mast cells, when 
stimulated with very high concentrations of antigen (data not shown).  
Taken together, our results suggest an intimate role for Tim-3 in regulating the intensity of 
FcRI signaling delivered through Lyn. Furthermore, the effects of Lyn knock-down allowed us 
to clarify the apparently paradoxical effects of Tim-3 knockout in the PCA model, where it is more 
difficult to control the strength of antigen receptor stimulation. 
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Figure 10-1: Tim-3 regulates FcRI positive vs. negative signaling. PCA responses in WT (n=13) and Tim-3 KO 
(n=11) mice were measured as described in the Materials and Methods. Results are representative of three independent 
experiments totaling 19 WT and 14 Tim-3 KO mice. Results are represented as the mean ± SEM. Two-way ANOVA 
analysis was performed with Bonferroni post hoc multiple comparison test. Outliers were removed using QuickCalcs 
(GraphPad Software). (D) Circulating serum IgE from Tim-3 WT and KO mice. Lyn siRNA-treated cells were 
sensitized with IgE and stimulated with low valency (E) or high valency (F) antigen, plus isotype control, Tim-3 pAb 
or Tim-3 mAb. (G) Efficiency of siRNA-mediated Lyn knockdown in BMMCs. Results shown are representative of 
three independent experiments performed in duplicate. *p <0.05; **p<0.005; ***p<0.005. 
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10.4 DISCUSSION 
Our PCA results revealed an unexpected Tim-3 involvement in balancing the positive and negative 
Ag receptor signaling. While we did not observe any difference in cytokine production, significant 
increase in ear thickness, an indication of tissue edema, was consistently observed in multiple 
experiments. In addition, we were not able to detect any TNF- from the tissue even though it was 
one of the main cytokines driving cellular infiltration into the inflamed ears (data not shown and 
(362)). Therefore, more studies are needed to ensure reliable cytokine measurement to confirm the 
effects of Tim-3 on late-phase PCA response. An alternative is to perform immunofluorescent 
staining of IL-6 and TNF- in situ to eliminate any potential technical issue with tissue extraction. 
It will be important to perform engraftment of WT, Tim-3 KO, or WeeB BMMCs into the mast 
cell-deficient c-kit W-sh/W-sh mice to confirm the modulatory activity of Tim-3 on Ag receptor 
signaling. Alternatively, we can attempt to address the requirement for Tim-3 in mast cell-
mediated allergic inflammation using the mast cell-dependent chronic lung inflammation model.  
In this model, mast cells are required for secretion of TNF to induce a Th2-biased response and 
lymphocyte recruitment into the airways and lungs (240). 
We propose a model in which Tim-3 crosslinking provides a co-stimulatory signal (or set 
of signals) that integrates into the stimulatory signals that regulate IgE/Ag-mediated mast cell 
activation. In the absence of Tim-3, there is reduced functional output as a result of decrease Ag 
receptor intensity. However, Ag receptor signaling at high concentrations (or valency) of Ag is 
more complex, and the altered output may be attributed to reduced Lyn activity, most of which is 
involved in negative feedback signaling (340), leaving the residual kinase activity to enhance 
biological functions (Fig. 10-2). Performing the PCA assays with “weaker” antigen stimulation 
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(i.e. varying either the dose or valency) may help to confirm or refine this model. However, with 
the standard PCA model, the response rapidly declines to undetectable levels below the amount of 
antigen that we and others have used (340). Further testing of this model in vivo will require more 
sensitive assays for mast cell function, as well as more sophisticated models of conditional Tim-3 
deficiency.  
 
 
 
 
Figure 10-2: Proposed model for Tim-3 function on FcRI signaling. Proposed model for the effects of Tim-3 
engagement or deficiency on the functional outputs downstream of FcRI signaling. Note that the effects of Tim-3 
deficiency closely mirror those of partial loss-of-function of Lyn kinase activity.  
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11.0  TIM-1: TIM-4 INTERACTION ENHANCES CYTOKINE PRODUCTION 
WITHOUT AFFECTING DEGRANULATION  
11.1 INTRODUCTION 
Tim-4, mainly expressed on macrophages and dendritic cells, was identified as a ligand for Tim-
1, and has been shown to co-stimulate T cell proliferation mediated by CD3/CD28 in vitro. 
Treatment with high avidity antibody to Tim-1 exacerbated severity of EAE in susceptible mice 
and broke EAE tolerance in a disease-resistant strain (241). However, Tim-4 can deliver an 
inhibitory or activating signal to T cells stimulated with low and high dose of CD3 respectively in 
vitro (195). Mast cells constitutively express surface Tim-1 and Tim-3, but not Tim-2 or Tim-4 
(240). Tim-1 cross-linking by Tim4-Fc was shown to enhance cytokine production in a dose-
dependent manner without affecting degranulation (240). Using a Tim4-Fc fusion protein, we 
determined if Tim-4 could augment FcRI-mediated mast cell activation under both high and low 
Ag valency stimulation that has been known to engage FcRI negative and positive signaling 
pathways respectively (109). Here, we show that Tim4-Fc promotes Ag-induced mast cell cytokine 
production without affecting degranulation. In addition, Tim4-Fc is more efficient at enhancing 
cytokine release at high Ag valency, thus suggesting a role for Tim-1 signaling in preventing 
engagement of Ag negative signaling.  
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11.2 MATERIALS AND METHODS 
11.2.1 BMMC isolation and culture 
C57BL/6 mice were purchased from the Jackson Laboratory (Bar Harbor, ME) for bone marrow 
isolation. Bone marrow cells were maintained in RPMI 1640 supplemented with 10% BGS, non-
essential amino acid, 2-ME, HEPES, pen/strep-glutamine, and 20% IL-3-conditioned media for 4-
6 weeks, after which >90% of viable cells are mature mast cells (c-kit+ FcRI+ by flow cytometry). 
11.2.2 Antibodies and reagents 
Monoclonal anti-dinitrophenyl (DNP), IgE isotype, clone SPE-7, DNP32-HSA, and 4-Nitrophenyl 
N-acetyl--D-glucosaminide (pNAG) were purchased from Sigma-Aldrich (St. Louis, MO). 
DNP5-BSA was from Biosearch Technologies (Petaluma, CA). Purified Tim4-Fc were obtained 
from Vijay Kuchroo (Harvard Medical School). Human IgG as isotype control for Tim4-Fc was 
purchased from Jackson ImmunoResearch Laboratories (West Grove, PA). Anti-mouse Fc block 
(2.4G2) was purchased from BD Biosciences (San Jose, CA). 
11.2.3 BMMC stimulation and cytokine measurement 
BMMCs were sensitized overnight with 1 μg/ml IgE without IL-3 conditioned media. Cells were 
stimulated with DNP32-HSA or DNP5-BSA, with either human IgG isotype or Tim4-Fc for 
indicated times. Six hours post stimulation, supernatants were collected and assayed for murine 
IL-6 and TNF- by ELISA (BioLegend). 
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11.2.4 Measurement of beta-hexosaminidase release  
BMMCs were sensitized and subsequently stimulated for thirty minutes in Tyrode’s buffer (135 
mM NaCl, 5 mM KCl, 5.6 mM glucose, 1.8 mM CaCl2, 1 mM MgCl2, 20 mM HEPES, and 0.5 
mg/ml BSA). Supernatants (stimulated release) were collected and cells were lysed (content) with 
0.5 % Triton-X100 in PBS for fifteen minutes on ice. Content and stimulated release fractions 
were incubated with 1mM pNAG substrate for 1 hour at 370C. Carbonate buffer (0.1M, pH 9.0) 
was added to stop reaction and absorbance was obtained at 405nm on a plate reader. Percentage 
of beta-hexosaminidase release was calculated as (releasestimulated/contenttotal) x 100.  
11.2.5 Mast cell degranulation by Annexin V-based flow cytometry 
Degranulation was measured as described previously (321, 363). Briefly, BMMCs were loaded 
with 0.1 μM of Lysotracker Deep Red (Invitrogen) for thirty minutes prior to sensitization with 
0.5 μg/ml IgE for 1 hour at 370C. Ninety minutes post antigen cross-linking by DNP32-HSA, cells 
were collected and stained with Annexin V (BioLegend). %degranulation was determined as 
percentage of BMMCs that is AnnexinV+Lysotrackerlo.  
11.2.6 Statistical analysis 
All statistical analysis was performed using Prism software (GraphPad Software). Paired, two-
tailed Student’s t-test, one-way and two-way ANOVA with Bonferroni post hoc test were used for 
data analysis and determination of p values, as appropriate. 
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11.3 RESULTS 
11.3.1 Tim-1 engagement by Tim4-Fc enhances IgE/Ag- stimulated mast cell cytokine 
production without affecting degranulation 
Similar to published findings (96), we observed similar effects of Tim4-mediated IL-6 production 
in IgE/Ag-stimulated BMMCs (Fig. 11-1B). In addition, we quantified the degranulation response 
by measuring beta-hexosaminidase release as well as with a flow cytometry-based assay that tracks 
both Annexin V binding to exposed phosphatidylserine (PS) and loss of Lysotracker staining, due 
to granule release (AnnexinV+Lysotrackerlo). The latter method has the advantage of a high signal-
to-noise ratio, and as such has been a robust assay for evaluating IgE/Ag-stimulated mast cell 
degranulation (321, 363). Thus, we showed that varying the concentration of Tim-4, along with 
suboptimal antigen concentration to observe potential co-stimulation, did not have an effect on the 
immediate degranulation response (Fig. 11-1C-D). These results indicate that Tim-1 ligation by 
Tim-4 can exert differential effects on the immediate degranulation response, vs. late-phase 
cytokine production.  
Antigen valency and concentration have been shown to control the outcomes of FcRI 
engagement in not just quantitative, but also qualitative, fashions (Xiao, 2005). Specifically, low 
antigen concentration or valency will activate only positive FcRI signaling pathways, while high 
antigen valency or concentration will preferentially engage negative signaling components 
downstream of FcRI. This is due to activity of the Src family kinase Lyn as a positive and/or 
negative regulator of FcRI signaling at low or high antigen valency, respectively (109). We 
stimulated BMMCs with low (DNP5-BSA) or high (DNP32-HSA) potency antigens in the presence 
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of Tim4-Fc or isotype control and assessed whether Tim-1 ligation could contribute to receptor 
signaling intensity. Thus, at high antigen valency, which also activates negative feedback of 
antigen receptor signaling, Tim-4 was able to maintain high IL-6 production but not at low antigen 
valency that induces robust antigen receptor signaling (Fig. 11-1E-F). Specifically, increasing the 
amount of Tim-4 further promoted cytokine secretion under high valency antigen stimulation, i.e. 
under conditions where the negative signaling loop is triggered. To exclude the possibility that Fc 
receptor binding may interfere with Tim1-Tim4 interaction, we compared IL-6 release by 
BMMCs, with or without addition of Fc blocking antibody, and found no differences, at least at 
the concentration of Tim4-Fc used throughout this study (5 μg/ml) (Fig. 11-1E-F). These findings 
indicate that Tim-1 ligation can modulate the intensity of the antigen-induced positive FcRI 
signaling pathways and may be able to bypass the negative feedback signaling loop controlled by 
Lyn.  
To determine if Tim-4 treatment could affect production of other mast cell mediators, we 
compared supernatant from cells co-stimulated with Ag and Tim4-Fc to cells stimulated with Ag 
alone in a chemiluminescence-based mouse cytokine array. Thus, Ag alone induced production of 
well-known mast cell cytokines and chemokines including IL-6, TNF, IL-13, CCL2, and CCL3, 
all of which were not detectable in the Tim4-Fc-treated sample. Furthermore, Tim-1 cross-linking 
promoted secretion of IL-7 and IL-12p70 from Ag-activated cells (Fig. 11-2). Therefore, it remains 
to be seen whether Tim-1 ligation engages specific signaling pathways for production of a distinct 
set of cytokines or augments the overall activation state of the mast cells.   
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Figure 11-1: Tim4-Fc enhances IgE/Ag-mediated mast cell cytokine production at high but not low antigen valency 
stimulation without affecting degranulation. BMMCs was incubated with 0.5 μg of Tim4-Fc or human IgG (iso) on 
ice for 20 minutes followed by flow cytometry analysis (A). BMMCs were sensitized overnight with 1μg/ml of IgE 
and stimulated with 50 ng/ml of DNP32-HSA, alone or with 5 μg/ml of Tim4-Fc or “iso” for six hours prior to IL-6 
measurement by ELISA (B). BMMCs were stimulated as indicated in the presence of increasing amount of Tim4-Fc 
(1-50 μg/ml) for thirty minutes prior to degranulation measurement by means of beta-hexosaminidase release (C). 
Cells were loaded with Lysotracker Deep Red, sensitized with IgE, and stimulated with antigen plus isotype control 
or Tim4-Fc for ninety minutes prior to Annexin V staining and flow cytometry analysis (D).  IgE-sensitized BMMCs 
were pre-treated with anti-mouse Fc blocking Ab (2.4G2) for ten minutes prior to stimulation with DNP32-HSA (E) 
or DNP5-HSA (F) alone or in conjunction with indicated amount of control Fc (“iso”) or Tim4-Fc for six hours. IL-6 
cytokine production was determined by ELISA. Results are representative of three independent experiments with 
duplicates in each. *p<0.05. 
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Figure 11-2: Ag and Tim4-Fc co-stimulate release of distinct cytokines compared to Ag alone. BMMCs were 
sensitized with IgE prior to stimulation with 50 ng/ml Ag, with or without 5 g/ml Tim4-Fc for six hours. Supernatant 
was collected and subjected to mouse cytokine array detection.  
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11.4 DISCUSSION 
Tim-4 treatment consistently enhanced IgE/Ag-mediated cytokine production but not 
degranulation, which may be a time- and/or signal intensity-dependent effect. Tim-4 was reported 
to have bimodal effects, either enhancing or inhibiting T cell proliferation, depending on anti-
CD3/CD28 concentrations (195). This bimodal regulation was later reported to be inhibitory for 
naïve T cells, which do not express Tim-1, and co-stimulatory for activated T cells, suggesting that 
Tim-4 either binds to an unknown ligand expressed only on naïve T cells or that Tim-4 has a higher 
affinity for Tim-1 expressed on activated T cells (364). In addition, Tim-4 can bind to naïve T cells 
that do not express Tim-1 and inhibit Th17 differentiation (365). This effect was shown to be 
independent of Tim-1 activity, since addition of Tim-1 blocking antibody, presumably to block 
the Tim1:Tim4 interaction, could not rescue Tim4-mediated inhibition (365). In contrast to such 
ligand-dependent effects observed on T cells, Tim-4 co-stimulates IgE/Ag-mediated mast cell 
activation by cross-linking Tim-1. Using low and high valency antigens to engage the positive and 
negative signaling pathways of FcRI, respectively, we showed that Tim-4 could enhance mast 
cell cytokine production in both settings. Specifically, Tim-4 co-stimulated cytokine release in a 
dose-dependent manner, under both high and low valency antigen stimulation, albeit less 
efficiently with low valency Ag. These results imply that Tim-4 contributes to FcRI signaling 
intensity and/or duration, and may potentially override negative feedback signals linked primarily 
to Lyn-mediated phosphatase activation. Together with findings that Tim-4 alone does not induce 
cytokine production in mast cells, our results demonstrate that Tim-1 signaling interfaces with 
common effector molecules downstream of FcRI signaling, rather than acting through a parallel 
pathway, to enhance mast cell functions. 
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12.0  TIM-1 ANTIBODIES DO NOT MODULATE MAST CELL ACTIVATION 
12.1 INTRODUCTION 
Since Tim-1 ligation with Tim-4 exhibited both positive and negative effects on T cell responses, 
it raised the possibility that Tim-4 may either have a different ligand on T cells or function as a 
dual regulator on T cells (195). These results also imply that Tim-1 may be a positive or negative 
regulator of T cell function depending on the molecule is engaged during T cell activation. 
Therefore, antibodies specific to Tim-1 have been generated to determine how antibody affinity 
and/or avidity can affect T cell activity. Of significance are the monoclonal antibodies (mAb) 3B3 
and RMT1-10, which have been termed “agonistic” and “antagonistic” antibodies, respectively, 
due to their ability to enhance or inhibit effector T cell activation (221). Since then, several 
antibodies against Tim-1 have been tested and showed no effects on either IgE/Ag-induced mast 
cell degranulation or cytokine production (240). Here, we determine whether antibody-mediated 
Tim-1 cross-linking can modulate Ag-induced cytokine production in a dose-dependent manner. 
Our results show that the existing Tim-1 antibodies with known function effects on T cells and B 
cells do not regulate FcRI-induced mast cell activation, suggesting they may have cell type-
dependent effects (195, 220, 221, 232, 240, 241).  
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12.2 MATERIALS AND METHODS 
12.2.1 BMMC isolation and culture 
Bone marrow cells from C57BL/6 mice were cultured in RPMI 1640 supplemented with 10% 
BGS, non-essential amino acid, 2-ME, HEPES, pen/strep-glutamine, and 20% IL-3-conditioned 
media for 4-6 weeks, after which >90% of viable cells are mature mast cells (c-kit+ FcRI+ by 
flow cytometry).  
12.2.2 Antibodies and reagents 
Monoclonal anti-dinitrophenyl (DNP), IgE isotype, clone SPE-7, and DNP32-HSA, were 
purchased from Sigma-Aldrich (St. Louis, MO). Monoclonal antibodies to murine Tim-1 (3B3, 
RMT1-10, 5G5, 5F12) were obtained from Vijay Kuchroo (Harvard Medical School). Monoclonal 
antibodies to murine Tim-1 (4A2, 5D1, 4G8, 4B2) were originally developed at Biogen and 
obtained under an MTA with CoStim Pharmaceuticals (Cambridge, MA). Purified rat IgG2a as 
isotype was from eBioscience (San Diego, CA).  
12.2.3 BMMC stimulation and cytokine measurement 
BMMCs were sensitized overnight with 1μg/ml IgE without IL-3 conditioned media. Cells were 
stimulated with DNP32-HSA and either rat isotype or the indicated Tim-1 antibodies. Six or 
twenty-four hours post stimulation, supernatants were collected and assayed for murine IL-6 and 
TNF- by ELISA (BioLegend) 
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12.3 RESULTS 
12.3.1 Tim-1 antibodies do not exert any effects on Ag-induced mast cell cytokine release 
We tested several antibodies that have been shown to modulate T cell responses including the well-
characterized mAb’s 3B3 and RMT1-10 (195, 221, 232, 240, 241). Compared to Tim4-Fc, we did 
not observe any dose-dependent effects of 3B3, RMT1-10, the mucin domain-specific mAb 5G5, 
and the IgV domain-binding mAb 5F12 on levels of IL-6 and TNF- secreted by IgE-sensitized 
and Ag-stimulated BMMCs at six or twenty-four post stimulation (Fig. 12-1A-H). We examined 
several other antibodies, generated against the BALB/c allele of Tim-1, which were shown to 
either exacerbate or ameliorate Th2-dependent OVA-induced lung inflammation in mice (220). 
Specifically, the mAb’s 3A2 and 4A2 bind to distinct epitopes near an N-linked glycosylation site 
in the stalk region and the IgV domain respectively and both can reduce lung inflammation and 
pathology (220). However, aside from 4G8, we detected neither significant binding of these 
antibodies to BALB/c Tim-1 nor any changes in cytokine production (Fig. 12-2A-C). Even though 
these antibodies were raised against the BALB/c allele of Tim-1, we also observed binding of 4G8 
to C57BL/6 Tim-1 (Fig. 12-2D). There was a small, although statistically insignificant, increase 
in IL-6 production when 4G8 was used in co-stimulation with FcRI crosslinking by IgE/Ag (Fig. 
12-2E). These results further support the concept that the effects of antibody modulation of Tim-
1 are cell-type and context-dependent (220, 240). 
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Figure 12-1: Tim-1 antibodies did not significantly alter IgE/Ag-mediated mast cell cytokine production compared to 
ligation by Tim4-Fc. C57BL/6 BMMCs were sensitized with IgE overnight and stimulated with DNP32-HSA in the 
presence of isotype control or monoclonal antibodies against Tim-1 3B3, RMT1-10, 5F12, 5G5 or Tim4-Fc for six 
(A) or twenty-four (B). BMMCs were stimulated as indicated for six hours (C-H). Supernatant was collected for IL-6 
and TNF- analysis by ELISA. Results are representative of two (A-B) and at least three independent experiments 
performed in duplicates (C-H). *p<0.05.    
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Figure 12-2: Specific antibodies to BALB/c Tim-1 do not modulate IgE/Ag-mediated mast cell cytokine production. 
The indicated antibodies were incubated with BALB/c BMMCs for 30 minutes on ice followed by anti-rat IgG-Alexa-
647 secondary antibody, prior to flow cytometry analysis (A). BALB/c BMMCs were sensitized with IgE overnight 
and stimulated with DNP32-HSA in the presence of isotype control or monoclonal antibodies 3A2, 4A2, 4B2, 4G8, 
1H9 (B-C) for six hours. Culture supernatants were analyzed for IL-6 and TNF- by ELISA. BL/6 BMMCs were 
incubated with 4G8, 4A2 and 5D1 antibodies followed by anti-rat IgG-Alexa 647 secondary antibody prior to flow 
cytometry analysis (D). BL/6 BMMCs were sensitized with IgE overnight and stimulated with DNP32-HSA together 
with either isotype control or the indicated antibodies for six hours prior to IL-6 measurement by ELISA (E). Results 
are representative of three independent experiments performed in duplicates.  
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12.4 DISCUSSION 
In this study, we aimed to determine how Tim-1 cross-linking by antibodies could modulate mast 
cell activation. Unlike in T cells or in vivo experiments, we and others found that mast cells did 
not respond to Tim-1 antibody treatment, as none of the antibodies elicited a change in mast cell 
degranulation or cytokine production (Fig. 11-1, 11-2, and (240)). Among the antibodies with 
defined epitopes and functional effects on T cells (220, 240), we observed very weak binding to 
Tim-1 by most of these antibodies, suggesting glycosylation patterns of Tim-1 among cell types 
may affect antibody recognition. The Tim-1 mucin and stalk region is heavily glycosylated with 
multiple N- and O—linked carbohydrate side chains (190). As a result, two different mAb’s 
recognizing the Tim-1 stalk elicited opposing effects in vivo, suggesting that antibody-mediated 
Tim-1 targeting may affect Tim-1 interaction with its ligands or with itself (220). Since Tim-4 is 
not expressed on mast cells, and thus is not an interference in Tim-1 recognition by antibodies. 
Phosphatidylserine (PS), another Tim-1 ligand, is present in our mast cell culture and binds 
primarily to the IgV domain of Tim-1. However, PS is unlikely to compete with Tim-1 antibodies 
for binding since it requires calcium ion to facilitate interaction with Tim-1, a component that is 
absent from our staining buffer. Overall, our results showed that Tim-4 is effective in ligating Tim-
1, leading to enhanced Ag-stimulated mast cell cytokine production without affecting 
degranulation while the existing Tim-1 antibodies largely have no functional effects on mast cell 
responses.  
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13.0  TIM-1 TRANSIENT EXPRESSION PROMOTES ANTIGEN-STIMULATED 
TRANSCRIPTIONAL ACTIVATION IN MAST CELLS 
13.1 INTRODUCTION 
We previously demonstrated that transient expression of Tim-1 co-stimulated TCR/CD28-
mediated transcriptional activation of IL-4 and IFN- production and NF-AT/AP1-dependent 
transcription. This co-stimulatory activity was dependent on tyrosine 276 in the Tim-1 cytoplasmic 
tail (222). Furthermore, phosphorylation of tyrosine 276 occurred in an Lck-dependent manner 
and allowed for recruitment of the p85 and  subunits of the PI3K, leading to activation of the 
downstream kinase Akt and subsequent activation of the transcription factors NFAT and AP-1 
(242). While Tim-1 ligation enhances FcRI-mediated mast cell activation, the precise signaling 
mechanisms by Tim-1 are currently unknown. Here, we show that  that ectopic expression of Tim-
1 alone can augment IgE/Ag-triggered NF-B and NFAT/AP-1 activation, leading to enhanced 
IL-6 transcriptional activation and cytokine production. Furthermore, our data provide evidence 
that these events are dependent on the tyrosine phosphorylation of Tim-1 cytoplasmic tail, further 
highlighting the importance of tyrosine phosphorylation in mediating Tim-1 co-stimulatory 
activity.  
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13.2 MATERIALS AND METHODS 
13.2.1 Antibodies and reagents 
Monoclonal anti-dinitrophenyl (DNP), IgE isotype, clone SPE-7, DNP32-HSA, and anti-FLAG M2 
antibody were purchased from Sigma-Aldrich (St. Louis, MO). IL-6 luciferase reporter constructs 
were obtained from Sarah Gaffen (University of Pittsburgh), originally from Oliver Eickelberg 
(Helmholtz Zentrum Munchen).   
13.2.2 Transcriptional reporter assays 
MC/9 mast cell line was maintained in DMEM supplemented with 10% BGS, 2-ME, Pen/Strep 
with Glutamine, and 10% IL3-conditioned media. MC/9 cells (15 x 106) were transfected with 15 
μg of IL6-luc, NF-B-luc, or NFAT/AP1-luc with 5 μg of pCDEF3 (empty vector), FLAG-tagged 
Tim-1 full length (FL), Tim-1 cytoplasmic deletion (Δcyto), or Tim-1 tyrosine mutant (Y276F). 
Electroporation was performed at 290V, 950 μF using a Gene Pulser II apparatus (Bio-Rad). 
Transfected cells were collected twenty-four hours and stimulated with 0.5 μg/ml IgE and 
indicated amount of DNP32-HSA as antigen for six hours. Luciferase assays were performed as 
previously described (366). 
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13.2.3 Statistical analysis 
All statistical analysis was performed using Prism software (GraphPad Software). Paired, two-
tailed Student’s t-test, one-way and two-way ANOVA with Bonferroni post hoc test were used for 
data analysis and determination of p values, as appropriate. 
 
13.3 RESULTS 
13.3.1 Tim-1 expression co-stimulates IgE/Ag-induced NF-B, NFAT/AP1, and IL-6 
transcriptional activation in a tyrosine phosphorylation-dependent manner 
Similar to our findings in T cells, ectopic expression of Tim-1 on MC/9 mast cells was able to 
enhance IgE/Ag-stimulated NF-B transcriptional activation (Fig. 13-1A). This enhancement was 
abrogated when the cytoplasmic tail of Tim-1 was deleted or when a tyrosine-phenylalanine 
mutant (Y276F) was used (Fig. 13-1A). Polymorphisms in Tim-1 have been associated with 
differential responses to OVA-induced allergic asthma (190). We found that both isoforms of Tim-
1 (BL/6 and BALB/c) could significantly enhance activation of an NF-B transcriptional reporter 
to a comparable extent (Fig. 13-1B). Consistent with findings in T cells and effects on mast cell 
cytokine production, transient expression of Tim-1 also up-regulated NF-AT/AP1 promoter 
activation, in a tyrosine phosphorylation-dependent manner (Fig. 13-1C).  
Since Tim4-Fc co-stimulated IgE/Ag-mediated mast cell IL-6 production, we determined 
if Tim-1 could promote IL-6 transcriptional activation using the previously described IL-6 
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promoter mutant constructs (363). Thus, expression of full length Tim-1 promoted IL-6 reporter 
activity, in a tyrosine phosphorylation-dependent manner (Fig. 13-2A). Using IL-6 promoter 
deletion constructs, we showed that Tim-1 mediated enhancement of transcriptional activation and 
subsequent production of IL-6 primarily through activation of NF-B and AP-1 transcription 
factors (Fig. 13-2B). While we have occasionally observed Tim-1-driven enhancement of IL-6 
reporter activity when the C/EBP binding site is absent, the Tim-1 effects are mainly through 
activating NF-B and AP-1 since an IL-6 promoter mutant lacking both NF-B and C/EBP binding 
site could not rescue the inhibition of IL-6 transcriptional activity due to lack of NF-B activity 
(Fig. 13-2C-D).  Unlike Tim-4 cross-linking of Tim-1, addition of anti-FLAG antibody could not 
further promote reporter activity, suggesting either that Tim-1 may have other ligands on MC/9 
mast cells or that Tim-1 can homodimerize after ectopic expression, via its heavily glycosylated 
mucin domain, leading to downstream signaling (Fig. 13-2A).    
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Figure 13-1: Tim1-mediated enhancement of NF-B and NF-AT/AP1 transcriptional activation is dependent on a 
tyrosine on its cytoplasmic tail. MC/9 mouse mast cells were transfected with empty vector (pCDEF3), BL/6 or 
BALB/c Tim-1 (full length (FL)), BL/6 Tim-1 lacking the cytoplasmic region (Δcyto) or full length Tim-1 (BL/6) 
with tyrosine to phenylalanine mutated at tyrosine 276 (Y276). Transfected cells were stimulated with 0.5 μg/ml IgE 
plus either 30 ng/ml or 100 ng/ml DNP32-HSA for six hours. MC/9 mast cells were co-transfected NF-B (A-B), or 
NFAT/AP1 (C) luciferase reporters. Results are representative of three independent experiments performed in 
triplicate. *p<0.05, **p<0.005, ****p<0.00005.  
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Figure 13-2: Tim-1 enhances IgE/Ag-mediated IL-6 transcriptional activation through NF-B and AP1 activation in 
a tyrosine phosphorylation-dependent manner. MC/9 mast cells were transfected with full length BL/6 Tim-1 along 
with the indicated IL-6 luciferase reporters (A-D). Transfected cells were stimulated with 0.5 μg/ml IgE plus either 
30 ng/ml or 100 ng/ml DNP32-HSA, with or without addition of anti-FLAG antibody for six hours. Results are 
representative of three (A, B, D) and two (C) independent experiments performed in triplicate. *p<0.05, **p<0.005, 
***p<0.0005; ****p<0.00005.  
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13.4 DISCUSSION 
Mast cells constitutively express high levels of cell-surface Tim-1, a molecule with co-stimulatory 
effects on many immune cell types, but with unclear mechanisms of action. Here we demonstrate 
that Tim-1 is a positive regulator of mast cell activation and cytokine production. Similar to our 
findings on the effects of Tim-3 on mast cells (363), Tim-1 expression alone could promote 
IgE/Ag-mediated NF-B and NF-AT/AP1 transcriptional activation, without additional cross-
linking antibodies or exogenous ligands. Tim-4 is a ligand for Tim-1, but the lack of Tim-4 
expression on mast cells makes it an unlikely explanation for this particular role of Tim-1 in mast 
cells. Tim-1 can also bind PS on apoptotic cells (214) or PS transiently exposed on degranulating 
mast cells, either of which could potentially contribute to enhance Tim-1 signaling, although 
whether PS binding to Tim-1 can lead to mast cell activation is still unknown. Tim-1 has also been 
reported to bind LMIR5/CD300b, a DAP12-coupled activating receptor expressed on myeloid 
cells (367). Thus, stimulation with TIM1-Fc was able to induce LMIR5-mediated ERK activation 
in mast cells, suggesting that LMIR5 is another potential endogenous ligand of Tim-1, driving the 
enhancement of transcriptional response. Finally, Tim-1 may homodimerize through its heavily 
glycosylated mucin domain, leading to its phosphorylation and downstream function. Regardless 
of its mode of activation, we showed that Tim-1 co-stimulation is dependent on the tyrosine 
phosphorylation motif of Tim-1 cytoplasmic tail as mutation of tyrosine 276 rendered Tim-1 
unable to mediate its co-stimulatory function. The Src kinase Fyn has been shown to phosphorylate 
Tim-1 in a B cell line (368). We showed that the Tim-1 cytoplasmic tail is phosphorylated upon 
TCR stimulation in an Lck-dependent manner and can recruit p85 binding (242). Therefore, Src 
family kinases like Lyn, Fyn or Hck are potential facilitators of Tim-1 phosphorylation upon 
IgE/Ag activation. 
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14.0  TIM-1 MUCIN DOMAIN IS NOT REQUIRED FOR TIM4-MEDIATED 
ENHANCEMENT OF MAST CELL CYTOKINE RELEASE 
14.1 INTRODUCTION 
Our findings thus far suggest that the Tim1-Tim4 interaction augments FcRI signaling itself, 
rather than acting through a parallel pathway, since Tim-4 treatment alone does not induce any 
significant cytokine production or degranulation. While the Tim1-Tim4 interaction has been 
attributed primarily to the IgV domain, Tim-4 has also been proposed to bind to the Tim-1 mucin 
domain (195). Intriguingly, the genetic linkage of Tim-1 to allergies and asthma is associated with 
polymorphisms in the mucin domain. On the other hand, two separate strains of Tim-1-deficient 
mice showed relatively unaltered IgE production and AHR development in an OVA-induced 
mouse model of asthma, even though one study did observe higher type 2 and Th17 cytokine 
production in Tim-1 knockout (KO) mice (238, 239). Furthermore, the importance of the Tim-1 
mucin domain has been demonstrated in T cell activation, differentiation, trafficking, and effector 
function in autoimmunity and airway inflammation (202, 365). It is also essential to regulatory B 
cell maintenance, signaling, transplant tolerance and induction of systemic autoimmunity (205, 
216, 231). Thus, we examine whether the Tim-1 mucin domain regulates mast cell activity, 
particularly in the context of Tim-4 treatment. Using a mutant mouse lacking only the Tim-1 mucin 
domain (Tim-1Δmucin) (205), we determine whether the Tim-1 mucin domain is necessary for mast 
cell responses and if Tim-1 mucin domain is required to relay the co-stimulatory effects of Tim-4 
binding.  
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14.2 MATERIALS AND METHODS 
14.2.1 Mice 
Mutant mice lacking Tim-1 mucin domain (Tim-1Δmucin) were obtained from David Rothstein 
(University of Pittsburgh), and were originally from Vijay Kuchroo (Harvard Medical School). 
Age-and sex-matched wild-type C57BL/6 were purchased from the Jackson Laboratory (Bar 
Harbor, ME) as control. All studies were performed in accordance with University of Pittsburgh 
Institutional Animal Care and Use Committee procedures. 
14.2.2 BMMC isolation and culture 
Bone marrow cells from C57BL/6 Tim-1 wild-type (WT) and mutant (Tim-1Δmucin) were cultured 
in RPMI 1640 supplemented with 10% BGS, non-essential amino acid, 2-ME, HEPES, pen/strep-
glutamine, and 20% IL-3-conditioned media for 4-6 weeks, after which >90% of viable cells are 
mature mast cells (c-kit+ FcRI+ by flow cytometry).  
14.2.3 Antibodies and reagents 
Monoclonal anti-dinitrophenyl (DNP), IgE isotype, clone SPE-7, DNP32-HSA, and 4-Nitrophenyl 
N-acetyl--D-glucosaminide (pNAG) were purchased from Sigma-Aldrich (St. Louis, MO). 
Purified Tim4-Fc were obtained from Vijay Kuchroo (Harvard Medical School). Human IgG as 
isotype control for Tim4-Fc was purchased from JacksoImmunoResearch Laboratories (West 
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Grove, PA). c-kit-APC and FcRI-PE (clone MAR-1) antibodies were from eBioscience (San 
Diego, CA). 
14.2.4 BMMC culture, stimulation, and cytokine measurement 
BMMCs were sensitized overnight with 1μg/ml IgE without IL-3 conditioned media. Cells were 
stimulated with DNP32-HSA or DNP5-BSA for indicated times. Six hours post stimulation, 
supernatants were collected and assayed for murine IL-6 and TNF- by ELISA (BioLegend). 
14.2.5 Degranulation assay by flow cytometry 
Degranulation was measured as described previously (363). Briefly, BMMCs were loaded with 
0.1μM of Lysotracker Deep Red (Invitrogen) for thirty minutes at 370C prior to sensitization with 
0.5 μg/ml IgE for 1 hour. Ninety minutes post antigen cross-linking by DNP32-HSA, cells were 
collected and stained with Annexin V (BioLegend). %degranulation was determined as percentage 
of BMMCs that is AnnexinV+Lysotrackerlo.  
14.2.6 Statistical analysis 
All statistical analysis was performed using Prism software (GraphPad Software). Paired, two-
tailed Student’s t-test, one-way and two-way ANOVA with Bonferroni post hoc test were used for 
data analysis and determination of p values, as appropriate. 
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14.3 RESULTS 
14.3.1 Tim-1 mucin domain is not required for normal degranulation, cytokine production 
or Tim-4-mediated co-stimulation in mast cells   
We noted no obvious defects in mast cell development or maturation, when BMMC were 
generated from Tim-1Δmucin bone marrow. Thus, WT and Tim-1Δmucin BMMCs expressed 
comparable levels of surface Tim-1, based on staining with IgV-binding Tim-1 antibodies (Fig. 
14-1A). Tim-1Δmucin BMMCs exhibited a similar extent of degranulation in response to antigen 
stimulation, compared to WT BMMCs, which was not altered by Tim-1 ligation (Fig. 14-1B-C). 
Next, we examined the ability of Tim-1Δmucin BMMCs to secrete cytokines in response to IgE/Ag. 
Tim-1Δmucin mast cells appeared to respond normally to antigen stimulation, and also to Tim4-
mediated co-stimulation (Fig. 14-2A). Using different batches of BMMCs over the course of 
multiple experiments, we were not able to consistently detect any major difference between WT 
and Tim-1Δmucin BMMCs. We did observe some variation in the amount of IL-6 produced by 
different batches of BMMCs, but this appeared to be largely due to the relative maturation status 
of the cells (Fig. 14-2B-E). These results indicated that the mucin domain of Tim-1 is not required 
for normal mast cell responses and also that Tim-4-mediated mast cell activation does not appear 
to involve the mucin domain of Tim-1, but rather its IgV domain.  
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Figure 14-1: Tim-1 mucin domain is not required for mast cell development and degranulation. Tim-1 surface 
expression and maturity of WT and Tim-1Δmucin BMMCs were determined by FcRI and c-kit staining (A). WT and 
Tim-1Δmucin BMMCs were sensitized overnight with IgE and stimulated with indicated amount of antigen and Tim4-
Fc. Mast cell degranulation was measured by Annexin V and Lysotracker staining (B-C). Results are average of three 
independent experiments performed in duplicate.  
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Figure 14-2: Tim-1 mucin domain is not required for Tim4-mediated enhancement of cytokine production in IgE/Ag-
stimulated Tim-1Δmucin BMMCs. WT and Tim-1Δmucin BMMCs were sensitized overnight with IgE and stimulated with 
indicated amount of antigen and Tim4-Fc. Culture supernatants were collected and analyzed for IL-6 by ELISA (A). 
WT and Tim-1Δmucin BMMCs were stimulated with indicated amount of antigen with either isotype control Fc (iso) or 
Tim4-Fc for six hours (B-E). Results are representative of six independent experiments from six separate batches of 
BMMCs.  
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14.4 DISCUSSION 
To determine whether Tim-1 plays a positive or negative regulatory role in mast cells, we first 
attempted siRNA-mediated knockdown of Tim-1 protein in BMMCs but were unsuccessful in 
obtaining efficient Tim-1 reduction (data not shown). Recent studies reveal that the Tim-1 mucin 
domain is important for both T cell activation and effector function as well as regulatory B cell 
activity (202, 205, 216, 231, 365). Thus, we examined whether the Tim-1 mucin domain regulates 
mast cell activity, particularly in the context of Tim-4 treatment. Contrary to the effects seen in B 
and T cells, the Tim-1 mucin domain is dispensable for mast cell activity, as mast cell 
degranulation and cytokine release remain intact in the absence of the mucin domain. It is worth 
noting that Tim-1Δmucin   BMMCs were actually able to secrete more cytokine than WT BMMCs in 
some instances. However, after testing six different batches of WT and Tim-1Δmucin BMMCs, it 
appeared that any differences observed were due to the maturation status of BMMCs and their 
FcRI surface expression, rather than any direct effect of deletion of the Tim-1 mucin domain.  
While our study focused on bone marrow-derived mast cells, absence of the Tim-1 mucin 
domain may nonetheless affect trafficking and/or differentiation of other mast cell types in their 
respective tissue microenvironments in vivo. Tim1-Tim4 interaction is thought to occur mostly 
through the IgV domains of the respective proteins, although there is evidence that Tim-4 may 
also bind to the Tim-1 mucin domain (195). We showed that Tim-4 mediated co-stimulation of 
mast cell function occurred independent of the mucin domain. It remains to be determined, in the 
absence of the Tim-1 mucin domain, whether Tim-4 has other unknown ligands on mast cells that 
can mediate this enhancement. 
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15.0  TIM-1: TIM-4 INTERACTION ENHANCES DISTAL RATHER THAN 
PROXIMAL ANTIGEN RECEPTOR SIGNALING 
15.1 INTRODUCTION 
We assessed the potential signaling pathways utilized by Tim1-Tim4 interaction downstream of 
FcRI signaling to upregulate mast cell cytokine production. Using a Nur77GFP reporter mouse, we 
previously showed that unlike the related family member Tim-3, engagement of Tim-1 did not 
enhance FcRI signal intensity, thereby showing that Tim-1 cross-linking does not augment 
antigen receptor-proximal signaling (363). We moved on to explore signaling pathways both 
proximal and distal to the FcRI complex, for any effects of Tim-1. Thus, the Zap70-related kinase 
Syk is an FcRI-associated activator integral to activation of LAT, SLP76, PLC and other 
adaptor molecules essential for signal transduction downstream of FcRI (369). Activation of the 
“primary” Lyn/Syk/SLP76/PLC and the “complementary” Fyn/Gab2/PI3K pathways upon Ag 
stimulation induces calcium mobilization necessary for degranulation, promotes activity of the 
MAPK kinases p38, ERK, JNK, and Akt, leading to NF-AT, NF-B and AP-1 transcriptional 
activation and subsequent cytokine production (351, 369). Here, we determine the signaling 
pathways by which Tim-1 ligation enhance IgE/Ag-mediated mast cell activation. We showe that 
Tim-1-mediated IgE/Ag-induced cytokine production is partly due to sustained ribosomal S6 
phosphorylation.  
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15.2 MATERIALS AND METHODS 
15.2.1 BMMC isolation and culture 
Bone marrow cells isolated from C57BL/6 WT mice were maintained in RPMI 1640 supplemented 
with 10% BGS, non-essential amino acid, 2-ME, HEPES, pen/strep-glutamine, and 20% IL-3-
conditioned media for 4-6 weeks, after which >90% of viable cells are mature mast cells (c-kit+ 
FcRI+ by flow cytometry).  
15.2.2 Antibodies and reagents 
Monoclonal anti-dinitrophenyl (DNP), IgE isotype, clone SPE-7, and DNP32-HSA were purchased 
from Sigma-Aldrich (St. Louis, MO). Purified Tim4-Fc were obtained from Vijay Kuchroo 
(Harvard Medical School) and human IgG as isotype control for Tim4-Fc was purchased from 
JacksoImmunoResearch Laboratories (West Grove, PA). Phospho-specific antibodies to Akt 
(S374), Syk (Y519/520), S6 (S235/236), p38 (T180/Y182), and SAPK/JNK (T183/Y185) were 
obtained from Cell Signaling Technology (Danvers, MA). Phospho-specific antibody to ERK 
(T202/Y204) was from BD Biosciences (San Jose, CA). 
15.2.3 BMMC stimulation and western blotting 
BMMCs were sensitized with 0.5 μg/ml IgE overnight at 370C in Tyrode’s buffer. Cells were then 
stimulated with DNP32-HSA for indicated times in Tyrode’s buffer. Cells were lysed in 1% 
Nonidet-P-40 lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl) supplemented with AEBSF, 
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aprotinin, leupeptin, pepstatin, sodium fluoride, sodium orthovanadate, and beta-glycerophosphate 
on ice for twenty minutes.  Lysates were centrifuged at 4oC for fifteen minutes. For western 
blotting analysis, SDS-containing sample buffer was added to lysates prior to loading onto 10% 
SDS-PAGE gels. Proteins were transferred onto polyvinylidene difluoride (PVDF) membranes 
using the PierceG2 fast blotter (Pierce), probed with appropriate antibodies, and imaged on a 
ProteinSimple Fluochem M cooled CCD imager (ProteinSimple).  
15.2.4 BMMC stimulation and phospho-flow cytometry 
BMMCs were sensitized overnight with 1 μg/ml IgE without IL-3 conditioned media. Cells were 
stimulated with DNP32-HSA for indicated times. Stimulated cells were fixed in 1.5% 
paraformaldehyde and permeabilized with ice cold methanol. Incubation with phospho-specific 
antibodies were performed per manufacturer’s instructions. Flow acquisition was performed on 
Fortessa or LSRII (BD Biosciences), and data were analyzed using FlowJo software (Tree Star).  
15.2.5 Statistical analysis 
All statistical analysis was performed using Prism software (GraphPad Software). Paired, two-
tailed Student’s t-test, one-way and two-way ANOVA with Bonferroni post hoc test were used for 
data analysis and determination of p values, as appropriate. 
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15.3 RESULTS 
15.3.1 Tim-1 enhances Ag-activated phosphorylation of ribosomal protein S6 without 
altering FcRI proximal signaling 
We first determined if Tim-4 treatment could modulate the general state of mast cell activation by 
assessing the total tyrosine phosphorylation in IgE/Ag-stimulated BMMCs in the presence of 
Tim4-Fc or Tim-3 pAb to cross-linking Tim-3, a co-stimulator of antigen-mediated mast cell 
responses (363). Thus, Tim4-Fc was not able to enhance tyrosine phosphorylation in mast cells 
compared to Ag stimulation alone or Ag with Tim-3 pAb co-stimulation (Fig. 15-1). Next, we 
specifically assessed the Zap70-related kinase Syk, an important initiator at the FcRI proximal 
level. Similarly, phosphorylation of Syk was not further increased by Tim-4 (Fig. 15-2A). While 
we observed robust phosphorylation of ERK and Akt upon IgE/Ag-induced activation, Tim-1 
engagement did not yield additional effects (Fig. 15-2B-C). These results demonstrated that 
MEK/ERK and PI3K/Akt pathways are not involved in enhancement of Ag-mediated mast cell 
function by Tim-1, even though we observed that phosphorylation of Tim-1 cytoplasmic tail by 
TCR activation led to recruitment of p85 subunit of PI3K (242). Nevertheless, we did detect a 
significant increase in phosphorylation of ribosomal protein S6, an important target of the 
PI3K/mTOR pathway regulating cell growth, survival, metabolism, and protein synthesis in mast 
cells (361). Mast cells exhibited robust phosphorylation of S6 (~80% of BMMCs) one hour post-
Ag stimulation, which did not increase further with Tim-4 addition. However, Tim-4 treatment 
was able to maintain a significant percentage of pS6-positive BMMCs for as long as four hours, 
even as the Ag-triggered signal returned to basal levels (Fig. 15-3A). Similar to our previous 
findings, Tim-1 engagement did not augment Ag receptor signaling as measured by Nur77GFP 
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expression (Fig. 15-3B and (363)). Overall, these results support a positive role of Tim-1 activation 
by Tim-4 to sustain mTOR-dependent mast cell metabolism and protein synthesis, leading to 
enhanced cytokine production. 
 
 
 
 
 
Figure 15-1: Tim-1 engagement did not enhance IgE/Ag-mediate total tyrosine phosphorylation. BMMCs were 
sensitized with IgE and stimulated with indicated amount of antigen, with 5 g/ml of either isotype control, Tim-3 
pAb, or Tim4-Fc for ten minutes. Cells were lysed and analyzed for total tyrosine phosphorylation by western blotting. 
Results are representative of two independent experiments.   
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Figure 15-2: Tim-1 ligation by Tim4-Fc did not alter IgE/Ag-mediate Syk, ERK, and Akt phosphorylation. BL/6 
BMMCs were sensitized with IgE and stimulated with DNP32-HSA in the presence of isotype control or Tim4-Fc for 
the indicated time. Syk phosphorylation (Y519/520) (A), pErk (T202/Y204) (B), and pAkt (S374) (C) were analyzed 
by phospho-flow cytometry. Results are representative of two independent experiments (A-B) and average of two 
independent experiments (C).  
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Figure 15-3: Tim-1 ligation by Tim4-Fc enhances mast cell cytokine production by sustaining ribosomal  protein S6 
phosphorylation upon IgE/Ag activation. BL/6 BMMCs were sensitized with IgE and stimulated with DNP32-HSA in 
the presence of isotype control or Tim4-Fc for the indicated time. pS6 (S235/236) was analyzed by phospho-flow 
cytometry. Results are average of three independent experiments (A). Nur77GFP BMMCs were stimulated as indicated 
prior to GFP quantification by flow cytometry (B). Results are representative two independent experiments.  
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15.4 DISCUSSION 
Here, we focused on examining the signaling pathways leading to enhanced transcriptional 
activation and cytokine production by Tim-1 and Ag co-stimulation in mast cells. Phosphorylation 
of Syk was not altered by Tim-4 treatment at the time points we examined. This is consistent with 
our finding that the Tim1-Tim4 interaction did not promote Ag-stimulated FcRI signaling 
intensity, using mast cells from a Nur77GFP mouse model (363). Syk is phosphorylated on multiple 
tyrosines by either auto-phosphorylation or trans-phosphorylation by Lyn, resulting in positive or 
negative regulation, respectively, of Ag-mediated FcRI signaling (131, 134, 136). Since we only 
examined tyrosines 519 and 520 in the kinase loop, which are sites of Syk auto-phosphorylation, 
it is possible that other tyrosine phosphorylation sites may be affected by Tim-1. One particular 
site of interest is tyrosine 346 in the linker region, which is important for PLC-1 binding and 
phosphorylation (155). Aside from positive signaling pathways, the relevant negative signaling 
pathways should be investigated for potential downregulation by Tim-1 engagement. Thus, a 
particular FcRI proximal phosphatase of interest is the Src homology-2-containing signaling 
protein (SHP)-2, which has been implicated in regulation of IgE/Ag-induced IL-6 production 
through inhibition of NF-B activity, both of which are enhanced by Tim-1 cross-linking in our 
study (370).  
In a previous study, Tim-4/CD3/CD28-coated beads enhanced phosphorylation of Erk and 
Akt in CD4 T cells (224). These results were not observed in previously study using both BMMCs 
and peritoneal mast cells (PMCs) (240). Similarly, we did not observe similar effect with soluble 
Tim-4 addition in Ag-mediated FcRI aggregation at the peak of antigen stimulation or when 
signals returned to basal. It is possible that Tim-4 signals are cell-type specific or that mast cells 
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require more robust aggregation of Tim-1 at the time of antigen stimulation to induce substantial 
effects. While phosphorylation of Akt was not affected, ribosomal protein S6 was significantly 
enhanced upon Tim-4 treatment. Specifically, Tim-1 cross-linking enhanced and sustained 
IgE/Ag-induced S6 phosphorylation, which correlates with enhanced cytokine production. 
Ribosomal protein S6 is a downstream effector of PI3K/mTOR signaling, and as such is essential 
for mast cell survival, proliferation, metabolism and protein synthesis. Consequently, further 
studies are needed to address whether Tim1-Tim4 interaction promotes mast cell metabolic 
responses and protein synthesis as well as whether the specific Tim-1 targets in this pathway 
leading to effector functions.   
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16.0   SUMMARY AND DISCUSSION 
IgE binding to the high affinity receptor FcRI, and subsequent aggregation by allergens, initiates 
the assembly of multi-molecular complexes leading to degranulation, transcriptional activation 
and cytokine production (351, 369). The state of mast cell activation depends on signal integration 
from both the Lyn/Syk/LAT/PLC “primary” pathway and the Fyn/Gab2/PI3K “complementary” 
pathway. Since Lyn, and to a lesser extent Fyn, can mediate both positive and negative signals 
upon Ag encounter, it is critical to define the precise molecular mechanisms discriminating 
activating and inhibitory signals (109, 113, 119, 121). Here, we have identified a co-stimulatory 
role for Tim-1 and Tim-3 in FcRI-mediated mast cell activation. Our findings are among the first 
to describe functions of the Tim family proteins in regulation of mast cell activation aside from 
their well-known roles in other innate and adaptive immune cell types including T cells, B cells, 
NK, DC and macrophages. 
 
16.1 TIM-3 REGULATES POSITIVE AND NEGATIVE ANTIGEN SIGNALING 
Contrary to the negative regulatory role that has been described in other innate and adaptive 
immune cells, Tim-3 activity in mast cells is unequivocally positive. This is despite the presence 
on mast cells of multiple Tim-3 ligands, which have been previously described to mediate 
inhibition of cellular activation through Tim-3. Our findings suggest that Tim-3 promotes mast 
cell activation and cytokine production by closely associating with FcRI and its proximal 
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signaling pathways. Specifically, our data reveal an active involvement of Tim-3 in controlling the 
positive and negative effects of Lyn kinase activity. Rather than using Lyn-deficient mast cells 
that have been associated with enhanced, similar, or reduced degranulation (105, 118, 119, 145), 
we employed siRNA-mediated Lyn knockdown to mimic the phenotype of WeeB mast cells with 
reduced Lyn catalytic activity (340). In doing so, our findings demonstrated that Tim-3 can either 
promote positive Ag signaling or actively suppress the negative signals that are normally engaged 
by stimulation with high Ag concentration or valency. The intensity of Lyn phosphorylation, and 
its target FcRI, is strictly controlled by the intensity of FcRI stimulation (109). Furthermore, 
under conditions of strong Ag stimulation, Lyn is responsible for recruitment to  FcRI of the 
phosphatases SHIP-1 and SHP-1, which carry out a negative feedback suppressive function (109). 
Therefore, we hypothesize that Tim-3 ligation can counteract the Lyn-dependent negative 
regulation brought on by high Ag concentration by interfering with SHIP-1 or SHP-1 association 
with FcRI. Our evidence of a close association between Tim-3 and FcRI subunits further 
supports this idea. 
Similar to the Tim-1: Tim-4 interaction, Tim-3 ligation sustains Ag-induced ribosomal S6 
phosphorylation. Tim-3 pAb could prevent mast cell apoptosis after IL-3 withdrawal, by 
promoting IL-3 secretion in BMMCs (240). The mTOR kinase is responsible for integrating 
environmental and intracellular cues such as nutrients, stress, energy and growth factors into 
diverse biological processes including growth, survival and metabolism (371). Thus, our results 
imply that Tim-3 engagement may participate in the mTOR signaling pathway to promote mast 
cell survival, proliferation and protein synthesis. The tuberous sclerosis complex 1 (TSC1) has 
been reported as a negative regulator of FcRI-dependent mast cell cytokine production in vitro 
and in vivo (372). TSC is also critical for mast cell survival by mediating downregulation of p53 
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and upregulation of Bcl-2 (372). Therefore, it would be interesting to test whether Tim-3 
engagement can enhance mTOR signaling in the absence of TSC1.  
mTOR exists as two complexes: mTORC1, which phosphorylates ribosomal S6 kinase and 
eIF4E-binding proteins (4E-BPs) to promote protein translation; and mTORC2, which 
phosphorylates Akt, which in turn further activates mTORC1 (371). FcRI-dependent stimulation 
of mast cells induces both mTORC1 and mTORC2 activation (178, 361). It is now known that T 
cells depend on the metabolic regulator mTOR to maintain metabolic programming essential for 
differentiation and effector responses (373, 374). In T cells, Akt and mTOR support effector T cell 
differentiation, growth and function by promoting aerobic glycolysis (374, 375). In the periphery, 
mature naïve T cells mainly oxidize glucose-derived pyruvate in their mitochondria in a process 
called oxidative phosphorylation (OXPHOS), or fatty acid oxidation (FAO), to generate ATP 
(373). TCR ligation and engagement of co-stimulatory molecules induces metabolic changes in 
naïve T cells, to promote more aerobic glycolysis and anabolic biomass accumulation. Thus, in 
this process, glucose is converted to lactate to generate the metabolic intermediates important for 
cell growth and proliferation (373). mTOR has also been shown to regulate metabolism in innate 
cells via similar mechanisms (376). Mitochondrial OXPHOS has recently been shown to 
participate in ATP-dependent exocytosis in mast cells (377). Nevertheless, the precise mechanisms 
and implications of mTOR-dependent metabolism in mast cells are virtually unknown. Our 
findings show that Tim-3 cross-linking promotes Ag-dependent mast cell signaling and cytokine 
production, all of which could potentially be mediated by mTOR. As a result, we propose that 
IgE/Ag and Tim-3 pAb co-stimulation can modulate the balance between OXPHOS and aerobic 
glycolysis as mast cells shift from resting to an activated state. It would be interesting to determine 
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the metabolic profile of mast cells, i.e. OXPHOS vs. aerobic glycolysis, in the resting state and 
upon Ag stimulation, and whether Tim-3 ligation can modulate these activities.  
Finally, to extend our findings into a clinically relevant setting, we propose to examine 
human nasal polyp tissue. Thus mast cells have been shown to reside in this tissue and can be 
activated in an IgE-dependent manner to secrete histamine, leukotrienes and prostaglandin D2 
(PGD2) (378). In addition, nasal polyps are found in patients with chronic rhinosinusitis (CR) and 
aspirin-exacerbated respiratory disease (AERD), a severe eosinophilic inflammatory disease of the 
airways that is also marked by mast cell activation (379), (380). Upon stimulation with anti-IgE, 
nasal polyp tissue from patients with chronic rhinosinusitis produced more IL-5, IL-2, IL-10, IL-
17 and PGD2 compared to non-atopic controls in a population in Western China (379). In addition, 
mast cells are among the major IL-25-secreting cells in the nasal polyps of CR patients and 
polyposis, mucosal edema thickness, and inflammatory cell infiltration (381).  AERD patients have 
increased epithelial expression of IL-33, which has been shown to drive mast cell activation 
contributing to AERD pathogenesis (380). Tim-3 cross-linking can also enhance Ag-mediated 
gene expression of IL-2, IL-10 and IL-33 (324). Furthermore, the precise contribution of mast cells 
in nasal polyp generation is not known and AERD also occurs in non-atopic patients with elevated 
serum IgE. Therefore, it will be important to determine if Tim-3 is expressed by mast cells in nasal 
polyp tissue and whether its expression correlates with onset or severity of allergic diseases (382, 
383).  
Mast cells are a central effector of allergic rhinitis and other inflammatory diseases. Aside 
from their well-known role in hypersensitivity, mast cell involvement in inflammation-associated 
with cancer and other non-allergic diseases has been increasingly appreciated (384). Tim-3 is 
detected on tumor infiltrating human mast cells and its expression is increased upon TGF-
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treatment (324). Increased numbers of Tim-3/chymase double-positive mast cells have been shown 
to correlate with the severity of chronic inflammatory periodontitis (330). Manipulation of Tim-3 
activity on mast cells could be a promising target for development of novel therapeutic modalities 
to combat cancer and allergic and autoimmune disease. 
 
16.2 TIM-1:TIM-4 INTERACTION ENHANCES MAST CELL ACTIVATION 
The association between atopy and Tim-1 polymorphisms, particularly in the mucin region, have 
prompted studies to elucidate the mechanisms of action by Tim-1 in allergic diseases (385). More 
importantly, antibodies to Tim-1 have demonstrated that Tim-1 is a co-stimulatory molecule on T 
cells, thus raising the possibility of targeting Tim-1 to control allergic inflammation (220, 386).  
Similarly, Tim-1 has also been identified as a positive regulator of mast cell function (240). Given 
the genetic and functional connection of Tim-1 to allergy and hypersensitivity as well as the 
sentinel role of mast cells in atopy, it will be important to determine how Tim-1 signaling 
contributes to the high affinity Fc receptor for IgE (FcRI)-mediated mast cell activation.   
 Taken together, our findings provide further evidence that Tim-1 signaling can promote 
cytokine production in FcRI-trigged mast cell activation, as well as mechanistic data for how this 
occurs. Specifically, Tim-1 promotes NF-B and NFAT/AP1 transcriptional activation, leading to 
enhanced IL-6 promoter activation and cytokine production in IgE/Ag-stimulated mast cells. This 
is in line with a co-stimulatory role for Tim-1 in T, B and NKT cells, both in vitro and in vivo (206, 
216, 231). Contrary to their previously described effects on these cell types, Tim-1 antibodies did 
not regulate mast cell degranulation and cytokine production in our hands. Nevertheless, Tim-1 
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ligation by Tim-4 consistently enhanced mast cell cytokine production, and this effect was not 
affected by loss of the Tim-1 mucin domain. We also showed, for the first time, that unlike in 
regulatory B cells, the Tim-1 mucin domain is dispensable for mast cell effector function. Finally, 
we showed that Tim-1, in contrast with Tim-3, acts more distal to FcRI to enhance S6 activation, 
without affecting proximal FcRI signaling. Overall, our findings provide a mechanistic 
explanation for the co-stimulatory effects of Tim-1 signaling on FcRI -mediated mast cell 
activation. 
Future studies will focus on identifying the precise mechanisms of Tim-1 cytoplasmic tail 
phosphorylation, the critical mediator of Tim-1 function, and the signaling complexes recruited by 
Tim-1 to transduce this positive signal. Our previous findings in T cells showed that Tim-1 can be 
phosphorylated in an Lck-dependent manner, and can recruit the p85 subunit of PI3K (242). Given 
other evidence connecting Tim-1 to the PI3K pathway, and the finding that Fyn can phosphorylate 
the adaptor Gab2 leading to PI3K binding via its SH2-containing domain, we hypothesize that Fyn 
may phosphorylate Tim-1 to enhance PI3K recruitment (113, 387). Therefore, assessing whether 
p85 can interact with the Tim-1 cytoplasmic tail in mast cells may reveal a mechanism for the 
tyrosine phosphorylation-dependent function of Tim-1.  
In mast cells, Akt-mediated NF-B activation and downstream cytokine production require 
PI3K activity (178). Since Tim-1 expression can augment NF-B activation in mast cells, we 
expected that Tim-1 cross-linking by Tim-4 would lead to enhanced Akt phosphorylation and 
subsequently NF-B activation. However, this does not seem to be the case as we observed no 
detectable change in Akt activation. However, ribosomal protein S6 phosphorylation was 
enhanced, which correlated with enhanced cytokine production. Ribosomal protein S6 is a 
downstream effector of PI3K/mTOR signaling, and as such is essential for mast cell survival, 
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proliferation, metabolism and protein synthesis. MALT1 and Bcl10, members of the Carma1-
MALT1-Bcl10 (CBM) complex, are essential regulators of FcRI-induced mast cell activation by 
selectively upregulating NF-B-dependent cytokine production without affecting degranulation 
and leukotriene synthesis (388). We previously identified a Carma1-MALT1-dependent activation 
of mTOR signaling after TCR engagement, leading to phosphorylation of S6 and another mTOR 
substrate 4E-BP1 (389). Thus, Tim-1 may preferentially engage the MALT1-Bcl10 pathway to 
modulate mTOR signaling and NF-B responses without affecting FcεRI-proximal signaling. 
Consequently, further studies are needed to address whether Tim1-Tim4 interaction promotes mast 
cell metabolic responses and protein synthesis, as well as whether the specific Tim-1 targets in this 
pathway leading to effector functions.  
Although induction of NF-AT is also augmented by Tim-1, it remains to be determined 
whether calcium mobilization is modulated upon Tim-1 expression or co-stimulation. The calcium 
connection is particularly intriguing, since it ties together NF-AT, calcium-binding PKC isoforms 
such as PKC, NF-B and AP-1 pathways. Specifically, the calcium-binding isoform PKC has 
been shown to mediate degranulation and IL-6 production in Ag-stimulated mast cells (390). In T 
and B cells, PKC- and -, respectively, act upstream of the MALT1-Bcl10 complex to regulate 
NF-B activation (391). In addition, diacylglycerol (DAG) generated by phosphorylated PLC1 
and PLC2 activates PKC and PKC in mast cells, and contributes to Fos and Jun activation 
(166). Although the precise role of PKC in NF-B activation is unknown, Tim-1 ligation may 
selectively direct calcium signaling to promote cytokine production, rather than degranulation, via 
NFAT and PKC-mediated NF-B and AP-1 activation. 
Finally, Tim-1 blockade or cross-linking by known antibodies and ligands has been shown 
to ameliorate or exacerbate allergic lung inflammation in vivo. In our studies, Tim-4 consistently 
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enhanced Ag-mediated cytokine production in mast cells. Tim-4 binding to mast cells has been 
shown to occur specifically through Tim-1, since addition of recombinant Tim-1 could interfere 
with Tim-4 binding to surface Tim-1 (240). In addition, we observe that Tim-4 binding cannot be 
detected on BMMCs that have lost Tim-1 expression after an extended time in culture (data not 
shown). These results indicate that the Tim-1: Tim-4 interaction is specific and that manipulation 
of Tim-1 activity on mast cells, particularly modulation of the Tim1-Tim4 interaction, could be a 
novel therapeutic target to control allergic and autoimmune disease.  
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17.0  CONCLUSION 
Allergic diseases, including allergic asthma, rhinitis, atopic dermatitis and food allergy, affect 
approximately 15 percent of the global population and are on the rise (392). The current treatments 
for allergic diseases includes antihistamines, glucocorticoids (GCs), leukotriene antagonists, mast 
cell stabilizers, -agonists and anticholinergic agents (393). However, these drugs are not an ideal 
solution as they, particularly GCs and antihistamines, can only control symptoms and often cause 
serious side-effects in patients (394). Consequently, there is a need to identify specific targets and 
develop more efficacious immunotherapies to treat atopic diseases. 
     In recent years, monoclonal anti-IgE antibody has shown promise in treating allergic 
diseases other than allergic asthma, further emphasizing the importance of targeting IgE-mediated 
cellular activation to effectively control disease severity (395). Mast cells are  among the key 
mediators of disease pathogenesis, as IgE primarily binds to FcRI on mast cells and triggers 
release of a diverse array of inflammatory mediators. Here, we provide evidence for Tim-1 and 
Tim-3 as regulators of mast cell responses. We show that Tim-1 and Tim-3 can enhance IgE-
mediated mast cell activation by augmenting both the immediate degranulation phase and cytokine 
production phase. There has been tremendous interest in development of antibodies targeting Tim-
1 and Tim-3 in allergy, autoimmunity, cancer and transplant tolerance, all of which involve some 
degrees of mast cell activation. Our findings not only support mast cell Tim-1 and Tim-3 as 
relevant therapeutic targets but also provide another layer of complexity in the cell type- and 
context-dependent effects of the Tim family proteins. 
 180 
BIBLIOGRAPHY 
1. Galli SJ, Kalesnikoff J, Grimbaldeston MA, Piliponsky AM, Williams CM, Tsai M. Mast 
cells as "tunable" effector and immunoregulatory cells: recent advances. Annu Rev Immunol. 
2005;23:749-86. 
2. Jamur MC, Grodzki AC, Berenstein EH, Hamawy MM, Siraganian RP, Oliver C. 
Identification and characterization of undifferentiated mast cells in mouse bone marrow. Blood. 
2005;105(11):4282-9. 
3. Metcalfe DD, Baram D, Mekori YA. Mast cells. Physiol Rev. 1997;77(4):1033-79. 
4. Metcalfe DD, Boyce JA. Mast cell biology in evolution. J Allergy Clin Immunol. 
2006;117(6):1227-9. 
5. Gurish MF, Austen KF. The diverse roles of mast cells. J Exp Med. 2001;194(1):F1-5. 
6. Gurish MF, Boyce JA. Mast cells: ontogeny, homing, and recruitment of a unique innate 
effector cell. J Allergy Clin Immunol. 2006;117(6):1285-91. 
7. Ikeda RK, Miller M, Nayar J, Walker L, Cho JY, McElwain K, et al. Accumulation of 
peribronchial mast cells in a mouse model of ovalbumin allergen induced chronic airway 
inflammation: modulation by immunostimulatory DNA sequences. J Immunol. 2003;171(9):4860-
7. 
8. Collington SJ, Westwick J, Williams TJ, Weller CL. The function of CCR3 on mouse bone 
marrow-derived mast cells in vitro. Immunology. 2010;129(1):115-24. 
9. de Cassia Campos MR, Toso VD, de Souza DA, Jr., Vieira GV, da Silva EZ, Oliver C, et 
al. Differential effects of chemoattractants on mast cell recruitment in vivo. Cellular immunology. 
2014;289(1-2):86-90. 
10. Taub D, Dastych J, Inamura N, Upton J, Kelvin D, Metcalfe D, et al. Bone marrow-derived 
murine mast cells migrate, but do not degranulate, in response to chemokines. J Immunol. 
1995;154(5):2393-402. 
11. Enerback L. Mast cells in rat gastrointestinal mucosa. 3. Reactivity towards compound 
48/80. Acta Pathol Microbiol Scand. 1966;66(3):313-22. 
12. da Silva EZ, Jamur MC, Oliver C. Mast cell function: a new vision of an old cell. J 
Histochem Cytochem. 2014;62(10):698-738. 
13. Ruitenberg EJ, Elgersma A. Absence of intestinal mast cell response in congenitally 
athymic mice during Trichinella spiralis infection. Nature. 1976;264(5583):258-60. 
 181 
14. Nakahata T, Kobayashi T, Ishiguro A, Tsuji K, Naganuma K, Ando O, et al. Extensive 
proliferation of mature connective-tissue type mast cells in vitro. Nature. 1986;324(6092):65-7. 
15. Gurish MF, Ghildyal N, McNeil HP, Austen KF, Gillis S, Stevens RL. Differential 
expression of secretory granule proteases in mouse mast cells exposed to interleukin 3 and c-kit 
ligand. J Exp Med. 1992;175(4):1003-12. 
16. Goldstein SM, Kaempfer CE, Proud D, Schwartz LB, Irani AM, Wintroub BU. Detection 
and partial characterization of a human mast cell carboxypeptidase. J Immunol. 1987;139(8):2724-
9. 
17. Irani AA, Schechter NM, Craig SS, DeBlois G, Schwartz LB. Two types of human mast 
cells that have distinct neutral protease compositions. Proc Natl Acad Sci U S A. 
1986;83(12):4464-8. 
18. Schwartz LB. Analysis of MC(T) and MC(TC) mast cells in tissue. Methods Mol Biol. 
2006;315:53-62. 
19. Zhao W, Oskeritzian CA, Pozez AL, Schwartz LB. Cytokine production by skin-derived 
mast cells: endogenous proteases are responsible for degradation of cytokines. J Immunol. 
2005;175(4):2635-42. 
20. Woska JR, Jr., Gillespie ME. Small-interfering RNA-mediated identification and 
regulation of the ternary SNARE complex mediating RBL-2H3 mast cell degranulation. Scand J 
Immunol. 2011;73(1):8-17. 
21. Holgate ST. Epithelial damage and response. Clin Exp Allergy. 2000;30 Suppl 1:37-41. 
22. Lundequist A, Pejler G. Biological implications of preformed mast cell mediators. Cell 
Mol Life Sci. 2011;68(6):965-75. 
23. Irani AM, Schwartz LB. Human mast cell heterogeneity. Allergy Proc. 1994;15(6):303-8. 
24. McNeil HP, Shin K, Campbell IK, Wicks IP, Adachi R, Lee DM, et al. The mouse mast 
cell-restricted tetramer-forming tryptases mouse mast cell protease 6 and mouse mast cell protease 
7 are critical mediators in inflammatory arthritis. Arthritis Rheum. 2008;58(8):2338-46. 
25. Scandiuzzi L, Beghdadi W, Daugas E, Abrink M, Tiwari N, Brochetta C, et al. Mouse mast 
cell protease-4 deteriorates renal function by contributing to inflammation and fibrosis in immune 
complex-mediated glomerulonephritis. J Immunol. 2010;185(1):624-33. 
26. Shin K, Watts GF, Oettgen HC, Friend DS, Pemberton AD, Gurish MF, et al. Mouse mast 
cell tryptase mMCP-6 is a critical link between adaptive and innate immunity in the chronic phase 
of Trichinella spiralis infection. J Immunol. 2008;180(7):4885-91. 
27. Waern I, Jonasson S, Hjoberg J, Bucht A, Abrink M, Pejler G, et al. Mouse mast cell 
protease 4 is the major chymase in murine airways and has a protective role in allergic airway 
inflammation. J Immunol. 2009;183(10):6369-76. 
 182 
28. Marcelo F, Jimenez-Barbero J, Marrot J, Rauter AP, Sinay P, Bleriot Y. Stereochemical 
assignment and first synthesis of the core of miharamycin antibiotics. Chemistry. 
2008;14(32):10066-73. 
29. Gordon JR, Galli SJ. Mast cells as a source of both preformed and immunologically 
inducible TNF-alpha/cachectin. Nature. 1990;346(6281):274-6. 
30. Di Nardo A, Vitiello A, Gallo RL. Cutting edge: mast cell antimicrobial activity is 
mediated by expression of cathelicidin antimicrobial peptide. J Immunol. 2003;170(5):2274-8. 
31. Boyce JA. Eicosanoid mediators of mast cells: receptors, regulation of synthesis, and 
pathobiologic implications. Chem Immunol Allergy. 2005;87:59-79. 
32. Gilfillan AM, Austin SJ, Metcalfe DD. Mast cell biology: introduction and overview. Adv 
Exp Med Biol. 2011;716:2-12. 
33. Hofmann AM, Abraham SN. New roles for mast cells in modulating allergic reactions and 
immunity against pathogens. Curr Opin Immunol. 2009;21(6):679-86. 
34. Brown JM, Wilson TM, Metcalfe DD. The mast cell and allergic diseases: role in 
pathogenesis and implications for therapy. Clin Exp Allergy. 2008;38(1):4-18. 
35. Grimbaldeston MA, Metz M, Yu M, Tsai M, Galli SJ. Effector and potential 
immunoregulatory roles of mast cells in IgE-associated acquired immune responses. Curr Opin 
Immunol. 2006;18(6):751-60. 
36. Williams CM, Galli SJ. The diverse potential effector and immunoregulatory roles of mast 
cells in allergic disease. J Allergy Clin Immunol. 2000;105(5):847-59. 
37. Brenner T, Soffer D, Shalit M, Levi-Schaffer F. Mast cells in experimental allergic 
encephalomyelitis: characterization, distribution in the CNS and in vitro activation by myelin basic 
protein and neuropeptides. J Neurol Sci. 1994;122(2):210-3. 
38. Brown MA, Tanzola MB, Robbie-Ryan M. Mechanisms underlying mast cell influence on 
EAE disease course. Mol Immunol. 2002;38(16-18):1373-8. 
39. Dines KC, Powell HC. Mast cell interactions with the nervous system: relationship to 
mechanisms of disease. J Neuropathol Exp Neurol. 1997;56(6):627-40. 
40. Ibrahim MZ, Reder AT, Lawand R, Takash W, Sallouh-Khatib S. The mast cells of the 
multiple sclerosis brain. J Neuroimmunol. 1996;70(2):131-8. 
41. Orr EL. Presence and distribution of nervous system-associated mast cells that may 
modulate experimental autoimmune encephalomyelitis. Ann N Y Acad Sci. 1988;540:723-6. 
42. Seeldrayers PA, Yasui D, Weiner HL, Johnson D. Treatment of experimental allergic 
neuritis with nedocromil sodium. J Neuroimmunol. 1989;25(2-3):221-6. 
 183 
43. Lee DM, Friend DS, Gurish MF, Benoist C, Mathis D, Brenner MB. Mast cells: a cellular 
link between autoantibodies and inflammatory arthritis. Science. 2002;297(5587):1689-92. 
44. Hueber AJ, Asquith DL, Miller AM, Reilly J, Kerr S, Leipe J, et al. Mast cells express IL-
17A in rheumatoid arthritis synovium. J Immunol. 2010;184(7):3336-40. 
45. Ji H, Ohmura K, Mahmood U, Lee DM, Hofhuis FM, Boackle SA, et al. Arthritis critically 
dependent on innate immune system players. Immunity. 2002;16(2):157-68. 
46. Ji H, Pettit A, Ohmura K, Ortiz-Lopez A, Duchatelle V, Degott C, et al. Critical roles for 
interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis. J Exp Med. 
2002;196(1):77-85. 
47. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol. 2001;19:275-90. 
48. Supajatura V, Ushio H, Wada A, Yahiro K, Okumura K, Ogawa H, et al. Cutting edge: 
VacA, a vacuolating cytotoxin of Helicobacter pylori, directly activates mast cells for migration 
and production of proinflammatory cytokines. J Immunol. 2002;168(6):2603-7. 
49. Varadaradjalou S, Feger F, Thieblemont N, Hamouda NB, Pleau JM, Dy M, et al. Toll-like 
receptor 2 (TLR2) and TLR4 differentially activate human mast cells. Eur J Immunol. 
2003;33(4):899-906. 
50. Feger F, Varadaradjalou S, Gao Z, Abraham SN, Arock M. The role of mast cells in host 
defense and their subversion by bacterial pathogens. Trends Immunol. 2002;23(3):151-8. 
51. Malaviya R, Twesten NJ, Ross EA, Abraham SN, Pfeifer JD. Mast cells process bacterial 
Ags through a phagocytic route for class I MHC presentation to T cells. J Immunol. 
1996;156(4):1490-6. 
52. Burke SM, Issekutz TB, Mohan K, Lee PW, Shmulevitz M, Marshall JS. Human mast cell 
activation with virus-associated stimuli leads to the selective chemotaxis of natural killer cells by 
a CXCL8-dependent mechanism. Blood. 2008;111(12):5467-76. 
53. Dawicki W, Marshall JS. New and emerging roles for mast cells in host defence. Curr Opin 
Immunol. 2007;19(1):31-8. 
54. Marshall JS, McCurdy JD, Olynych T. Toll-like receptor-mediated activation of mast cells: 
implications for allergic disease? Int Arch Allergy Immunol. 2003;132(2):87-97. 
55. St John AL, Rathore AP, Yap H, Ng ML, Metcalfe DD, Vasudevan SG, et al. Immune 
surveillance by mast cells during dengue infection promotes natural killer (NK) and NKT-cell 
recruitment and viral clearance. Proc Natl Acad Sci U S A. 2011;108(22):9190-5. 
56. Wang Z, Lai Y, Bernard JJ, Macleod DT, Cogen AL, Moss B, et al. Skin mast cells protect 
mice against vaccinia virus by triggering mast cell receptor S1PR2 and releasing antimicrobial 
peptides. J Immunol. 2012;188(1):345-57. 
 184 
57. Hepworth MR, Maurer M, Hartmann S. Regulation of type 2 immunity to helminths by 
mast cells. Gut Microbes. 2012;3(5):476-81. 
58. Poncet P, Arock M, David B. MHC class II-dependent activation of CD4+ T cell 
hybridomas by human mast cells through superantigen presentation. J Leukoc Biol. 
1999;66(1):105-12. 
59. Stelekati E, Bahri R, D'Orlando O, Orinska Z, Mittrucker HW, Langenhaun R, et al. Mast 
cell-mediated antigen presentation regulates CD8+ T cell effector functions. Immunity. 
2009;31(4):665-76. 
60. Heib V, Becker M, Warger T, Rechtsteiner G, Tertilt C, Klein M, et al. Mast cells are 
crucial for early inflammation, migration of Langerhans cells, and CTL responses following 
topical application of TLR7 ligand in mice. Blood. 2007;110(3):946-53. 
61. Suto H, Nakae S, Kakurai M, Sedgwick JD, Tsai M, Galli SJ. Mast cell-associated TNF 
promotes dendritic cell migration. J Immunol. 2006;176(7):4102-12. 
62. Skokos D, Botros HG, Demeure C, Morin J, Peronet R, Birkenmeier G, et al. Mast cell-
derived exosomes induce phenotypic and functional maturation of dendritic cells and elicit specific 
immune responses in vivo. J Immunol. 2003;170(6):3037-45. 
63. Nakae S, Suto H, Iikura M, Kakurai M, Sedgwick JD, Tsai M, et al. Mast cells enhance T 
cell activation: importance of mast cell costimulatory molecules and secreted TNF. J Immunol. 
2006;176(4):2238-48. 
64. Nakae S, Suto H, Kakurai M, Sedgwick JD, Tsai M, Galli SJ. Mast cells enhance T cell 
activation: Importance of mast cell-derived TNF. Proc Natl Acad Sci U S A. 2005;102(18):6467-
72. 
65. Hart PH, Grimbaldeston MA, Swift GJ, Jaksic A, Noonan FP, Finlay-Jones JJ. Dermal 
mast cells determine susceptibility to ultraviolet B-induced systemic suppression of contact 
hypersensitivity responses in mice. J Exp Med. 1998;187(12):2045-53. 
66. Rao KN, Brown MA. Mast cells: multifaceted immune cells with diverse roles in health 
and disease. Ann N Y Acad Sci. 2008;1143:83-104. 
67. Hershko AY, Suzuki R, Charles N, Alvarez-Errico D, Sargent JL, Laurence A, et al. Mast 
cell interleukin-2 production contributes to suppression of chronic allergic dermatitis. Immunity. 
2011;35(4):562-71. 
68. Lu LF, Lind EF, Gondek DC, Bennett KA, Gleeson MW, Pino-Lagos K, et al. Mast cells 
are essential intermediaries in regulatory T-cell tolerance. Nature. 2006;442(7106):997-1002. 
69. Gri G, Piconese S, Frossi B, Manfroi V, Merluzzi S, Tripodo C, et al. CD4+CD25+ 
regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L 
interaction. Immunity. 2008;29(5):771-81. 
 185 
70. Piconese S, Gri G, Tripodo C, Musio S, Gorzanelli A, Frossi B, et al. Mast cells counteract 
regulatory T-cell suppression through interleukin-6 and OX40/OX40L axis toward Th17-cell 
differentiation. Blood. 2009;114(13):2639-48. 
71. Bossi F, Frossi B, Radillo O, Cugno M, Tedeschi A, Riboldi P, et al. Mast cells are critically 
involved in serum-mediated vascular leakage in chronic urticaria beyond high-affinity IgE receptor 
stimulation. Allergy. 2011;66(12):1538-45. 
72. Harizi H, Gualde N. Pivotal role of PGE2 and IL-10 in the cross-regulation of dendritic 
cell-derived inflammatory mediators. Cell Mol Immunol. 2006;3(4):271-7. 
73. Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S. Prostaglandin E2 promotes 
tumor progression by inducing myeloid-derived suppressor cells. Cancer Res. 2007;67(9):4507-
13. 
74. McGlade JP, Gorman S, Lenzo JC, Tan JW, Watanabe T, Finlay-Jones JJ, et al. Effect of 
both ultraviolet B irradiation and histamine receptor function on allergic responses to an inhaled 
antigen. J Immunol. 2007;178(5):2794-802. 
75. Weller CL, Collington SJ, Williams T, Lamb JR. Mast cells in health and disease. Clin Sci 
(Lond). 2011;120(11):473-84. 
76. Abe M, Kurosawa M, Igarashi Y, Ishikawa O, Miyachi Y. Influence of IgE-mediated 
activation of cultured human mast cells on proliferation and type I collagen production by human 
dermal fibroblasts. J Allergy Clin Immunol. 2000;106(1 Pt 2):S72-7. 
77. Noli C, Miolo A. The mast cell in wound healing. Vet Dermatol. 2001;12(6):303-13. 
78. Mekori YA, Zeidan Z. Mast cells in nonallergic immune responses in vivo. Isr J Med Sci. 
1990;26(6):337-41. 
79. Huang C, Wong GW, Ghildyal N, Gurish MF, Sali A, Matsumoto R, et al. The tryptase, 
mouse mast cell protease 7, exhibits anticoagulant activity in vivo and in vitro due to its ability to 
degrade fibrinogen in the presence of the diverse array of protease inhibitors in plasma. J Biol 
Chem. 1997;272(50):31885-93. 
80. Gottwald T, Coerper S, Schaffer M, Koveker G, Stead RH. The mast cell-nerve axis in 
wound healing: a hypothesis. Wound Repair Regen. 1998;6(1):8-20. 
81. Hebda PA, Collins MA, Tharp MD. Mast cell and myofibroblast in wound healing. 
Dermatol Clin. 1993;11(4):685-96. 
82. Chiappetta N, Gruber B. The role of mast cells in osteoporosis. Semin Arthritis Rheum. 
2006;36(1):32-6. 
83. Crivellato E, Beltrami CA, Mallardi F, Ribatti D. The mast cell: an active participant or an 
innocent bystander? Histol Histopathol. 2004;19(1):259-70. 
 186 
84. D'Amore PA, Thompson RW. Mechanisms of angiogenesis. Annu Rev Physiol. 
1987;49:453-64. 
85. Constantinides P. Infiltrates of activated mast cells at the site of coronary atheromatous 
erosion or rupture in myocardial infarction. Circulation. 1995;92(5):1083. 
86. Lee M, Kovanen PT, Tedeschi G, Oungre E, Franceschini G, Calabresi L. Apolipoprotein 
composition and particle size affect HDL degradation by chymase: effect on cellular cholesterol 
efflux. J Lipid Res. 2003;44(3):539-46. 
87. Lindstedt L, Lee M, Castro GR, Fruchart JC, Kovanen PT. Chymase in exocytosed rat mast 
cell granules effectively proteolyzes apolipoprotein AI-containing lipoproteins, so reducing the 
cholesterol efflux-inducing ability of serum and aortic intimal fluid. J Clin Invest. 
1996;97(10):2174-82. 
88. Maltby S, Khazaie K, McNagny KM. Mast cells in tumor growth: angiogenesis, tissue 
remodelling and immune-modulation. Biochim Biophys Acta. 2009;1796(1):19-26. 
89. Coussens LM, Raymond WW, Bergers G, Laig-Webster M, Behrendtsen O, Werb Z, et al. 
Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. 
Genes Dev. 1999;13(11):1382-97. 
90. Baram D, Mekori YA, Sagi-Eisenberg R. Synaptotagmin regulates mast cell functions. 
Immunol Rev. 2001;179:25-34. 
91. Norrby K. Mast cells and angiogenesis. APMIS. 2002;110(5):355-71. 
92. Dyduch G, Kaczmarczyk K, Okon K. Mast cells and cancer: enemies or allies? Pol J Pathol. 
2012;63(1):1-7. 
93. Oldford SA, Haidl ID, Howatt MA, Leiva CA, Johnston B, Marshall JS. A critical role for 
mast cells and mast cell-derived IL-6 in TLR2-mediated inhibition of tumor growth. J Immunol. 
2010;185(11):7067-76. 
94. Blank U, Ra C, Miller L, White K, Metzger H, Kinet JP. Complete structure and expression 
in transfected cells of high affinity IgE receptor. Nature. 1989;337(6203):187-9. 
95. Hakimi J, Seals C, Kondas JA, Pettine L, Danho W, Kochan J. The alpha subunit of the 
human IgE receptor (FcERI) is sufficient for high affinity IgE binding. J Biol Chem. 
1990;265(36):22079-81. 
96. Nakae S, Iwakura Y, Suto H, Galli SJ. Phenotypic differences between Th1 and Th17 cells 
and negative regulation of Th1 cell differentiation by IL-17. J Leukoc Biol. 2007;81(5):1258-68. 
97. Ra C, Jouvin MH, Kinet JP. Complete structure of the mouse mast cell receptor for IgE 
(Fc epsilon RI) and surface expression of chimeric receptors (rat-mouse-human) on transfected 
cells. J Biol Chem. 1989;264(26):15323-7. 
 187 
98. Sakurai D, Yamasaki S, Arase K, Park SY, Arase H, Konno A, et al. Fc epsilon RI gamma-
ITAM is differentially required for mast cell function in vivo. J Immunol. 2004;172(4):2374-81. 
99. Blank U, Rivera J. The ins and outs of IgE-dependent mast-cell exocytosis. Trends 
Immunol. 2004;25(5):266-73. 
100. Lin S, Cicala C, Scharenberg AM, Kinet JP. The Fc(epsilon)RIbeta subunit functions as an 
amplifier of Fc(epsilon)RIgamma-mediated cell activation signals. Cell. 1996;85(7):985-95. 
101. Pribluda VS, Pribluda C, Metzger H. Transphosphorylation as the mechanism by which 
the high-affinity receptor for IgE is phosphorylated upon aggregation. Proc Natl Acad Sci U S A. 
1994;91(23):11246-50. 
102. Jouvin MH, Adamczewski M, Numerof R, Letourneur O, Valle A, Kinet JP. Differential 
control of the tyrosine kinases Lyn and Syk by the two signaling chains of the high affinity 
immunoglobulin E receptor. J Biol Chem. 1994;269(8):5918-25. 
103. Kimura T, Kihara H, Bhattacharyya S, Sakamoto H, Appella E, Siraganian RP. 
Downstream signaling molecules bind to different phosphorylated immunoreceptor tyrosine-based 
activation motif (ITAM) peptides of the high affinity IgE receptor. J Biol Chem. 
1996;271(44):27962-8. 
104. Shiue L, Zoller MJ, Brugge JS. Syk is activated by phosphotyrosine-containing peptides 
representing the tyrosine-based activation motifs of the high affinity receptor for IgE. J Biol Chem. 
1995;270(18):10498-502. 
105. Furumoto Y, Nunomura S, Terada T, Rivera J, Ra C. The FcepsilonRIbeta immunoreceptor 
tyrosine-based activation motif exerts inhibitory control on MAPK and IkappaB kinase 
phosphorylation and mast cell cytokine production. J Biol Chem. 2004;279(47):49177-87. 
106. On M, Billingsley JM, Jouvin MH, Kinet JP. Molecular dissection of the FcRbeta signaling 
amplifier. J Biol Chem. 2004;279(44):45782-90. 
107. Kimura T, Sakamoto H, Appella E, Siraganian RP. The negative signaling molecule SH2 
domain-containing inositol-polyphosphate 5-phosphatase (SHIP) binds to the tyrosine-
phosphorylated beta subunit of the high affinity IgE receptor. J Biol Chem. 1997;272(21):13991-
6. 
108. Kimura T, Zhang J, Sagawa K, Sakaguchi K, Appella E, Siraganian RP. Syk-independent 
tyrosine phosphorylation and association of the protein tyrosine phosphatases SHP-1 and SHP-2 
with the high affinity IgE receptor. J Immunol. 1997;159(9):4426-34. 
109. Xiao W, Nishimoto H, Hong H, Kitaura J, Nunomura S, Maeda-Yamamoto M, et al. 
Positive and negative regulation of mast cell activation by Lyn via the FcepsilonRI. J Immunol. 
2005;175(10):6885-92. 
 188 
110. Pasquier B, Launay P, Kanamaru Y, Moura IC, Pfirsch S, Ruffie C, et al. Identification of 
FcalphaRI as an inhibitory receptor that controls inflammation: dual role of FcRgamma ITAM. 
Immunity. 2005;22(1):31-42. 
111. Yamaguchi M, Lantz CS, Oettgen HC, Katona IM, Fleming T, Miyajima I, et al. IgE 
enhances mouse mast cell Fc(epsilon)RI expression in vitro and in vivo: evidence for a novel 
amplification mechanism in IgE-dependent reactions. J Exp Med. 1997;185(4):663-72. 
112. Asai K, Kitaura J, Kawakami Y, Yamagata N, Tsai M, Carbone DP, et al. Regulation of 
mast cell survival by IgE. Immunity. 2001;14(6):791-800. 
113. Parravicini V, Gadina M, Kovarova M, Odom S, Gonzalez-Espinosa C, Furumoto Y, et al. 
Fyn kinase initiates complementary signals required for IgE-dependent mast cell degranulation. 
Nat Immunol. 2002;3(8):741-8. 
114. Hong H, Kitaura J, Xiao W, Horejsi V, Ra C, Lowell CA, et al. The Src family kinase Hck 
regulates mast cell activation by suppressing an inhibitory Src family kinase Lyn. Blood. 
2007;110(7):2511-9. 
115. Vonakis BM, Chen H, Haleem-Smith H, Metzger H. The unique domain as the site on Lyn 
kinase for its constitutive association with the high affinity receptor for IgE. J Biol Chem. 
1997;272(38):24072-80. 
116. Vonakis BM, Haleem-Smith H, Benjamin P, Metzger H. Interaction between the 
unphosphorylated receptor with high affinity for IgE and Lyn kinase. J Biol Chem. 
2001;276(2):1041-50. 
117. Kovarova M, Tolar P, Arudchandran R, Draberova L, Rivera J, Draber P. Structure-
function analysis of Lyn kinase association with lipid rafts and initiation of early signaling events 
after Fcepsilon receptor I aggregation. Mol Cell Biol. 2001;21(24):8318-28. 
118. Hibbs ML, Tarlinton DM, Armes J, Grail D, Hodgson G, Maglitto R, et al. Multiple defects 
in the immune system of Lyn-deficient mice, culminating in autoimmune disease. Cell. 
1995;83(2):301-11. 
119. Odom S, Gomez G, Kovarova M, Furumoto Y, Ryan JJ, Wright HV, et al. Negative 
regulation of immunoglobulin E-dependent allergic responses by Lyn kinase. J Exp Med. 
2004;199(11):1491-502. 
120. Hernandez-Hansen V, Mackay GA, Lowell CA, Wilson BS, Oliver JM. The Src kinase 
Lyn is a negative regulator of mast cell proliferation. J Leukoc Biol. 2004;75(1):143-51. 
121. Gomez G, Gonzalez-Espinosa C, Odom S, Baez G, Cid ME, Ryan JJ, et al. Impaired 
FcepsilonRI-dependent gene expression and defective eicosanoid and cytokine production as a 
consequence of Fyn deficiency in mast cells. J Immunol. 2005;175(11):7602-10. 
122. Gu H, Saito K, Klaman LD, Shen J, Fleming T, Wang Y, et al. Essential role for Gab2 in 
the allergic response. Nature. 2001;412(6843):186-90. 
 189 
123. Hisatsune C, Kuroda Y, Nakamura K, Inoue T, Nakamura T, Michikawa T, et al. 
Regulation of TRPC6 channel activity by tyrosine phosphorylation. J Biol Chem. 
2004;279(18):18887-94. 
124. Olivera A, Urtz N, Mizugishi K, Yamashita Y, Gilfillan AM, Furumoto Y, et al. IgE-
dependent activation of sphingosine kinases 1 and 2 and secretion of sphingosine 1-phosphate 
requires Fyn kinase and contributes to mast cell responses. J Biol Chem. 2006;281(5):2515-25. 
125. Macurek L, Draberova E, Richterova V, Sulimenko V, Sulimenko T, Draberova L, et al. 
Regulation of microtubule nucleation from membranes by complexes of membrane-bound 
gamma-tubulin with Fyn kinase and phosphoinositide 3-kinase. Biochem J. 2008;416(3):421-30. 
126. Sulimenko V, Draberova E, Sulimenko T, Macurek L, Richterova V, Draber P, et al. 
Regulation of microtubule formation in activated mast cells by complexes of gamma-tubulin with 
Fyn and Syk kinases. J Immunol. 2006;176(12):7243-53. 
127. Zhang J, Berenstein EH, Evans RL, Siraganian RP. Transfection of Syk protein tyrosine 
kinase reconstitutes high affinity IgE receptor-mediated degranulation in a Syk-negative variant 
of rat basophilic leukemia RBL-2H3 cells. J Exp Med. 1996;184(1):71-9. 
128. Costello PS, Turner M, Walters AE, Cunningham CN, Bauer PH, Downward J, et al. 
Critical role for the tyrosine kinase Syk in signalling through the high affinity IgE receptor of mast 
cells. Oncogene. 1996;13(12):2595-605. 
129. de Castro RO, Zhang J, Jamur MC, Oliver C, Siraganian RP. Tyrosines in the carboxyl 
terminus regulate Syk kinase activity and function. J Biol Chem. 2010;285(34):26674-84. 
130. Grodzki AC, Moon KD, Berenstein EH, Siraganian RP. FcepsilonRI-induced activation by 
low antigen concentrations results in nuclear signals in the absence of degranulation. Mol 
Immunol. 2009;46(13):2539-47. 
131. Sanderson MP, Wex E, Kono T, Uto K, Schnapp A. Syk and Lyn mediate distinct Syk 
phosphorylation events in FcvarepsilonRI-signal transduction: implications for regulation of IgE-
mediated degranulation. Mol Immunol. 2010;48(1-3):171-8. 
132. Zhang J, Billingsley ML, Kincaid RL, Siraganian RP. Phosphorylation of Syk activation 
loop tyrosines is essential for Syk function. An in vivo study using a specific anti-Syk activation 
loop phosphotyrosine antibody. J Biol Chem. 2000;275(45):35442-7. 
133. Furlong MT, Mahrenholz AM, Kim KH, Ashendel CL, Harrison ML, Geahlen RL. 
Identification of the major sites of autophosphorylation of the murine protein-tyrosine kinase Syk. 
Biochim Biophys Acta. 1997;1355(2):177-90. 
134. Sada K, Zhang J, Siraganian RP. Point mutation of a tyrosine in the linker region of Syk 
results in a gain of function. J Immunol. 2000;164(1):338-44. 
135. Zhang J, Berenstein E, Siraganian RP. Phosphorylation of Tyr342 in the linker region of 
Syk is critical for Fc epsilon RI signaling in mast cells. Mol Cell Biol. 2002;22(23):8144-54. 
 190 
136. Zhang J, Kimura T, Siraganian RP. Mutations in the activation loop tyrosines of protein 
tyrosine kinase Syk abrogate intracellular signaling but not kinase activity. J Immunol. 
1998;161(8):4366-74. 
137. Paolini R, Molfetta R, Beitz LO, Zhang J, Scharenberg AM, Piccoli M, et al. Activation of 
Syk tyrosine kinase is required for c-Cbl-mediated ubiquitination of Fcepsilon RI and Syk in RBL 
cells. J Biol Chem. 2002;277(40):36940-7. 
138. Deindl S, Kadlecek TA, Brdicka T, Cao X, Weiss A, Kuriyan J. Structural basis for the 
inhibition of tyrosine kinase activity of ZAP-70. Cell. 2007;129(4):735-46. 
139. Choi WS, Hiragun T, Lee JH, Kim YM, Kim HP, Chahdi A, et al. Activation of RBL-2H3 
mast cells is dependent on tyrosine phosphorylation of phospholipase D2 by Fyn and Fgr. Mol 
Cell Biol. 2004;24(16):6980-92. 
140. Germano P, Gomez J, Kazanietz MG, Blumberg PM, Rivera J. Phosphorylation of the 
gamma chain of the high affinity receptor for immunoglobulin E by receptor-associated protein 
kinase C-delta. J Biol Chem. 1994;269(37):23102-7. 
141. Felices M, Falk M, Kosaka Y, Berg LJ. Tec kinases in T cell and mast cell signaling. Adv 
Immunol. 2007;93:145-84. 
142. Rawlings DJ, Scharenberg AM, Park H, Wahl MI, Lin S, Kato RM, et al. Activation of 
BTK by a phosphorylation mechanism initiated by SRC family kinases. Science. 
1996;271(5250):822-5. 
143. Iwaki S, Tkaczyk C, Metcalfe DD, Gilfillan AM. Roles of adaptor molecules in mast cell 
activation. Chem Immunol Allergy. 2005;87:43-58. 
144. Yao L, Kawakami Y, Kawakami T. The pleckstrin homology domain of Bruton tyrosine 
kinase interacts with protein kinase C. Proc Natl Acad Sci U S A. 1994;91(19):9175-9. 
145. Kawakami Y, Kitaura J, Hata D, Yao L, Kawakami T. Functions of Bruton's tyrosine 
kinase in mast and B cells. J Leukoc Biol. 1999;65(3):286-90. 
146. Iyer AS, August A. The Tec family kinase, IL-2-inducible T cell kinase, differentially 
controls mast cell responses. J Immunol. 2008;180(12):7869-77. 
147. Saitoh S, Arudchandran R, Manetz TS, Zhang W, Sommers CL, Love PE, et al. LAT is 
essential for Fc(epsilon)RI-mediated mast cell activation. Immunity. 2000;12(5):525-35. 
148. Saitoh S, Odom S, Gomez G, Sommers CL, Young HA, Rivera J, et al. The four distal 
tyrosines are required for LAT-dependent signaling in FcepsilonRI-mediated mast cell activation. 
J Exp Med. 2003;198(5):831-43. 
149. Ishiai M, Kurosaki M, Inabe K, Chan AC, Sugamura K, Kurosaki T. Involvement of LAT, 
Gads, and Grb2 in compartmentation of SLP-76 to the plasma membrane. J Exp Med. 
2000;192(6):847-56. 
 191 
150. Yablonski D, Weiss A. Mechanisms of signaling by the hematopoietic-specific adaptor 
proteins, SLP-76 and LAT and their B cell counterpart, BLNK/SLP-65. Adv Immunol. 
2001;79:93-128. 
151. Liu SK, Fang N, Koretzky GA, McGlade CJ. The hematopoietic-specific adaptor protein 
gads functions in T-cell signaling via interactions with the SLP-76 and LAT adaptors. Curr Biol. 
1999;9(2):67-75. 
152. Liu Q, Berry D, Nash P, Pawson T, McGlade CJ, Li SS. Structural basis for specific binding 
of the Gads SH3 domain to an RxxK motif-containing SLP-76 peptide: a novel mode of peptide 
recognition. Molecular cell. 2003;11(2):471-81. 
153. Pivniouk VI, Martin TR, Lu-Kuo JM, Katz HR, Oettgen HC, Geha RS. SLP-76 deficiency 
impairs signaling via the high-affinity IgE receptor in mast cells. J Clin Invest. 1999;103(12):1737-
43. 
154. Kim SK, Wee SM, Chang JS, Kwon TK, Min DS, Lee YH, et al. Point mutations in the 
split PLC-gamma1 PH domain modulate phosphoinositide binding. J Biochem Mol Biol. 
2004;37(6):720-5. 
155. Law CL, Chandran KA, Sidorenko SP, Clark EA. Phospholipase C-gamma1 interacts with 
conserved phosphotyrosyl residues in the linker region of Syk and is a substrate for Syk. Mol Cell 
Biol. 1996;16(4):1305-15. 
156. Takata M, Kurosaki T. A role for Bruton's tyrosine kinase in B cell antigen receptor-
mediated activation of phospholipase C-gamma 2. J Exp Med. 1996;184(1):31-40. 
157. Hoth M, Penner R. Depletion of intracellular calcium stores activates a calcium current in 
mast cells. Nature. 1992;355(6358):353-6. 
158. Guo Z, Turner C, Castle D. Relocation of the t-SNARE SNAP-23 from lamellipodia-like 
cell surface projections regulates compound exocytosis in mast cells. Cell. 1998;94(4):537-48. 
159. Jahn R, Sudhof TC. Membrane fusion and exocytosis. Annual review of biochemistry. 
1999;68:863-911. 
160. Logan MR, Odemuyiwa SO, Moqbel R. Understanding exocytosis in immune and 
inflammatory cells: the molecular basis of mediator secretion. J Allergy Clin Immunol. 
2003;111(5):923-32; quiz 33. 
161. Paumet F, Le Mao J, Martin S, Galli T, David B, Blank U, et al. Soluble NSF attachment 
protein receptors (SNAREs) in RBL-2H3 mast cells: functional role of syntaxin 4 in exocytosis 
and identification of a vesicle-associated membrane protein 8-containing secretory compartment. 
J Immunol. 2000;164(11):5850-7. 
162. Teramoto H, Salem P, Robbins KC, Bustelo XR, Gutkind JS. Tyrosine phosphorylation of 
the vav proto-oncogene product links FcepsilonRI to the Rac1-JNK pathway. J Biol Chem. 
1997;272(16):10751-5. 
 192 
163. Hata D, Kitaura J, Hartman SE, Kawakami Y, Yokota T, Kawakami T. Bruton's tyrosine 
kinase-mediated interleukin-2 gene activation in mast cells. Dependence on the c-Jun N-terminal 
kinase activation pathway. J Biol Chem. 1998;273(18):10979-87. 
164. Marquardt DL, Walker LL. Dependence of mast cell IgE-mediated cytokine production on 
nuclear factor-kappaB activity. J Allergy Clin Immunol. 2000;105(3):500-5. 
165. Pelletier C, Guerin-Marchand C, Iannascoli B, Marchand F, David B, Weyer A, et al. 
Specific signaling pathways in the regulation of TNF-alpha mRNA synthesis and TNF-alpha 
secretion in RBL-2H3 mast cells stimulated through the high affinity IgE receptor. Inflamm Res. 
1998;47(12):493-500. 
166. Razin E, Szallasi Z, Kazanietz MG, Blumberg PM, Rivera J. Protein kinases C-beta and 
C-epsilon link the mast cell high-affinity receptor for IgE to the expression of c-fos and c-jun. Proc 
Natl Acad Sci U S A. 1994;91(16):7722-6. 
167. Hirasawa N, Santini F, Beaven MA. Activation of the mitogen-activated protein 
kinase/cytosolic phospholipase A2 pathway in a rat mast cell line. Indications of different 
pathways for release of arachidonic acid and secretory granules. J Immunol. 1995;154(10):5391-
402. 
168. Borsch-Haubold AG, Ghomashchi F, Pasquet S, Goedert M, Cohen P, Gelb MH, et al. 
Phosphorylation of cytosolic phospholipase A2 in platelets is mediated by multiple stress-activated 
protein kinase pathways. European journal of biochemistry / FEBS. 1999;265(1):195-203. 
169. Hutchinson LE, McCloskey MA. Fc epsilon RI-mediated induction of nuclear factor of 
activated T-cells. J Biol Chem. 1995;270(27):16333-8. 
170. Rivera J. Molecular adapters in Fc(epsilon)RI signaling and the allergic response. Curr 
Opin Immunol. 2002;14(6):688-93. 
171. Melendez AJ, Allen JM. Phospholipase D and immune receptor signalling. Semin 
Immunol. 2002;14(1):49-55. 
172. Choi OH, Kim JH, Kinet JP. Calcium mobilization via sphingosine kinase in signalling by 
the Fc epsilon RI antigen receptor. Nature. 1996;380(6575):634-6. 
173. Rivera J. NTAL/LAB and LAT: a balancing act in mast-cell activation and function. 
Trends Immunol. 2005;26(3):119-22. 
174. Tkaczyk C, Beaven MA, Brachman SM, Metcalfe DD, Gilfillan AM. The phospholipase 
C gamma 1-dependent pathway of Fc epsilon RI-mediated mast cell activation is regulated 
independently of phosphatidylinositol 3-kinase. J Biol Chem. 2003;278(48):48474-84. 
175. Tkaczyk C, Horejsi V, Iwaki S, Draber P, Samelson LE, Satterthwaite AB, et al. NTAL 
phosphorylation is a pivotal link between the signaling cascades leading to human mast cell 
degranulation following Kit activation and Fc epsilon RI aggregation. Blood. 2004;104(1):207-14. 
 193 
176. Ali K, Bilancio A, Thomas M, Pearce W, Gilfillan AM, Tkaczyk C, et al. Essential role for 
the p110delta phosphoinositide 3-kinase in the allergic response. Nature. 2004;431(7011):1007-
11. 
177. Stephens L, Anderson K, Stokoe D, Erdjument-Bromage H, Painter GF, Holmes AB, et al. 
Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent 
activation of protein kinase B. Science. 1998;279(5351):710-4. 
178. Kitaura J, Asai K, Maeda-Yamamoto M, Kawakami Y, Kikkawa U, Kawakami T. Akt-
dependent cytokine production in mast cells. J Exp Med. 2000;192(5):729-40. 
179. Linnekin D. Early signaling pathways activated by c-Kit in hematopoietic cells. Int J 
Biochem Cell Biol. 1999;31(10):1053-74. 
180. Hundley TR, Gilfillan AM, Tkaczyk C, Andrade MV, Metcalfe DD, Beaven MA. Kit and 
FcepsilonRI mediate unique and convergent signals for release of inflammatory mediators from 
human mast cells. Blood. 2004;104(8):2410-7. 
181. Cook DN, Pisetsky DS, Schwartz DA. Toll-like receptors in the pathogenesis of human 
disease. Nat Immunol. 2004;5(10):975-9. 
182. Basu S, Fenton MJ. Toll-like receptors: function and roles in lung disease. Am J Physiol 
Lung Cell Mol Physiol. 2004;286(5):L887-92. 
183. Nigrovic PA, Lee DM. Mast cells in autoantibody responses and arthritis. Novartis Found 
Symp. 2005;271:200-9; discussion 10-4. 
184. Okayama Y, Kirshenbaum AS, Metcalfe DD. Expression of a functional high-affinity IgG 
receptor, Fc gamma RI, on human mast cells: Up-regulation by IFN-gamma. J Immunol. 
2000;164(8):4332-9. 
185. Okayama Y, Hagaman DD, Metcalfe DD. A comparison of mediators released or generated 
by IFN-gamma-treated human mast cells following aggregation of Fc gamma RI or Fc epsilon RI. 
J Immunol. 2001;166(7):4705-12. 
186. Malbec O, Fong DC, Turner M, Tybulewicz VL, Cambier JC, Fridman WH, et al. Fc 
epsilon receptor I-associated lyn-dependent phosphorylation of Fc gamma receptor IIB during 
negative regulation of mast cell activation. J Immunol. 1998;160(4):1647-58. 
187. Shik D, Munitz A. Regulation of allergic inflammatory responses by inhibitory receptors. 
Clin Exp Allergy. 2010;40(5):700-9. 
188. Venkatesha RT, Berla Thangam E, Zaidi AK, Ali H. Distinct regulation of C3a-induced 
MCP-1/CCL2 and RANTES/CCL5 production in human mast cells by extracellular signal 
regulated kinase and PI3 kinase. Mol Immunol. 2005;42(5):581-7. 
 194 
189. Tkaczyk C, Jensen BM, Iwaki S, Gilfillan AM. Adaptive and innate immune reactions 
regulating mast cell activation: from receptor-mediated signaling to responses. Immunol Allergy 
Clin North Am. 2006;26(3):427-50. 
190. McIntire JJ, Umetsu SE, Akbari O, Potter M, Kuchroo VK, Barsh GS, et al. Identification 
of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene family. Nat Immunol. 
2001;2(12):1109-16. 
191. Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T, et al. Th1-specific 
cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. 
Nature. 2002;415(6871):536-41. 
192. Cao E, Zang X, Ramagopal UA, Mukhopadhaya A, Fedorov A, Fedorov E, et al. T cell 
immunoglobulin mucin-3 crystal structure reveals a galectin-9-independent ligand-binding 
surface. Immunity. 2007;26(3):311-21. 
193. Santiago C, Ballesteros A, Tami C, Martinez-Munoz L, Kaplan GG, Casasnovas JM. 
Structures of T Cell immunoglobulin mucin receptors 1 and 2 reveal mechanisms for regulation 
of immune responses by the TIM receptor family. Immunity. 2007;26(3):299-310. 
194. DeKruyff RH, Bu X, Ballesteros A, Santiago C, Chim YL, Lee HH, et al. T 
cell/transmembrane, Ig, and mucin-3 allelic variants differentially recognize phosphatidylserine 
and mediate phagocytosis of apoptotic cells. J Immunol. 2010;184(4):1918-30. 
195. Meyers JH, Chakravarti S, Schlesinger D, Illes Z, Waldner H, Umetsu SE, et al. TIM-4 is 
the ligand for TIM-1, and the TIM-1-TIM-4 interaction regulates T cell proliferation. Nat 
Immunol. 2005;6(5):455-64. 
196. Zhang Q, Wang H, Wu X, Liu B, Liu W, Wang R, et al. TIM-4 promotes the growth of 
non-small-cell lung cancer in a RGD motif-dependent manner. Br J Cancer. 2015;113(10):1484-
92. 
197. Bailly V, Zhang Z, Meier W, Cate R, Sanicola M, Bonventre JV. Shedding of kidney injury 
molecule-1, a putative adhesion protein involved in renal regeneration. J Biol Chem. 
2002;277(42):39739-48. 
198. Kumanogoh A, Marukawa S, Suzuki K, Takegahara N, Watanabe C, Ch'ng E, et al. Class 
IV semaphorin Sema4A enhances T-cell activation and interacts with Tim-2. Nature. 
2002;419(6907):629-33. 
199. Park D, Hochreiter-Hufford A, Ravichandran KS. The phosphatidylserine receptor TIM-4 
does not mediate direct signaling. Curr Biol. 2009;19(4):346-51. 
200. Ichimura T, Bonventre JV, Bailly V, Wei H, Hession CA, Cate RL, et al. Kidney injury 
molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel 
immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem. 
1998;273(7):4135-42. 
 195 
201. Umetsu DT, McIntire JJ, DeKruyff RH. TIM-1, hepatitis A virus and the hygiene theory 
of atopy: association of TIM-1 with atopy. J Pediatr Gastroenterol Nutr. 2005;40 Suppl 1:S43. 
202. Angiari S, Donnarumma T, Rossi B, Dusi S, Pietronigro E, Zenaro E, et al. TIM-1 
glycoprotein binds the adhesion receptor P-selectin and mediates T cell trafficking during 
inflammation and autoimmunity. Immunity. 2014;40(4):542-53. 
203. Xiao L, Fu ZR, Liu F, Zhang LD, Shi XM, Shen XY, et al. Suppression of allograft 
rejection by Tim-1-Fc through cross-linking with a novel Tim-1 binding partner on T cells. PLoS 
One. 2011;6(7):e21697. 
204. Ma J, Usui Y, Takeda K, Harada N, Yagita H, Okumura K, et al. TIM-1 signaling in B 
cells regulates antibody production. Biochem Biophys Res Commun. 2011;406(2):223-8. 
205. Xiao S, Brooks CR, Zhu C, Wu C, Sweere JM, Petecka S, et al. Defect in regulatory B-cell 
function and development of systemic autoimmunity in T-cell Ig mucin 1 (Tim-1) mucin domain-
mutant mice. Proc Natl Acad Sci U S A. 2012;109(30):12105-10. 
206. Kim HS, Kim HS, Lee CW, Chung DH. T cell Ig domain and mucin domain 1 engagement 
on invariant NKT cells in the presence of TCR stimulation enhances IL-4 production but inhibits 
IFN-gamma production. J Immunol. 2010;184(8):4095-106. 
207. Kaplan G, Totsuka A, Thompson P, Akatsuka T, Moritsugu Y, Feinstone SM. 
Identification of a surface glycoprotein on African green monkey kidney cells as a receptor for 
hepatitis A virus. Embo j. 1996;15(16):4282-96. 
208. Feigelstock D, Thompson P, Mattoo P, Zhang Y, Kaplan GG. The human homolog of 
HAVcr-1 codes for a hepatitis A virus cellular receptor. J Virol. 1998;72(8):6621-8. 
209. Silberstein E, Xing L, van de Beek W, Lu J, Cheng H, Kaplan GG. Alteration of hepatitis 
A virus (HAV) particles by a soluble form of HAV cellular receptor 1 containing the 
immunoglobin-and mucin-like regions. J Virol. 2003;77(16):8765-74. 
210. Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N 
Engl J Med. 2002;347(12):911-20. 
211. McIntire JJ, Umetsu SE, Macaubas C, Hoyte EG, Cinnioglu C, Cavalli-Sforza LL, et al. 
Immunology: hepatitis A virus link to atopic disease. Nature. 2003;425(6958):576. 
212. Lee J, Phong B, Egloff AM, Kane LP. TIM polymorphisms--genetics and function. Genes 
Immun. 2011;12(8):595-604. 
213. Fadok VA, Bratton DL, Frasch SC, Warner ML, Henson PM. The role of 
phosphatidylserine in recognition of apoptotic cells by phagocytes. Cell death and differentiation. 
1998;5(7):551-62. 
 196 
214. Kobayashi N, Karisola P, Pena-Cruz V, Dorfman DM, Jinushi M, Umetsu SE, et al. TIM-
1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells. 
Immunity. 2007;27(6):927-40. 
215. Kim HY, Chang YJ, Chuang YT, Lee HH, Kasahara DI, Martin T, et al. T-cell 
immunoglobulin and mucin domain 1 deficiency eliminates airway hyperreactivity triggered by 
the recognition of airway cell death. J Allergy Clin Immunol. 2013;132(2):414-25.e6. 
216. Yeung MY, Ding Q, Brooks CR, Xiao S, Workman CJ, Vignali DA, et al. TIM-1 signaling 
is required for maintenance and induction of regulatory B cells. Am J Transplant. 2015;15(4):942-
53. 
217. Li M, Ablan SD, Miao C, Zheng YM, Fuller MS, Rennert PD, et al. TIM-family proteins 
inhibit HIV-1 release. Proc Natl Acad Sci U S A. 2014;111(35):E3699-707. 
218. Tami C, Silberstein E, Manangeeswaran M, Freeman GJ, Umetsu SE, DeKruyff RH, et al. 
Immunoglobulin A (IgA) is a natural ligand of hepatitis A virus cellular receptor 1 (HAVCR1), 
and the association of IgA with HAVCR1 enhances virus-receptor interactions. J Virol. 
2007;81(7):3437-46. 
219. Wilker PR, Sedy JR, Grigura V, Murphy TL, Murphy KM. Evidence for carbohydrate 
recognition and homotypic and heterotypic binding by the TIM family. Int Immunol. 
2007;19(6):763-73. 
220. Sizing ID, Bailly V, McCoon P, Chang W, Rao S, Pablo L, et al. Epitope-dependent effect 
of anti-murine TIM-1 monoclonal antibodies on T cell activity and lung immune responses. J 
Immunol. 2007;178(4):2249-61. 
221. Xiao S, Najafian N, Reddy J, Albin M, Zhu C, Jensen E, et al. Differential engagement of 
Tim-1 during activation can positively or negatively costimulate T cell expansion and effector 
function. J Exp Med. 2007;204(7):1691-702. 
222. de Souza AJ, Oriss TB, O'Malley K J, Ray A, Kane LP. T cell Ig and mucin 1 (TIM-1) is 
expressed on in vivo-activated T cells and provides a costimulatory signal for T cell activation. 
Proc Natl Acad Sci U S A. 2005;102(47):17113-8. 
223. Encinas JA, Janssen EM, Weiner DB, Calarota SA, Nieto D, Moll T, et al. Anti-T-cell Ig 
and mucin domain-containing protein 1 antibody decreases TH2 airway inflammation in a mouse 
model of asthma. J Allergy Clin Immunol. 2005;116(6):1343-9. 
224. Rodriguez-Manzanet R, Meyers JH, Balasubramanian S, Slavik J, Kassam N, Dardalhon 
V, et al. TIM-4 expressed on APCs induces T cell expansion and survival. J Immunol. 
2008;180(7):4706-13. 
225. Degauque N, Mariat C, Kenny J, Zhang D, Gao W, Vu MD, et al. Immunostimulatory Tim-
1-specific antibody deprograms Tregs and prevents transplant tolerance in mice. J Clin Invest. 
2008;118(2):735-41. 
 197 
226. Ueno T, Habicht A, Clarkson MR, Albin MJ, Yamaura K, Boenisch O, et al. The emerging 
role of T cell Ig mucin 1 in alloimmune responses in an experimental mouse transplant model. J 
Clin Invest. 2008;118(2):742-51. 
227. Anderson AC, Anderson DE, Bregoli L, Hastings WD, Kassam N, Lei C, et al. Promotion 
of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science. 
2007;318(5853):1141-3. 
228. Yanaba K, Bouaziz JD, Matsushita T, Magro CM, St Clair EW, Tedder TF. B-lymphocyte 
contributions to human autoimmune disease. Immunol Rev. 2008;223:284-99. 
229. Mauri C, Ehrenstein MR. The 'short' history of regulatory B cells. Trends Immunol. 
2008;29(1):34-40. 
230. Mizoguchi A, Bhan AK. A case for regulatory B cells. J Immunol. 2006;176(2):705-10. 
231. Ding Q, Yeung M, Camirand G, Zeng Q, Akiba H, Yagita H, et al. Regulatory B cells are 
identified by expression of TIM-1 and can be induced through TIM-1 ligation to promote tolerance 
in mice. J Clin Invest. 2011;121(9):3645-56. 
232. Lee KM, Kim JI, Stott R, Soohoo J, O'Connor MR, Yeh H, et al. Anti-CD45RB/anti-TIM-
1-induced tolerance requires regulatory B cells. Am J Transplant. 2012;12(8):2072-8. 
233. Bendelac A, Lantz O, Quimby ME, Yewdell JW, Bennink JR, Brutkiewicz RR. CD1 
recognition by mouse NK1+ T lymphocytes. Science. 1995;268(5212):863-5. 
234. Akbari O, Stock P, Meyer E, Kronenberg M, Sidobre S, Nakayama T, et al. Essential role 
of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway 
hyperreactivity. Nat Med. 2003;9(5):582-8. 
235. Chen H, Paul WE. Cultured NK1.1+ CD4+ T cells produce large amounts of IL-4 and IFN-
gamma upon activation by anti-CD3 or CD1. J Immunol. 1997;159(5):2240-9. 
236. Geissmann F, Cameron TO, Sidobre S, Manlongat N, Kronenberg M, Briskin MJ, et al. 
Intravascular immune surveillance by CXCR6+ NKT cells patrolling liver sinusoids. PLoS Biol. 
2005;3(4):e113. 
237. Kim HY, Eyheramonho MB, Pichavant M, Gonzalez Cambaceres C, Matangkasombut P, 
Cervio G, et al. A polymorphism in TIM1 is associated with susceptibility to severe hepatitis A 
virus infection in humans. J Clin Invest. 2011;121(3):1111-8. 
238. Barlow JL, Wong SH, Ballantyne SJ, Jolin HE, McKenzie AN. Tim1 and Tim3 are not 
essential for experimental allergic asthma. Clin Exp Allergy. 2011;41(7):1012-21. 
239. Curtiss ML, Gorman JV, Businga TR, Traver G, Singh M, Meyerholz DK, et al. Tim-1 
regulates Th2 responses in an airway hypersensitivity model. Eur J Immunol. 2012;42(3):651-61. 
 198 
240. Nakae S, Iikura M, Suto H, Akiba H, Umetsu DT, Dekruyff RH, et al. TIM-1 and TIM-3 
enhancement of Th2 cytokine production by mast cells. Blood. 2007;110(7):2565-8. 
241. Xiao S, Zhu B, Jin H, Zhu C, Umetsu DT, DeKruyff RH, et al. Tim-1 stimulation of 
dendritic cells regulates the balance between effector and regulatory T cells. Eur J Immunol. 
2011;41(6):1539-49. 
242. de Souza AJ, Oak JS, Jordanhazy R, DeKruyff RH, Fruman DA, Kane LP. T cell Ig and 
mucin domain-1-mediated T cell activation requires recruitment and activation of 
phosphoinositide 3-kinase. J Immunol. 2008;180(10):6518-26. 
243. Binne LL, Scott ML, Rennert PD. Human TIM-1 associates with the TCR complex and 
up-regulates T cell activation signals. J Immunol. 2007;178(7):4342-50. 
244. Frisancho-Kiss S, Nyland JF, Davis SE, Barrett MA, Gatewood SJ, Njoku DB, et al. 
Cutting edge: T cell Ig mucin-3 reduces inflammatory heart disease by increasing CTLA-4 during 
innate immunity. J Immunol. 2006;176(11):6411-5. 
245. Khademi M, Illes Z, Gielen AW, Marta M, Takazawa N, Baecher-Allan C, et al. T Cell Ig- 
and mucin-domain-containing molecule-3 (TIM-3) and TIM-1 molecules are differentially 
expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived mononuclear cells in 
multiple sclerosis. J Immunol. 2004;172(11):7169-76. 
246. Oikawa T, Kamimura Y, Akiba H, Yagita H, Okumura K, Takahashi H, et al. Preferential 
involvement of Tim-3 in the regulation of hepatic CD8+ T cells in murine acute graft-versus-host 
disease. J Immunol. 2006;177(7):4281-7. 
247. Geng H, Zhang GM, Li D, Zhang H, Yuan Y, Zhu HG, et al. Soluble form of T cell Ig 
mucin 3 is an inhibitory molecule in T cell-mediated immune response. J Immunol. 
2006;176(3):1411-20. 
248. Schweigert O, Dewitz C, Moller-Hackbarth K, Trad A, Garbers C, Rose-John S, et al. 
Soluble T cell immunoglobulin and mucin domain (TIM)-1 and -4 generated by A Disintegrin And 
Metalloprotease (ADAM)-10 and -17 bind to phosphatidylserine. Biochim Biophys Acta. 
2014;1843(2):275-87. 
249. Anderson AC, Lord GM, Dardalhon V, Lee DH, Sabatos-Peyton CA, Glimcher LH, et al. 
T-bet, a Th1 transcription factor regulates the expression of Tim-3. Eur J Immunol. 
2010;40(3):859-66. 
250. Yoon SJ, Lee MJ, Shin DC, Kim JS, Chwae YJ, Kwon MH, et al. Activation of mitogen 
activated protein kinase-Erk kinase (MEK) increases T cell immunoglobulin mucin domain-3 
(TIM-3) transcription in human T lymphocytes and a human mast cell line. Mol Immunol. 
2011;48(15-16):1778-83. 
251. Zhu C, Sakuishi K, Xiao S, Sun Z, Zaghouani S, Gu G, et al. An IL-27/NFIL3 signalling 
axis drives Tim-3 and IL-10 expression and T-cell dysfunction. Nature communications. 
2015;6:6072. 
 199 
252. Rabinovich GA, Ramhorst RE, Rubinstein N, Corigliano A, Daroqui MC, Kier-Joffe EB, 
et al. Induction of allogenic T-cell hyporesponsiveness by galectin-1-mediated apoptotic and non-
apoptotic mechanisms. Cell death and differentiation. 2002;9(6):661-70. 
253. Nagae M, Nishi N, Murata T, Usui T, Nakamura T, Wakatsuki S, et al. Structural analysis 
of the recognition mechanism of poly-N-acetyllactosamine by the human galectin-9 N-terminal 
carbohydrate recognition domain. Glycobiology. 2009;19(2):112-7. 
254. Asakura H, Kashio Y, Nakamura K, Seki M, Dai S, Shirato Y, et al. Selective eosinophil 
adhesion to fibroblast via IFN-gamma-induced galectin-9. J Immunol. 2002;169(10):5912-8. 
255. Imaizumi T, Kumagai M, Sasaki N, Kurotaki H, Mori F, Seki M, et al. Interferon-gamma 
stimulates the expression of galectin-9 in cultured human endothelial cells. J Leukoc Biol. 
2002;72(3):486-91. 
256. Yoshida H, Imaizumi T, Kumagai M, Kimura K, Satoh C, Hanada N, et al. Interleukin-
1beta stimulates galectin-9 expression in human astrocytes. Neuroreport. 2001;12(17):3755-8. 
257. Sabatos CA, Chakravarti S, Cha E, Schubart A, Sanchez-Fueyo A, Zheng XX, et al. 
Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of 
peripheral tolerance. Nat Immunol. 2003;4(11):1102-10. 
258. Sanchez-Fueyo A, Tian J, Picarella D, Domenig C, Zheng XX, Sabatos CA, et al. Tim-3 
inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological 
tolerance. Nat Immunol. 2003;4(11):1093-101. 
259. Wada J, Kanwar YS. Identification and characterization of galectin-9, a novel beta-
galactoside-binding mammalian lectin. J Biol Chem. 1997;272(9):6078-86. 
260. Kashio Y, Nakamura K, Abedin MJ, Seki M, Nishi N, Yoshida N, et al. Galectin-9 induces 
apoptosis through the calcium-calpain-caspase-1 pathway. J Immunol. 2003;170(7):3631-6. 
261. Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, et al. The Tim-3 ligand 
galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 2005;6(12):1245-52. 
262. Su EW, Bi S, Kane LP. Galectin-9 regulates T helper cell function independently of Tim-
3. Glycobiology. 2011;21(10):1258-65. 
263. Katoh S, Ishii N, Nobumoto A, Takeshita K, Dai SY, Shinonaga R, et al. Galectin-9 inhibits 
CD44-hyaluronan interaction and suppresses a murine model of allergic asthma. Am J Respir Crit 
Care Med. 2007;176(1):27-35. 
264. Niki T, Tsutsui S, Hirose S, Aradono S, Sugimoto Y, Takeshita K, et al. Galectin-9 is a 
high affinity IgE-binding lectin with anti-allergic effect by blocking IgE-antigen complex 
formation. J Biol Chem. 2009;284(47):32344-52. 
265. Nakayama M, Akiba H, Takeda K, Kojima Y, Hashiguchi M, Azuma M, et al. Tim-3 
mediates phagocytosis of apoptotic cells and cross-presentation. Blood. 2009;113(16):3821-30. 
 200 
266. Miyanishi M, Tada K, Koike M, Uchiyama Y, Kitamura T, Nagata S. Identification of 
Tim4 as a phosphatidylserine receptor. Nature. 2007;450(7168):435-9. 
267. Tian J, Avalos AM, Mao SY, Chen B, Senthil K, Wu H, et al. Toll-like receptor 9-
dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. 
Nat Immunol. 2007;8(5):487-96. 
268. Yanai H, Ban T, Wang Z, Choi MK, Kawamura T, Negishi H, et al. HMGB proteins 
function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature. 
2009;462(7269):99-103. 
269. Yuan F, Gu L, Guo S, Wang C, Li GM. Evidence for involvement of HMGB1 protein in 
human DNA mismatch repair. J Biol Chem. 2004;279(20):20935-40. 
270. Chiba S, Baghdadi M, Akiba H, Yoshiyama H, Kinoshita I, Dosaka-Akita H, et al. Tumor-
infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions 
between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol. 2012;13(9):832-42. 
271. Huang YH, Zhu C, Kondo Y, Anderson AC, Gandhi A, Russell A, et al. CEACAM1 
regulates TIM-3-mediated tolerance and exhaustion. Nature. 2015;517(7534):386-90. 
272. Gray-Owen SD, Blumberg RS. CEACAM1: contact-dependent control of immunity. Nat 
Rev Immunol. 2006;6(6):433-46. 
273. Nakajima A, Iijima H, Neurath MF, Nagaishi T, Nieuwenhuis EE, Raychowdhury R, et al. 
Activation-induced expression of carcinoembryonic antigen-cell adhesion molecule 1 regulates 
mouse T lymphocyte function. J Immunol. 2002;168(3):1028-35. 
274. Morales VM, Christ A, Watt SM, Kim HS, Johnson KW, Utku N, et al. Regulation of 
human intestinal intraepithelial lymphocyte cytolytic function by biliary glycoprotein (CD66a). J 
Immunol. 1999;163(3):1363-70. 
275. Chen CJ, Shively JE. The cell-cell adhesion molecule carcinoembryonic antigen-related 
cellular adhesion molecule 1 inhibits IL-2 production and proliferation in human T cells by 
association with Src homology protein-1 and down-regulates IL-2 receptor. J Immunol. 
2004;172(6):3544-52. 
276. Tan K, Zelus BD, Meijers R, Liu JH, Bergelson JM, Duke N, et al. Crystal structure of 
murine sCEACAM1a[1,4]: a coronavirus receptor in the CEA family. Embo j. 2002;21(9):2076-
86. 
277. Watt SM, Teixeira AM, Zhou GQ, Doyonnas R, Zhang Y, Grunert F, et al. Homophilic 
adhesion of human CEACAM1 involves N-terminal domain interactions: structural analysis of the 
binding site. Blood. 2001;98(5):1469-79. 
278. Koguchi K, Anderson DE, Yang L, O'Connor KC, Kuchroo VK, Hafler DA. Dysregulated 
T cell expression of TIM3 in multiple sclerosis. J Exp Med. 2006;203(6):1413-8. 
 201 
279. Yang L, Anderson DE, Kuchroo J, Hafler DA. Lack of TIM-3 immunoregulation in 
multiple sclerosis. J Immunol. 2008;180(7):4409-14. 
280. Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S, Kalia V, et al. Molecular signature 
of CD8+ T cell exhaustion during chronic viral infection. Immunity. 2007;27(4):670-84. 
281. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, et al. PD-1 
expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. 
Nature. 2006;443(7109):350-4. 
282. Petrovas C, Price DA, Mattapallil J, Ambrozak DR, Geldmacher C, Cecchinato V, et al. 
SIV-specific CD8+ T cells express high levels of PD1 and cytokines but have impaired 
proliferative capacity in acute and chronic SIVmac251 infection. Blood. 2007;110(3):928-36. 
283. Jones RB, Ndhlovu LC, Barbour JD, Sheth PM, Jha AR, Long BR, et al. Tim-3 expression 
defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive 
HIV-1 infection. J Exp Med. 2008;205(12):2763-79. 
284. Golden-Mason L, Palmer BE, Kassam N, Townshend-Bulson L, Livingston S, McMahon 
BJ, et al. Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus 
infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells. J Virol. 
2009;83(18):9122-30. 
285. Jin HT, Anderson AC, Tan WG, West EE, Ha SJ, Araki K, et al. Cooperation of Tim-3 and 
PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc Natl Acad Sci U S A. 
2010;107(33):14733-8. 
286. Sakhdari A, Mujib S, Vali B, Yue FY, MacParland S, Clayton K, et al. Tim-3 negatively 
regulates cytotoxicity in exhausted CD8+ T cells in HIV infection. PLoS One. 2012;7(7):e40146. 
287. Moller-Hackbarth K, Dewitz C, Schweigert O, Trad A, Garbers C, Rose-John S, et al. A 
disintegrin and metalloprotease (ADAM) 10 and ADAM17 are major sheddases of T cell 
immunoglobulin and mucin domain 3 (Tim-3). J Biol Chem. 2013;288(48):34529-44. 
288. Clayton KL, Douglas-Vail MB, Nur-ur Rahman AK, Medcalf KE, Xie IY, Chew GM, et 
al. Soluble T cell immunoglobulin mucin domain 3 is shed from CD8+ T cells by the sheddase 
ADAM10, is increased in plasma during untreated HIV infection, and correlates with HIV disease 
progression. J Virol. 2015;89(7):3723-36. 
289. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting 
Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp 
Med. 2010;207(10):2187-94. 
290. Zhou Q, Munger ME, Veenstra RG, Weigel BJ, Hirashima M, Munn DH, et al. 
Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with 
disseminated acute myelogenous leukemia. Blood. 2011;117(17):4501-10. 
 202 
291. Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, et al. Upregulation 
of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction 
in melanoma patients. J Exp Med. 2010;207(10):2175-86. 
292. Yang ZZ, Grote DM, Ziesmer SC, Niki T, Hirashima M, Novak AJ, et al. IL-12 upregulates 
TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin 
lymphoma. J Clin Invest. 2012;122(4):1271-82. 
293. Gao X, Zhu Y, Li G, Huang H, Zhang G, Wang F, et al. TIM-3 expression characterizes 
regulatory T cells in tumor tissues and is associated with lung cancer progression. PLoS One. 
2012;7(2):e30676. 
294. Jayaraman P, Sada-Ovalle I, Beladi S, Anderson AC, Dardalhon V, Hotta C, et al. Tim3 
binding to galectin-9 stimulates antimicrobial immunity. J Exp Med. 2010;207(11):2343-54. 
295. Qiu Y, Chen J, Liao H, Zhang Y, Wang H, Li S, et al. Tim-3-expressing CD4+ and CD8+ 
T cells in human tuberculosis (TB) exhibit polarized effector memory phenotypes and stronger 
anti-TB effector functions. PLoS Pathog. 2012;8(11):e1002984. 
296. Gorman JV, Starbeck-Miller G, Pham NL, Traver GL, Rothman PB, Harty JT, et al. Tim-
3 directly enhances CD8 T cell responses to acute Listeria monocytogenes infection. J Immunol. 
2014;192(7):3133-42. 
297. Yang X, Jiang X, Chen G, Xiao Y, Geng S, Kang C, et al. T cell Ig mucin-3 promotes 
homeostasis of sepsis by negatively regulating the TLR response. J Immunol. 2013;190(5):2068-
79. 
298. Zhang Y, Ma CJ, Wang JM, Ji XJ, Wu XY, Jia ZS, et al. Tim-3 negatively regulates IL-12 
expression by monocytes in HCV infection. PLoS One. 2011;6(5):e19664. 
299. Zhang Y, Ma CJ, Wang JM, Ji XJ, Wu XY, Moorman JP, et al. Tim-3 regulates pro- and 
anti-inflammatory cytokine expression in human CD14+ monocytes. J Leukoc Biol. 
2012;91(2):189-96. 
300. Gleason MK, Lenvik TR, McCullar V, Felices M, O'Brien MS, Cooley SA, et al. Tim-3 is 
an inducible human natural killer cell receptor that enhances interferon gamma production in 
response to galectin-9. Blood. 2012;119(13):3064-72. 
301. Ndhlovu LC, Lopez-Verges S, Barbour JD, Jones RB, Jha AR, Long BR, et al. Tim-3 
marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood. 
2012;119(16):3734-43. 
302. da Silva IP, Gallois A, Jimenez-Baranda S, Khan S, Anderson AC, Kuchroo VK, et al. 
Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade. Cancer Immunol Res. 
2014;2(5):410-22. 
303. Hou H, Liu W, Wu S, Lu Y, Peng J, Zhu Y, et al. Tim-3 negatively mediates natural killer 
cell function in LPS-induced endotoxic shock. PLoS One. 2014;9(10):e110585. 
 203 
304. Wang F, Hou H, Wu S, Tang Q, Huang M, Yin B, et al. Tim-3 pathway affects NK cell 
impairment in patients with active tuberculosis. Cytokine. 2015;76(2):270-9. 
305. Wiener Z, Kohalmi B, Pocza P, Jeager J, Tolgyesi G, Toth S, et al. TIM-3 is expressed in 
melanoma cells and is upregulated in TGF-beta stimulated mast cells. J Invest Dermatol. 
2007;127(4):906-14. 
306. Clayton KL, Haaland MS, Douglas-Vail MB, Mujib S, Chew GM, Ndhlovu LC, et al. T 
cell Ig and mucin domain-containing protein 3 is recruited to the immune synapse, disrupts stable 
synapse formation, and associates with receptor phosphatases. J Immunol. 2014;192(2):782-91. 
307. van de Weyer PS, Muehlfeit M, Klose C, Bonventre JV, Walz G, Kuehn EW. A highly 
conserved tyrosine of Tim-3 is phosphorylated upon stimulation by its ligand galectin-9. Biochem 
Biophys Res Commun. 2006;351(2):571-6. 
308. Lee J, Su EW, Zhu C, Hainline S, Phuah J, Moroco JA, et al. Phosphotyrosine-dependent 
coupling of Tim-3 to T-cell receptor signaling pathways. Mol Cell Biol. 2011;31(19):3963-74. 
309. Rangachari M, Zhu C, Sakuishi K, Xiao S, Karman J, Chen A, et al. Bat3 promotes T cell 
responses and autoimmunity by repressing Tim-3-mediated cell death and exhaustion. Nat Med. 
2012;18(9):1394-400. 
310. Shakhov AN, Rybtsov S, Tumanov AV, Shulenin S, Dean M, Kuprash DV, et al. 
SMUCKLER/TIM4 is a distinct member of TIM family expressed by stromal cells of secondary 
lymphoid tissues and associated with lymphotoxin signaling. Eur J Immunol. 2004;34(2):494-503. 
311. Yang PC, Xing Z, Berin CM, Soderholm JD, Feng BS, Wu L, et al. TIM-4 expressed by 
mucosal dendritic cells plays a critical role in food antigen-specific Th2 differentiation and 
intestinal allergy. Gastroenterology. 2007;133(5):1522-33. 
312. Chen TT, Li L, Chung DH, Allen CD, Torti SV, Torti FM, et al. TIM-2 is expressed on B 
cells and in liver and kidney and is a receptor for H-ferritin endocytosis. J Exp Med. 
2005;202(7):955-65. 
313. Chakravarti S, Sabatos CA, Xiao S, Illes Z, Cha EK, Sobel RA, et al. Tim-2 regulates T 
helper type 2 responses and autoimmunity. J Exp Med. 2005;202(3):437-44. 
314. Han J, Seaman WE, Di X, Wang W, Willingham M, Torti FM, et al. Iron uptake mediated 
by binding of H-ferritin to the TIM-2 receptor in mouse cells. PLoS One. 2011;6(8):e23800. 
315. Rennert PD, Ichimura T, Sizing ID, Bailly V, Li Z, Rennard R, et al. T cell, Ig domain, 
mucin domain-2 gene-deficient mice reveal a novel mechanism for the regulation of Th2 immune 
responses and airway inflammation. J Immunol. 2006;177(7):4311-21. 
316. Knickelbein JE, de Souza AJ, Tosti R, Narayan P, Kane LP. Cutting edge: inhibition of T 
cell activation by TIM-2. J Immunol. 2006;177(8):4966-70. 
 204 
317. Kalesnikoff J, Galli SJ. New developments in mast cell biology. Nat Immunol. 
2008;9(11):1215-23. 
318. Abraham SN, St John AL. Mast cell-orchestrated immunity to pathogens. Nat Rev 
Immunol. 2010;10(6):440-52. 
319. Lin J, Chen L, Kane LP. Murine Tim-1 is excluded from the immunological synapse. 
F1000Res. 2012;1:10. 
320. Gallois A, Silva I, Osman I, Bhardwaj N. Reversal of natural killer cell exhaustion by TIM-
3 blockade. Oncoimmunology. 2014;3(12):e946365. 
321. Demo SD, Masuda E, Rossi AB, Throndset BT, Gerard AL, Chan EH, et al. Quantitative 
measurement of mast cell degranulation using a novel flow cytometric annexin-V binding assay. 
Cytometry. 1999;36(4):340-8. 
322. Sumpter TL, Ho CH, Pleet AR, Tkacheva OA, Shufesky WJ, Rojas-Canales DM, et al. 
Autocrine hemokinin-1 functions as an endogenous adjuvant for IgE-mediated mast cell 
inflammatory responses. J Allergy Clin Immunol. 2015;135(4):1019-30 e8. 
323. Malbec O, Daeron M. The mast cell IgG receptors and their roles in tissue inflammation. 
Immunol Rev. 2007;217:206-21. 
324. Wiener Z GA, Molnar V, Buzas E, Falus A. The effect of TIM-3 stimulation on the gene 
expression profile of IgE/antigen-activated mouse mast cells. . BioProject [Internet]. Bethesda, 
MD: National Library of Medicine (US), National Center for Biotechnology Information2009. 
325. Mombaerts P. Seven-transmembrane proteins as odorant and chemosensory receptors. 
Science. 1999;286(5440):707-11. 
326. Zaiss DM, van Loosdregt J, Gorlani A, Bekker CP, Grone A, Sibilia M, et al. Amphiregulin 
enhances regulatory T cell-suppressive function via the epidermal growth factor receptor. 
Immunity. 2013;38(2):275-84. 
327. Anderson AC. Tim-3: an emerging target in the cancer immunotherapy landscape. Cancer 
Immunol Res. 2014;2(5):393-8. 
328. Perez-Gracia JL, Labiano S, Rodriguez-Ruiz ME, Sanmamed MF, Melero I. Orchestrating 
immune check-point blockade for cancer immunotherapy in combinations. Curr Opin Immunol. 
2014;27:89-97. 
329. Dardalhon V, Anderson AC, Karman J, Apetoh L, Chandwaskar R, Lee DH, et al. Tim-
3/galectin-9 pathway: regulation of Th1 immunity through promotion of CD11b+Ly-6G+ myeloid 
cells. J Immunol. 2010;185(3):1383-92. 
330. Huang S, Lu F, Li J, Lan T, Huang B, Yin X, et al. Quantification of tryptase-TIM-3 
double-positive mast cells in human chronic periodontitis. Arch Oral Biol. 2014;59(6):654-61. 
 205 
331. Veenstra RG, Taylor PA, Zhou Q, Panoskaltsis-Mortari A, Hirashima M, Flynn R, et al. 
Contrasting acute graft-versus-host disease effects of Tim-3/galectin-9 pathway blockade 
dependent upon the presence of donor regulatory T cells. Blood. 2012;120(3):682-90. 
332. Freeman GJ, Casasnovas JM, Umetsu DT, DeKruyff RH. TIM genes: a family of cell 
surface phosphatidylserine receptors that regulate innate and adaptive immunity. Immunol Rev. 
2010;235(1):172-89. 
333. Hochreiter-Hufford A, Ravichandran KS. Clearing the dead: apoptotic cell sensing, 
recognition, engulfment, and digestion. Cold Spring Harb Perspect Biol. 2013;5(1):a008748. 
334. Ravichandran KS. Beginnings of a good apoptotic meal: the find-me and eat-me signaling 
pathways. Immunity. 2011;35(4):445-55. 
335. Nobumoto A, Nagahara K, Oomizu S, Katoh S, Nishi N, Takeshita K, et al. Galectin-9 
suppresses tumor metastasis by blocking adhesion to endothelium and extracellular matrices. 
Glycobiology. 2008;18(9):735-44. 
336. Tanikawa R, Tanikawa T, Hirashima M, Yamauchi A, Tanaka Y. Galectin-9 induces 
osteoblast differentiation through the CD44/Smad signaling pathway. Biochem Biophys Res 
Commun. 2010;394(2):317-22. 
337. Wu C, Thalhamer T, Franca RF, Xiao S, Wang C, Hotta C, et al. Galectin-9-CD44 
interaction enhances stability and function of adaptive regulatory T cells. Immunity. 
2014;41(2):270-82. 
338. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in inflammation 
and cancer. Annu Rev Immunol. 2010;28:367-88. 
339. Monu N, Frey AB. Suppression of proximal T cell receptor signaling and lytic function in 
CD8+ tumor-infiltrating T cells. Cancer Res. 2007;67(23):11447-54. 
340. Poderycki M, Tomimori Y, Ando T, Xiao W, Maeda-Yamamoto M, Sauer K, et al. A minor 
catalytic activity of Src family kinases is sufficient for maximal activation of mast cells via the 
high-affinity IgE receptor. J Immunol. 2010;184(1):84-93. 
341. Mahajan A, Barua D, Cutler P, Lidke DS, Espinoza FA, Pehlke C, et al. Optimal 
aggregation of FcepsilonRI with a structurally defined trivalent ligand overrides negative 
regulation driven by phosphatases. ACS chemical biology. 2014;9(7):1508-19. 
342. Han G, Chen G, Shen B, Li Y. Tim-3: an activation marker and activation limiter of innate 
immune cells. Front Immunol. 2013;4:449. 
343. Kearley J, McMillan SJ, Lloyd CM. Th2-driven, allergen-induced airway inflammation is 
reduced after treatment with anti-Tim-3 antibody in vivo. J Exp Med. 2007;204(6):1289-94. 
 206 
344. Maurya N, Gujar R, Gupta M, Yadav V, Verma S, Sen P. Immunoregulation of dendritic 
cells by the receptor T cell Ig and mucin protein-3 via Bruton's tyrosine kinase and c-Src. J 
Immunol. 2014;193(7):3417-25. 
345. Akira S. NF-IL6 and gene regulation. Res Immunol. 1992;143(7):734-6. 
346. Akira S, Isshiki H, Sugita T, Tanabe O, Kinoshita S, Nishio Y, et al. A nuclear factor for 
IL-6 expression (NF-IL6) is a member of a C/EBP family. EMBO J. 1990;9(6):1897-906. 
347. Betts JC, Cheshire JK, Akira S, Kishimoto T, Woo P. The role of NF-kappa B and NF-IL6 
transactivating factors in the synergistic activation of human serum amyloid A gene expression by 
interleukin-1 and interleukin-6. J Biol Chem. 1993;268(34):25624-31. 
348. Isshiki H, Akira S, Tanabe O, Nakajima T, Shimamoto T, Hirano T, et al. Constitutive and 
interleukin-1 (IL-1)-inducible factors interact with the IL-1-responsive element in the IL-6 gene. 
Mol Cell Biol. 1990;10(6):2757-64. 
349. Libermann TA, Baltimore D. Activation of interleukin-6 gene expression through the NF-
kappa B transcription factor. Mol Cell Biol. 1990;10(5):2327-34. 
350. Gilfillan AM, Rivera J. The tyrosine kinase network regulating mast cell activation. 
Immunol Rev. 2009;228(1):149-69. 
351. Rivera J, Gilfillan AM. Molecular regulation of mast cell activation. J Allergy Clin 
Immunol. 2006;117(6):1214-25; quiz 26. 
352. El-Hillal O, Kurosaki T, Yamamura H, Kinet JP, Scharenberg AM. syk kinase activation 
by a src kinase-initiated activation loop phosphorylation chain reaction. Proc Natl Acad Sci U S 
A. 1997;94(5):1919-24. 
353. Zikherman J, Parameswaran R, Weiss A. Endogenous antigen tunes the responsiveness of 
naive B cells but not T cells. Nature. 2012;489(7414):160-4. 
354. Kurakula K, Koenis DS, van Tiel CM, de Vries CJ. NR4A nuclear receptors are orphans 
but not lonesome. Biochim Biophys Acta. 2014;1843(11):2543-55. 
355. Mohan HM, Aherne CM, Rogers AC, Baird AW, Winter DC, Murphy EP. Molecular 
pathways: the role of NR4A orphan nuclear receptors in cancer. Clin Cancer Res. 
2012;18(12):3223-8. 
356. Zhao Y, Bruemmer D. NR4A orphan nuclear receptors: transcriptional regulators of gene 
expression in metabolism and vascular biology. Arterioscler Thromb Vasc Biol. 2010;30(8):1535-
41. 
357. Lundequist A, Calounova G, Wensman H, Ronnberg E, Pejler G. Differential regulation 
of Nr4a subfamily nuclear receptors following mast cell activation. Mol Immunol. 2011;48(15-
16):1753-61. 
 207 
358. Moran AE, Holzapfel KL, Xing Y, Cunningham NR, Maltzman JS, Punt J, et al. T cell 
receptor signal strength in Treg and iNKT cell development demonstrated by a novel fluorescent 
reporter mouse. J Exp Med. 2011;208(6):1279-89. 
359. Borkowski TA, Jouvin MH, Lin SY, Kinet JP. Minimal requirements for IgE-mediated 
regulation of surface Fc epsilon RI. J Immunol. 2001;167(3):1290-6. 
360. Molfetta R, Gasparrini F, Santoni A, Paolini R. Ubiquitination and endocytosis of the high 
affinity receptor for IgE. Mol Immunol. 2010;47(15):2427-34. 
361. Kim MS, Kuehn HS, Metcalfe DD, Gilfillan AM. Activation and function of the mTORC1 
pathway in mast cells. J Immunol. 2008;180(7):4586-95. 
362. Wershil BK, Furuta GT, Wang ZS, Galli SJ. Mast cell-dependent neutrophil and 
mononuclear cell recruitment in immunoglobulin E-induced gastric reactions in mice. 
Gastroenterology. 1996;110(5):1482-90. 
363. Phong BL, Avery L, Sumpter TL, Gorman JV, Watkins SC, Colgan JD, et al. Tim-3 
enhances FcepsilonRI-proximal signaling to modulate mast cell activation. J Exp Med. 
2015;212(13):2289-304. 
364. Mizui M, Shikina T, Arase H, Suzuki K, Yasui T, Rennert PD, et al. Bimodal regulation 
of T cell-mediated immune responses by TIM-4. Int Immunol. 2008;20(5):695-708. 
365. Cao W, Ryan M, Buckley D, O'Connor R, Clarkson MR. Tim-4 inhibition of T-cell 
activation and T helper type 17 differentiation requires both the immunoglobulin V and mucin 
domains and occurs via the mitogen-activated protein kinase pathway. Immunology. 
2011;133(2):179-89. 
366. Kane LP, Shapiro VS, Stokoe D, Weiss A. Induction of NF-kappaB by the Akt/PKB 
kinase. Curr Biol. 1999;9(11):601-4. 
367. Yamanishi Y, Kitaura J, Izawa K, Kaitani A, Komeno Y, Nakamura M, et al. TIM1 is an 
endogenous ligand for LMIR5/CD300b: LMIR5 deficiency ameliorates mouse kidney 
ischemia/reperfusion injury. J Exp Med. 2010;207(7):1501-11. 
368. Curtiss ML, Hostager BS, Stepniak E, Singh M, Manhica N, Knisz J, et al. Fyn binds to 
and phosphorylates T cell immunoglobulin and mucin domain-1 (Tim-1). Mol Immunol. 
2011;48(12-13):1424-31. 
369. Kambayashi T, Koretzky GA. Proximal signaling events in Fc epsilon RI-mediated mast 
cell activation. J Allergy Clin Immunol. 2007;119(3):544-52; quiz 53-4. 
370. Kalesnikoff J, Baur N, Leitges M, Hughes MR, Damen JE, Huber M, et al. SHIP negatively 
regulates IgE + antigen-induced IL-6 production in mast cells by inhibiting NF-kappa B activity. 
J Immunol. 2002;168(9):4737-46. 
371. Laplante M, Sabatini DM. mTOR Signaling. Cold Spring Harb Perspect Biol. 2012;4(2). 
 208 
372. Shin J, Pan H, Zhong XP. Regulation of mast cell survival and function by tuberous 
sclerosis complex 1. Blood. 2012;119(14):3306-14. 
373. Buck MD, O'Sullivan D, Pearce EL. T cell metabolism drives immunity. J Exp Med. 
2015;212(9):1345-60. 
374. Pollizzi KN, Powell JD. Regulation of T cells by mTOR: the known knowns and the known 
unknowns. Trends Immunol. 2015;36(1):13-20. 
375. Delgoffe GM, Pollizzi KN, Waickman AT, Heikamp E, Meyers DJ, Horton MR, et al. The 
kinase mTOR regulates the differentiation of helper T cells through the selective activation of 
signaling by mTORC1 and mTORC2. Nat Immunol. 2011;12(4):295-303. 
376. Weichhart T, Hengstschlager M, Linke M. Regulation of innate immune cell function by 
mTOR. Nat Rev Immunol. 2015;15(10):599-614. 
377. Erlich TH, Yagil Z, Kay G, Peretz A, Migalovich-Sheikhet H, Tshori S, et al. 
Mitochondrial STAT3 plays a major role in IgE-antigen-mediated mast cell exocytosis. J Allergy 
Clin Immunol. 2014;134(2):460-9. 
378. Patou J, Holtappels G, Affleck K, Gevaert P, Perez-Novo C, Van Cauwenberge P, et al. 
Enhanced release of IgE-dependent early phase mediators from nasal polyp tissue. J Inflamm 
(Lond). 2009;6:11. 
379. Ba L, Du J, Liu F, Yang F, Han M, Liu S, et al. Distinct inflammatory profiles in atopic 
and nonatopic patients with chronic rhinosinustis accompanied by nasal polyps in Western china. 
Allergy, asthma & immunology research. 2015;7(4):346-58. 
380. Liu T, Kanaoka Y, Barrett NA, Feng C, Garofalo D, Lai J, et al. Aspirin-Exacerbated 
Respiratory Disease Involves a Cysteinyl Leukotriene-Driven IL-33-Mediated Mast Cell 
Activation Pathway. J Immunol. 2015;195(8):3537-45. 
381. Shin HW, Kim DK, Park MH, Eun KM, Lee M, So D, et al. IL-25 as a novel therapeutic 
target in nasal polyps of patients with chronic rhinosinusitis. J Allergy Clin Immunol. 
2015;135(6):1476-85 e7. 
382. Johns CB, Laidlaw TM. Elevated total serum IgE in nonatopic patients with aspirin-
exacerbated respiratory disease. American journal of rhinology & allergy. 2014;28(4):287-9. 
383. Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. 
AIANE Investigators. European Network on Aspirin-Induced Asthma. Eur Respir J. 
2000;16(3):432-6. 
384. Bischoff SC. Role of mast cells in allergic and non-allergic immune responses: comparison 
of human and murine data. Nat Rev Immunol. 2007;7(2):93-104. 
385. McIntire JJ, Umetsu DT, DeKruyff RH. TIM-1, a novel allergy and asthma susceptibility 
gene. Springer Semin Immunopathol. 2004;25(3-4):335-48. 
 209 
386. Umetsu SE, Lee WL, McIntire JJ, Downey L, Sanjanwala B, Akbari O, et al. TIM-1 
induces T cell activation and inhibits the development of peripheral tolerance. Nat Immunol. 
2005;6(5):447-54. 
387. Yu M, Lowell CA, Neel BG, Gu H. Scaffolding adapter Grb2-associated binder 2 requires 
Syk to transmit signals from FcepsilonRI. J Immunol. 2006;176(4):2421-9. 
388. Klemm S, Gutermuth J, Hultner L, Sparwasser T, Behrendt H, Peschel C, et al. The Bcl10-
Malt1 complex segregates Fc epsilon RI-mediated nuclear factor kappa B activation and cytokine 
production from mast cell degranulation. J Exp Med. 2006;203(2):337-47. 
389. Hamilton KS, Phong B, Corey C, Cheng J, Gorentla B, Zhong X, et al. T cell receptor-
dependent activation of mTOR signaling in T cells is mediated by Carma1 and MALT1, but not 
Bcl10. Sci Signal. 2014;7(329):ra55. 
390. Nechushtan H, Leitges M, Cohen C, Kay G, Razin E. Inhibition of degranulation and 
interleukin-6 production in mast cells derived from mice deficient in protein kinase Cbeta. Blood. 
2000;95(5):1752-7. 
391. Thome M. CARMA1, BCL-10 and MALT1 in lymphocyte development and activation. 
Nat Rev Immunol. 2004;4(5):348-59. 
392. Pawankar R. Allergic diseases and asthma: a global public health concern and a call to 
action. World Allergy Organ J. 2014;7(1):12. 
393. Trevor JL, Deshane JS. Refractory asthma: mechanisms, targets, and therapy. Allergy. 
2014;69(7):817-27. 
394. Quax RA, Manenschijn L, Koper JW, Hazes JM, Lamberts SW, van Rossum EF, et al. 
Glucocorticoid sensitivity in health and disease. Nat Rev Endocrinol. 2013;9(11):670-86. 
395. Stokes JR, Casale TB. The use of anti-IgE therapy beyond allergic asthma. J Allergy Clin 
Immunol Pract. 2015;3(2):162-6. 
 
